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Abstract: Antibiotic resistance of pathogenic bacteria is an emerging threat to global public health.
The increased tolerance to antimicrobial drugs is mainly due to the efflux of these substrates out of
bacterial cells mediated by multidrug resistance (MDR) transporters. In Gram-negative bacteria such as
Escherichia coli or Pseudomonas aeruginosa, highly effective tripartite multidrug efflux systems extrude a
large variety of noxious substrates from the cell interior or the inner membrane directly into the medium.
In E. coli, the major multidrug efflux pump is the tripartite AcrA/AcrB/TolC complex, which extrudes
structurally and functionally diverse chemical compounds. This complex is composed of the outer mem-
brane factor (OMF) TolC spanning the outer membrane and protruding 100 Å into the periplasmic space.
The membrane fusion protein (MFP) AcrA links the proximal end of TolC with the periplasmic domain
of the inner membrane component AcrB. The latter protein belongs to the resistance-nodulation-cell
division (RND) superfamily of transport proteins and is both the substrate specificity determinant and
the energy module of the AcrA/AcrB/TolC efflux system. While in prokaryotes the main physiological
function of RND proteins is associated with extrusion of noxious substrates, they seem to be involved in
lipid homeostasis and cell morphogenesis in eukaryotic cells. One of the most intensively studied human
RND proteins is Niemann-Pick C1, which is engaged in salvage of lipids from the endosomal/lysosomal
pathway. Recently, an asymmetric structure of AcrB in which the monomers adopt the three different
conformations called loose, tight and open was determined. Binding of the substrates minocyclin and
doxorubicin to a hydrophobic pocket in the periplasmic domain of the tight conformer was observed. In
the loose and tight state, tunnels lead from a lateral periplasmic entrance towards the location of the
binding pocket, while in the open conformer, this pocket is exclusively connected via another tunnel to
a funnel at the centre of the AcrB trimer ultimately leading towards the TolC channel. The current
hypothesis states that transport of substrate is accomplished by functional rotation, meaning that each
monomer cycles in a connected and concerted fashion from the loose to tight to open conformation and
back to the loose conformation in analogy to the functional rotation of the catalytic ￿-subunit observed in
the F1Fo 3 ATPase. Since AcrB is driven by the proton motive force, the energy conversion to drive the
large conformational changes observed in the periplasmic domain is considered to be generated by pro-
tonation and deprotonation of essential charged residues residing in the transmembrane domain. In my
PhD thesis, the focus was on the binding of substrate to the hydrophobic pocket and on the translocation
of protons through the transmembrane domain, which was analyzed by structural and functional exper-
iments with wild-type and mutant AcrB. Substitution of the binding pocket residue F610 with alanine
resulted in E. coli mutants with an impaired phenotype for all the substrate tested, whereas the binding
pocket residue V612 to phenylalanine conversion changed the substrate specificity of the V612F mutant
including an increased resistance towards linezolid. Crystallization of the V612F variant in the presence
and absence of Designed Ankyrin Repeat Proteins (DARPins) and subsequent X-ray crystallography
revealed that AcrB_V612F comprises a novel conformation in which each of the monomers were present
in the tight state. The “all-tight” conformation observed for AcrB_V612F is postulated to be adopted
by wild-type AcrB during functional rotation as well, for example when the concentration of substrate
is high. To shed light on the protonation and deprotonation events in the transmembrane domain, four
essential charged residues D407, D408, K940 and R971 - also referred to as proton relay network - as
well as the important polar residue T978 were substituted with asparagine (D407, D408) or with alanine
(K940, R971, T978) and the structures of both wild-type and mutant AcrB/DARPin complexes were
determined at a resolution of 2.0-3.0 Å. The most prominent differences between wild-type and mutant
protein were observed in the tight conformation near the proton relay network. Here, the AcrB_D407N
and AcrB_R971A mutant exhibited structural features that are typical for the open conformer, implying
that the structure of these mutant proteins might resemble intermediate conformations at different steps
during the transition from tight to the open state. Additionally, we identified water molecules in the
transmembrane domain that exhibit distinct positions in the three monomers. Based on these high resolu-
tion structural information, a putative pathway for protons through the transmembrane domain from the
periplasm to the cytoplasm is proposed, and a detailed model for protonation and deprotonation events
during functional rotation is presented. Die Verbreitung von antibiotikaresistenten pathogenen Bakterien
ist eine zunehmende Gefahr für die weltweite Gesundheit. Erhöhte Toleranz gegenüber multiplen an-
tibakteriellen Substanzen wird hauptsächlich durch sogenannte „multidrug resistance“ Transportproteine
verursacht, welche verschiedenste toxische Stoffe aus der bakteriellen Zelle befördern. In Gram-negativen
Bakterien wie zum Beispiel Escherichia coli oder Pseudomonas aeruginosa transportieren dreiteilige Ef-
fluxsysteme äusserst effektiv eine Vielzahl von schädlichen Substanzen entweder aus dem Zellinnern oder
von der inneren Membran direkt ins umgebende Medium. Das wichtigste „multidrug“ Transportsystem
in E. coli ist der dreiteilige AcrA/AcrB/TolC-Komplex, welcher strukturell und funktionell verschieden-
ste Chemikalien transportiert. Dieser Komplex besteht aus dem „Outer Membrane Factor (OMF)“
TolC, welcher die äussere Membran durchdringt und 100 Å weit ins Periplasma ragt; der inneren Mem-
brankomponente AcrB, ein trimeres Transportprotein der „Resistance-Nodulation-cell Division (RND)“
Superfamilie, welches die Substratsdeterminante und das Energiemodul des gesamten AcrA/AcrB/TolC-
Komplexes darstellt; und des „Membrane Fusion Protein (MFP)“ AcrA, welches das proximale Ende von
TolC mit der periplasmatischen Domäne von AcrB verbindet. Während die RND Proteine in Prokary-
oten hauptsächlich mit dem Export von schädlichen Stoffen in Verbindung gebracht werden, scheinen sie
in Eukaryoten in Lipid-Homöostase und Zellmorphogenese involviert zu sein. Eines der am intensivsten
untersuchten menschlichen RND Proteine ist Niemann-Pick C1, welches am „salvage-pathway“ von Lipi-
den aus dem endosomal/lysosomalen System beteiligt ist. Kürzlich wurde eine asymmetrische Struktur
von trimerem AcrB bestimmt, in welchem die Monomere die drei Konformationen „loose“, „tight“ und
„open“ einnehmen. Des weiteren konnte die Bindung der Substrate Minocyclin und Doxorubicin in einer
hydrophoben Bindungstasche in der periplasmatischen Domäne des „tight“ Konformers nachgewiesen
werden. Im „loose“ und „tight“ Zustand führen Tunnel von einem periplasmatisch lokalisierten lateralen
Eingang zur Position der Bindungstasche, während im „open“ Konformer ein neuer Tunnel diese Stelle mit
einem Ausgangstrichter verbindet, welcher sich in der Mitte der drei Monomere befindet und zum TolC
Kanal führt. Gemäss der aktuellen Hypothese wird der Transport von Substraten durch funktionelle Rota-
tion bewerkstelligt: analog zur funktionellen Rotation der katalytischen ￿-Untereinheit der F1Fo-ATPase
nimmt jeder der drei Monomere in einer abgestimmten Art und Weise nacheinander die Zustände „loose“,
„tight“ und „open“ an. Es wird angenommen, dass in AcrB, welches durch die protonenmotorische Kraft
angetrieben wird, titrierbare Aminosäurereste in der Transmembrandomäne protoniert und deprotoniert
werden. Dadurch würden die grossen konformationellen Änderungen in der periplasmatischen Domäne
energetisiert, welche zu Substrattransport führten. Der Fokus meiner Doktorarbeit war auf die Bindung
von Substraten in der periplasmatischen AcrB-Bindungstasche und auf die Translokation von Protonen
durch die Transmembrandomäne gerichtet. Dafür wurde wildtyp und mutiertes AcrB funktionell und
strukturell untersucht. Die Alanin-Substitution von F610, welches sich in der Bindungstasche befindet,
führte zu einem eingeschränkten Transport für alle getesteten Substrate, während die V612F Punktmuta-
tion spezifisch die Substratspezifität von AcrB veränderte: gegenüber den meisten Substraten wurde die
in E. coli gemessene Resistenz zwar erniedrigt, die Toleranz gegenüber Linezolid jedoch spezifisch erhöht.
Röntgenstruktur-Analysen der AcrB Variante V612F mit und ohne „Designed Ankyrin Repeat Proteins“
(DARPins) zeigten das Transportprotein in einer neuen Konformation, in welcher alle Monomere den
„tight“ Zustand einnahmen. Es wird postuliert, dass während der funktionellen Rotation die „all-tight“
Konformation auch in wildtyp AcrB vorkommt, zum Beispiel bei hoher Substratkonzentration. Um
Protonierungs- und Deprotonierungsereignisse in der Transmembrandomäne zu untersuchen, wurde das
sogenannte „proton relay network“, bestehend aus den vier essentiellen und titrierbaren Aminosäureresten
D407, D408, K940 und R971, und der funktionell wichtige polare Aminosäurerest T978 durch Asparagin
(D407, D408) oder durch Alanin (K940, R971, T978) ersetzt und die Strukturen von wildtyp und mutan-
ten AcrB/DARPin-Komplexen bei einer Auflösung von 2.0 bis 3.0 Å bestimmt. Die auffallendste Unter-
schiede zwischen dem Wildtyp und den mutierten AcrB Varianten wurden im „tight“ Konformer nahe des
„proton relay network“ beobachtet: AcrB_D407N und AcrB_R971A wiesen strukturelle Eigenschaften
sowohl des „tight“ wie auch des „open“ Monomers auf. Möglicherweise repräsentieren diese Strukturen
unterschiedlich weit fortgeschrittene Intermediate während der Konversion vom „tight“ zum „open“ Kon-
former. Zusätzlich identifizierten wir in der Transmembrandomäne Wassermolekülen, welche in den drei
2
Konformationen unterschiedliche Positionen aufwiesen. Basierend auf diesen hochauflösenden Struktur-
informationen wird ein möglicher Weg der Protonen durch die Transmembrandomäne vom Periplasma ins
Zytoplasma vorgeschlagen und ein detailliertes Modell der Protonierungs- und Deprotonierungsereignisse
während der funktionellen Rotation präsentiert.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-163861
Dissertation
Published Version
Originally published at:
Eicher, Thomas. Structural and functional studies on AcrB, a bacterial multidrug efflux pump and
homologue of Niemann-Pick C1 protein. 2009, University of Zurich, Faculty of Science.
3
 Structural and Functional Studies on 
AcrB, a Bacterial Multidrug Efflux 
Pump and Homologue of Niemann-
Pick C1 Protein 
 
 
 
 
Dissertation 
 
zur 
 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
vorgelegt der 
 
Mathematisch-naturwissenschaftlichen Fakultät 
 
der 
 
Universität Zürich 
 
 
 
von 
 
Thomas Eicher 
 
von 
 
Goldingen SG 
 
 
 
 
 
Promotionskomitee 
 
Prof. Dr. François Verrey 
Prof. Dr. Klaas Martinus Pos 
Prof. Dr. Raimund Dutzler 
 
 
 
Zürich, 2009 
 
 1 
 
Table of Contents 
1. Summary ....................................................................................................................2 
1. Zusammenfassung......................................................................................................4 
2. Introduction................................................................................................................7 
2.1 Antibiotic resistance.............................................................................................7 
2.2 Multidrug resistance transporters.........................................................................9 
2.3 Niemann-Pick C1 and homologous eukaryotic RND proteins ..........................14 
2.4 Tripartite MFP/RND/OMF complexes ..............................................................17 
2.5 Outer membrane factors (OMFs) - TolC ...........................................................18 
2.6 Membrane Fusion Proteins (MFPs) - AcrA.......................................................21 
2.7 AcrB as a paradigm for Resistance-Nodulation-cell Division (RND) 
  superfamily proteins........................................................................................23 
2.8 Tripartite AcrA/AcrB/TolC complex.................................................................33 
2.9 Multispecificity ..................................................................................................37 
2.10 Proton translocation .........................................................................................44 
3. The all-tight conformation of AcrB trimer is in support of bi-site activation of  
 drug transport ...................................................................................................52 
4. The AcrB proton pathway........................................................................................80 
5. Structural and functional aspects of the multidrug efflux pump AcrB..................110 
6. Discussion ..............................................................................................................118 
6.1 Proton relay network: VexF vs. HAE1 superfamily consensus sequence .......118 
6.2 The putative sodium binding site of VexF.......................................................119 
6.3 Composition of putative proton relay network in HME vs. HAE1  
 superfamily ....................................................................................................124 
6.4 Substrate specificity determinants in HAE1 vs. HME superfamily ................126 
6.5 Substrate specificity determinants within HAE1 superfamily.........................129 
7. Conclusions and outlook........................................................................................132 
7.1 Energization of AcrB .......................................................................................132 
7.2 Substrate binding by AcrB...............................................................................133 
7.3 Methods to obtain structural information on AcrB in additional  
 conformations ................................................................................................135 
8. References..............................................................................................................139 
9. Curriculum Vitae ...................................................................................................148 
10. Acknowledgements..............................................................................................150 
 
 
1. Summary 
2 
 
1. Summary 
 
Antibiotic resistance of pathogenic bacteria is an emerging threat to global public 
health. The increased tolerance to antimicrobial drugs is mainly due to the efflux of 
these substrates out of bacterial cells mediated by multidrug resistance (MDR) 
transporters. 
In Gram-negative bacteria such as Escherichia coli or Pseudomonas aeruginosa, 
highly effective tripartite multidrug efflux systems extrude a large variety of noxious 
substrates from the cell interior or the inner membrane directly into the medium. 
In E. coli, the major multidrug efflux pump is the tripartite AcrA/AcrB/TolC 
complex, which extrudes structurally and functionally diverse chemical compounds. 
This complex is composed of the outer membrane factor (OMF) TolC spanning the 
outer membrane and protruding 100 Å into the periplasmic space. The membrane 
fusion protein (MFP) AcrA links the proximal end of TolC with the periplasmic 
domain of the inner membrane component AcrB. The latter protein belongs to the 
resistance-nodulation-cell division (RND) superfamily of transport proteins and is 
both the substrate specificity determinant and the energy module of the 
AcrA/AcrB/TolC efflux system. While in prokaryotes the main physiological function 
of RND proteins is associated with extrusion of noxious substrates, they seem to be 
involved in lipid homeostasis and cell morphogenesis in eukaryotic cells. One of the 
most intensively studied human RND proteins is Niemann-Pick C1, which is engaged 
in salvage of lipids from the endosomal/lysosomal pathway. 
Recently, an asymmetric structure of AcrB in which the monomers adopt the three 
different conformations called loose, tight and open was determined. Binding of the 
substrates minocyclin and doxorubicin to a hydrophobic pocket in the periplasmic 
domain of the tight conformer was observed. In the loose and tight state, tunnels lead 
from a lateral periplasmic entrance towards the location of the binding pocket, while 
in the open conformer, this pocket is exclusively connected via another tunnel to a 
funnel at the centre of the AcrB trimer ultimately leading towards the TolC channel. 
The current hypothesis states that transport of substrate is accomplished by functional 
rotation, meaning that each monomer cycles in a connected and concerted fashion 
from the loose to tight to open conformation and back to the loose conformation in 
analogy to the functional rotation of the catalytic β-subunit observed in the F1Fo 
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ATPase. Since AcrB is driven by the proton motive force, the energy conversion to 
drive the large conformational changes observed in the periplasmic domain is 
considered to be generated by protonation and deprotonation of essential charged 
residues residing in the transmembrane domain.  
In my PhD thesis, the focus was on the binding of substrate to the hydrophobic pocket 
and on the translocation of protons through the transmembrane domain, which was 
analyzed by structural and functional experiments with wild-type and mutant AcrB.  
Substitution of the binding pocket residue F610 with alanine resulted in E. coli 
mutants with an impaired phenotype for all the substrate tested, whereas the binding 
pocket residue V612 to phenylalanine conversion changed the substrate specificity of 
the V612F mutant including an increased resistance towards linezolid. Crystallization 
of the V612F variant in the presence and absence of Designed Ankyrin Repeat 
Proteins (DARPins) and subsequent X-ray crystallography revealed that AcrB_V612F 
comprises a novel conformation in which each of the monomers were present in the 
tight state. The “all-tight” conformation observed for AcrB_V612F is postulated to be 
adopted by wild-type AcrB during functional rotation as well, for example when the 
concentration of substrate is high.  
To shed light on the protonation and deprotonation events in the transmembrane 
domain, four essential charged residues D407, D408, K940 and R971 - also referred 
to as proton relay network - as well as the important polar residue T978 were 
substituted with asparagine (D407, D408) or with alanine (K940, R971, T978) and the 
structures of both wild-type and mutant AcrB/DARPin complexes were determined at 
a resolution of 2.0-3.0 Å. The most prominent differences between wild-type and 
mutant protein were observed in the tight conformation near the proton relay network. 
Here, the AcrB_D407N and AcrB_R971A mutant exhibited structural features that 
are typical for the open conformer, implying that the structure of these mutant 
proteins might resemble intermediate conformations at different steps during the 
transition from tight to the open state. Additionally, we identified water molecules in 
the transmembrane domain that exhibit distinct positions in the three monomers. 
Based on these high resolution structural information, a putative pathway for protons 
through the transmembrane domain from the periplasm to the cytoplasm is proposed, 
and a detailed model for protonation and deprotonation events during functional 
rotation is presented. 
1. Zusammenfassung 
4 
 
1. Zusammenfassung 
 
Die Verbreitung von antibiotikaresistenten pathogenen Bakterien ist eine zunehmende 
Gefahr für die weltweite Gesundheit. Erhöhte Toleranz gegenüber multiplen 
antibakteriellen Substanzen wird hauptsächlich durch sogenannte „multidrug 
resistance“ Transportproteine verursacht, welche verschiedenste toxische Stoffe aus 
der bakteriellen Zelle befördern. In Gram-negativen Bakterien wie zum Beispiel 
Escherichia coli oder Pseudomonas aeruginosa transportieren dreiteilige 
Effluxsysteme äusserst effektiv eine Vielzahl von schädlichen Substanzen entweder 
aus dem Zellinnern oder von der inneren Membran direkt ins umgebende Medium. 
Das wichtigste „multidrug“ Transportsystem in E. coli ist der dreiteilige 
AcrA/AcrB/TolC-Komplex, welcher strukturell und funktionell verschiedenste 
Chemikalien transportiert. Dieser Komplex besteht aus dem „Outer Membrane Factor 
(OMF)“ TolC, welcher die äussere Membran durchdringt und 100 Å weit ins 
Periplasma ragt; der inneren Membrankomponente AcrB, ein trimeres 
Transportprotein der „Resistance-Nodulation-cell Division (RND)“ Superfamilie, 
welches die Substratsdeterminante und das Energiemodul des gesamten 
AcrA/AcrB/TolC-Komplexes darstellt; und des „Membrane Fusion Protein (MFP)“ 
AcrA, welches das proximale Ende von TolC mit der periplasmatischen Domäne von 
AcrB verbindet. Während die RND Proteine in Prokaryoten hauptsächlich mit dem 
Export von schädlichen Stoffen in Verbindung gebracht werden, scheinen sie in 
Eukaryoten in Lipid-Homöostase und Zellmorphogenese involviert zu sein. Eines der 
am intensivsten untersuchten menschlichen RND Proteine ist Niemann-Pick C1, 
welches am „salvage-pathway“ von Lipiden aus dem endosomal/lysosomalen System 
beteiligt ist. 
Kürzlich wurde eine asymmetrische Struktur von trimerem AcrB bestimmt, in 
welchem die Monomere die drei Konformationen „loose“, „tight“ und „open“ 
einnehmen. Des weiteren konnte die Bindung der Substrate Minocyclin und 
Doxorubicin in einer hydrophoben Bindungstasche in der periplasmatischen Domäne 
des „tight“ Konformers nachgewiesen werden. Im „loose“ und „tight“ Zustand führen 
Tunnel von einem periplasmatisch lokalisierten lateralen Eingang zur Position der 
Bindungstasche, während im „open“ Konformer ein neuer Tunnel diese Stelle mit 
einem Ausgangstrichter verbindet, welcher sich in der Mitte der drei Monomere 
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5 
 
befindet und zum TolC Kanal führt. Gemäss der aktuellen Hypothese wird der 
Transport von Substraten durch funktionelle Rotation bewerkstelligt: analog zur 
funktionellen Rotation der katalytischen β-Untereinheit der F1Fo-ATPase nimmt jeder 
der drei Monomere in einer abgestimmten Art und Weise nacheinander die Zustände 
„loose“, „tight“ und „open“ an. Es wird angenommen, dass in AcrB, welches durch 
die protonenmotorische Kraft angetrieben wird, titrierbare Aminosäurereste in der 
Transmembrandomäne protoniert und deprotoniert werden. Dadurch würden die 
grossen konformationellen Änderungen in der periplasmatischen Domäne 
energetisiert, welche zu Substrattransport führten. 
Der Fokus meiner Doktorarbeit war auf die Bindung von Substraten in der 
periplasmatischen AcrB-Bindungstasche und auf die Translokation von Protonen 
durch die Transmembrandomäne gerichtet. Dafür wurde wildtyp und mutiertes AcrB 
funktionell und strukturell untersucht. 
Die Alanin-Substitution von F610, welches sich in der Bindungstasche befindet, 
führte zu einem eingeschränkten Transport für alle getesteten Substrate, während die 
V612F Punktmutation spezifisch die Substratspezifität von AcrB veränderte: 
gegenüber den meisten Substraten wurde die in E. coli gemessene Resistenz zwar 
erniedrigt, die Toleranz gegenüber Linezolid jedoch spezifisch erhöht. 
Röntgenstruktur-Analysen der AcrB Variante V612F mit und ohne „Designed 
Ankyrin Repeat Proteins“ (DARPins) zeigten das Transportprotein in einer neuen 
Konformation, in welcher alle Monomere den „tight“ Zustand einnahmen. Es wird 
postuliert, dass während der funktionellen Rotation die „all-tight“ Konformation auch 
in wildtyp AcrB vorkommt, zum Beispiel bei hoher Substratkonzentration. 
Um Protonierungs- und Deprotonierungsereignisse in der Transmembrandomäne zu 
untersuchen, wurde das sogenannte „proton relay network“, bestehend aus den vier 
essentiellen und titrierbaren Aminosäureresten D407, D408, K940 und R971, und der 
funktionell wichtige polare Aminosäurerest T978 durch Asparagin (D407, D408) oder 
durch Alanin (K940, R971, T978) ersetzt und die Strukturen von wildtyp und 
mutanten AcrB/DARPin-Komplexen bei einer Auflösung von 2.0 bis 3.0 Å bestimmt. 
Die auffallendste Unterschiede zwischen dem Wildtyp und den mutierten AcrB 
Varianten wurden im „tight“ Konformer nahe des „proton relay network“ beobachtet: 
AcrB_D407N und AcrB_R971A wiesen strukturelle Eigenschaften sowohl des „tight“ 
wie auch des „open“ Monomers auf. Möglicherweise repräsentieren diese Strukturen 
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unterschiedlich weit fortgeschrittene Intermediate während der Konversion vom 
„tight“ zum „open“ Konformer. Zusätzlich identifizierten wir in der 
Transmembrandomäne Wassermolekülen, welche in den drei Konformationen 
unterschiedliche Positionen aufwiesen. Basierend auf diesen hochauflösenden 
Strukturinformationen wird ein möglicher Weg der Protonen durch die 
Transmembrandomäne vom Periplasma ins Zytoplasma vorgeschlagen und ein 
detailliertes Modell der Protonierungs- und Deprotonierungsereignisse während der 
funktionellen Rotation präsentiert. 
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2. Introduction 
2.1 Antibiotic resistance 
 
In the late 1960´s, the US Surgeon General William H. Stewart declared “...that we 
had essentially defeated infectious diseases and could close the book on them 
[infectious diseases]...” (1). This statement, however, turned out to be incorrect, since 
during the upcoming decades many infections reemerged to become the second most 
cause of death worldwide (2). 
The main reason for failure in the fight against pathogenic organisms causing 
infectious disease is the emergence of antibiotic resistance. Consequently, our existing 
arsenal of antibiotics is failing ever often due to the increasing numbers of multiple 
drug resistant organisms. In 1993, the World Health Organization (WHO) declared 
Mycobacterium tuberculosis, formerly believed to be defeated with the help of 
antibiotics, to be a global emergency, the first such designation ever made by the 
organization (3). 
The intrinsic development of resistance to antibiotics as soon as the drug is deployed 
urges the design and production of new antibiotics. However, the trend goes in the 
opposite direction: over the past 20 years, there has been a 56% decline in the number 
of antibiotics approved annually by the American Food and Drug Administration 
(FDA) and over the last decade, only 22 new antibacterial drugs have been launched 
(4). In fact, many large pharmaceutical companies have reprioritized their research 
and development (R&D) efforts to either de-emphasize or to no longer include 
antibacterials (5-9). The most likely reason for disinterest to develop new antibiotics 
is their low monetary value in the marketplace: they are administered in 
predominantly acute situations to reduce infection and prevent mortality. Because of 
their effectiveness, the number of patients-days1 is small and revenue low. In contrast, 
drugs prescribed for chronic diseases are more attractive since patients most likely are 
prescribed these drugs over a long period of time or even life-long (e.g. obesity, pain 
relief, asthma treatment, erectile dysfunction). To reduce the expenses of R&D of 
antibiotics, the remaining antibiotic developing companies mainly focus on modifying 
the safe and proven classes of antibiotics and high through-put screening (HTS) of 
pre-existing synthetic libraries of compounds made primarily for other purposes. As a 
                                                 
1 total number of days an individual patient is on drug therapy 
2. Introduction 
8 
 
consequence of the former approach no new classes of antibiotics are developed 
(Figure 1), with the notable exception of the oxazolidinones (e.g. linezolid). Despite 
the fact that excellent in vitro target inhibitors could be identified using HTS, 
restricted permeation of the bacterial cell membranes rendered those ineffective 
against bacteria (10).  
 
 
Figure 1: Deployment of new classes of antibiotics and development of resistance. Between the 1930s 
and 1960s, many new classes of antibiotics were introduced into clinical practice. There is an 
innovation gap of 38 years between deployment of ciprofloxacin (1962) and linezolid (2000). 
Development of resistance was observed within one year (linezolid) and 36 years (erythromycin) after 
deployment (see horizontal bar). One name of a representative antibiotic of a chemical class is 
displayed (trimetoprim for sulfonamides, penicillin for β-lactams, streptomycin for aminoglycosides, 
tetracycline for polyketitedes, erythromycin for macrolides, vancomycin for glycopeptides, ampicillin 
for aminopenicillins, ciprofloxacin for fluoroquinolones, and linezolid for oxazolidinones). Year of 
introduction into clinical practice (i) and of observation of resistance (r) is indicated. (11-13) 
 
The reason for the inevitable development of antibiotic resistance in bacteria is the 
combination of short replication time and spontaneous mutation events. Already in a 
Escherichia coli population of 1.3*105 cells (corresponding to 13µl of a culture at 
OD600 = 1.0), each of the 4500 genes carries at least one mutation after one replication 
cycle given the typical error frequency of the bacterial DNA polymerase of 10-7 and 
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the genome size of 4.6 million nucleotides2. If one of these mutations confers some 
degree of resistance, the mutants have a selective advantage and will prevail. 
Resistance of bacteria towards antibiotics are known to be evoked by at least three 
different mechanisms: (i) target modification (e.g. resistance against macrolides 
mediated by methylation of the ribosome (14-16) or resistance against 
fluoroquinolones by mutations in DNA gyrase, (17,18), (ii) antibiotic modification 
(e.g. hydrolysis of β-lactam ring by β-lactamase (19) or acetylation of 
aminoglycosides, (20)) and (iii) reduced uptake of antibiotics in the target 
compartment (periplasm, cytoplasm) through suppression of porin synthesis (21) 
and/or overproduction of efflux pumps (22-27). 
Resistance conferred by antibiotic and target modification is often restricted to a 
single class of antibiotics or even a single compound. In contrast, multidrug resistance 
(MDR) transporters enable the bacteria to efflux a broad range of substances and 
hence confer resistance to unrelated compounds. The central role of MDR transporters 
was highlighted by Lomovskaya et al. by analyzing resistance of Pseudomonas 
aeruginosa towards the antibiotic levofloxacin. Their findings suggested that (i) 
overexpression of MDR transporters is the first resistance mechanism that can be 
observed when the cells are exposed to antibiotics, that (ii) the probability of other 
resistance mechanism to develop is significantly higher when MDR transporters are 
present and that (iii) MDR transporters increase the resistance conferred by other 
mechanisms (23). 
 
2.2 Multidrug resistance transporters 
 
Based on a systematic genome-wide analysis of membrane transport systems (28), 
solute transporters were identified and classified into about 550 families and 
superfamilies (Transport Classification Database (tcdb), http://www.tcdb.org/). 
According to this transporter classification system, all the MDRs known belong to 
five superfamilies. These are the ATP binding cassette (ABC) superfamily 
(TC#3.A.1), the major facilitator superfamily (MFS) (TC#2.A.1), the drug/metabolite 
transporter (DMT) superfamily (TC#2.A.7), the multidrug/oligosaccharidyl-
                                                 
2 ( )( ) 99.011 * =−− gxlf , where 0.99 is the statistical probability, f the error frequency of the DNA 
polymerase, l the average gene lenght, x the number of cells an g the number of genes in the genome. 
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lipid/polysaccharide (MOP) flippase superfamily (TC#2.A.66) and the resistance-
nodulation-cell division (RND) superfamily (TC#2.A.6). It has to be stated that not all 
the proteins assigned to these families are actual multidrug efflux transporters but are 
rather involved in transport of pivotal substrates (e.g. lipids, nutrients, signalling 
molecules) or have hitherto unknown function. 
 
The primary active MDR ABC transporters are typical for eukaryotes where they play 
a major role in exporting noxious substrates out of the cell. Among these substrates 
are also chemotherapeutics and therefore members of the superfamily of ABC 
transporters such as the human P-glycoprotein negatively affect the effectiveness of 
cancer therapy. It is estimated that around 40% of human tumors develop resistance to 
chemotherapeutic drugs (29). 
The minimal requirements for ABC transporters are two transmembrane domains 
(TMDs) and two nucleotide binding domains (NBDs). In mammalian ABC 
transporters these domains are located on a single polypeptide, whereas in bacteria 
most commonly two monomers comprising one TMD and one NBD form a functional 
homodimer. Besides mammalian P-glycoprotein (30), prominent members of the 
ABC superfamily are the human multidrug exporter MRP1 (31,32), the cystic fibrosis 
transmembrane conductance regulator CFTR (33), LmrA of Lactococcus lactis (34) 
and Sav1866 of Staphylococcus aureus, the first ABC transporter whose structure was 
determined at high resolution (35). 
 
The drug-translocating members of the other four subfamilies belong to the class of 
secondary active transporters and hence utilize the electrochemical gradient of ions 
(mostly protons) across the membrane. 
 
Members of the MFS typically consist of a single polypeptide with 12 or 14 
transmembrane helices. X-ray structural data are available for the E. coli proteins 
EmrD (Yin 2006), LacY (36,37) and GlpT (38). Whereas EmrD is an MDR with 
broad substrate specificity, LacY and GlpT exhibit narrow substrate specificity.  
The structures of all three proteins resemble a membrane embedded bowl with two 
linings of transmembrane α-helices. Whereas the α-helices of the outer lining adopt a 
similar configuration in all three proteins, the arrangement of the inner layer is quite 
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distinct, forming a larger internal cavity in EmrD compared to LacY and GlpT. 
Although no bound substrate could be detected in EmrD, mutational analysis in its 
homologues LmrP and MdfA imply that residues located at the surface of this large 
internal cavity are involved in substrate recognition and translocation. Furthermore, 
whereas the interior of LacY and GlpT is rather hydrophilic, the residues lining the 
internal cavity of EmrD are aliphatic or aromatic, a common feature for MDR 
proteins transporting charged amphipathic compounds (39-41). Thus, the voluminous 
internal cavity may accommodate several binding sites or a single, large and flexible 
binding site, both of which would account for the broad substrate specificity of EmrD 
(29). 
 
Whereas the other four superfamilies of MDRs are present in all phyla, small 
multidrug resistance (SMR) transporters (TC#2.A.7.1), a subdivision of the DMT 
superfamily, are only found in prokaryotes. With only four transmembrane α-helices 
per monomer and no significant extramembrane domain, these are considered as the 
smallest MDRs up to date. The most probable functional unit is a bundle of eight 
transmembrane helices, formed either by homodimerization (EmrE) or by a 
heterodimerization (YdfEF). The topological orientation of the two monomers in the 
membrane is still controversial: crosslink studies performed by Schuldiner and 
colleagues suggest a parallel arrangement with cytoplasmic N- and C-termini (42,43), 
whereas a genome wide screen with C-terminal tagged membrane proteins (44,45), 
manipulation of the K+R bias of EmrE (46) as well as structure determination by X-
ray crystallography (47) support an antiparallel orientation of the two monomers. 
Like the structurally characterized MFS transporters, the SMR transporters appear to 
have an overlapping binding site for the substrate and the coupling ion suggesting a 
common transport pathway. In EmrE, this pathway involves the essential residue E14 
(48,49). 
 
The multi antimicrobial extrusion (MATE) family (TC#2.A.66.1), a subdivision of the 
MOP flippase superfamily, is the most recently classified and least characterized class 
of MDRs. Members of this family consist of twelve transmembrane α-helices and are 
energized either by the influx of Na+ (50) or by protons (51). Prominent members of 
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this family are NorM of Vibrio paraphaemolyticus and Neisseria gonorrhoeae and 
YdhE of E. coli. 
 
Proteins of the RND superfamily are ubiquitous in all phyla. In prokaryotes their main 
physiological function seems to be associated with the extrusion of noxious substrates 
and hence function as a typical MDR transporter, with notable exceptions like the 
secretory accessory proteins SecDF (52,53), lipid exporter MmpL7 (54,55) and the 
putative lipooligosaccharide nodulation factor exporter NolG (56). In eukarya, 
however, the functionally characterized RND proteins seem to be involved in lipid 
homeostasis (57-59) and cell morphogenesis (60,61). For the proteobacterial heavy 
metal (HM) efflux pump CzcA (Ralstonia sp. CH34), it was shown that the transport 
of Zn2+ ions is coupled to the antiport of protons (62). As phylogenetic analyses 
suggest, energization via the proton motive force might be a common feature for all 
RND transporters (28). 
Most members of the RND superfamily are located in the inner-membrane of 
proteobacteria. They typically assemble with two accessory proteins, a membrane 
fusion protein (MFP; TC#8.A.1) and an outer membrane factor (OMF; TC#1.B.17). 
The so formed tripartite complex spans the outer membrane, the periplasm as well as 
the inner membrane of the Gram-negative bacterium. The outer membrane, besides 
the tripartite efflux pumps, is considered to be the main barrier for drugs on their way 
to the inside of the cell (63,64) The combination of the intrinsic impermeability of the 
outer membrane, the reduction of the number of outer membrane pores and the 
upregulation of tripartite MDRs enables effective synergistic drug resistance (65).  
 
Within the phylogentic tree (Figure 2), the clustering pattern of proteobacterial RND 
protein mirrors their substrate specificity with the heavy metal efflux (HME; 
TC#2.A.6.1) family catalyzing export of heavy metal ions, the 
hydrophobe/amphiphile efflux-1 (HAE1; TC#2.A.6.2) family catalyzing export of 
multiple drugs and the putative nodulation factor exporter (NFE; TC#2.A.6.3) family 
exporting lipooligosaccharides involved in plant nodulation. The remaining families 
comprise also proteins of firmicutes (HAE2; TC#2.A.6.5), archaea (HAE3; 
TC#2.A.6.7) and eukaryotes (EST; TC#2.A.6.6 and Dispatched; TC#2.A.6.9). It was 
not until 2000 that the first mammalian RND protein – Niemann-Pick Type C1 – was 
detected and characterized (66). 
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Figure 2: Maximum-
likelihood phylogenetic 
tree of proteins of the 
RND superfamily. 
Proteins of the 
proteobacterial HME and 
HAE1 family are 
depicted in blue and red, 
respectively. Members of 
the eukaryotic EST, the 
archeal HAE3 family and 
proteins of HAE2 in 
firmicutes are shown in 
green, violet and grey, 
respectively. Note that, 
with the exception of the 
proteobacterial SecDF 
transporter, the clustering 
of the proteins mirrors 
their phylogenetic origin. 
Orf4 is a proteobacterial 
protein and the only 
member of the 
Brominated, Aryl 
Polyene Pigment 
Exporter (APPE) family. 
Protein families that are 
represented by only one 
member in the Transport 
Classification Database 
(NFE, APPE, Dispatched 
SecDF) are shown in 
black. 3-hydroxy-3-
methylglutaryl (HMG)-  
CoA reductase, a human protein of the EST family, is not shown. For construction of the tree, a multiple 
sequence alignment was built using Mafft (67) with default settings. The tree was inferred using PHYML (68) 
with the JTT matrix (69) 
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2.3 Niemann-Pick C1 and homologous eukaryotic RND proteins 
 
The Niemann-Pick C1 transporter is localized in the lysosomal membrane of 
eukaryotic cells (66,70). Mutations in this protein have been shown to cause the fatal 
neurodegenerative Niemann-Pick disease that is characterized by accumulation of 
lipids in endosomal/lysosomal (E/L) pathway causing death in early childhood 
(71,72). Human and murine NPC1 as well as drosophila NPC1a seem to be 
ubiquitously expressed housekeeping proteins located on the membrane of late 
endosomes (73) and are indispensable for proper lipid turnover. In 5% of patients 
showing Niemann-Pick C phenotype, another protein, designated NPC2 (formerly 
known as HE1) is mutated. NPC2 is a small soluble lysosomal glycoprotein (74) that 
binds cholesterol and other sterols (75) and transfers cholesterol to phospholipid 
membranes (58). The structure of the NPC2/cholesterol sulfate comples was solved 
by X-ray crystallography and showed the iso-octyl side chain deeply buried in a 
hydrophobic pocket, whereas the A ring is exposed to the solvent (76). This is in 
accordance with the observation that binding of cholesterol derivatives having 
modifications at the iso-octyl side chain (for example 25-hydroxycholesterol) by 
NPC2 is inhibited, whereas the ligand/protein interaction is not affected when the A 
ring of cholesterol (for example epicholesterol) is modified (59).  
Unlike conventional RND proteins which are composed of twelve transmembrane 
helices (TM) and two large hydrophilic loops, NPC1 exhibits at its N-terminus an 
extended luminal loop plus an additional transmembrane helix (66,70) (Figure 3). It 
was recently shown that cholesterol is bound by this additional N-terminal domain 
(NTD). In direct contrast to the findings with NPC2, binding of sterol to NPC1(NTD) 
is not inhibited by hydroxylation of the iso-octyl side chain, but rather by 
modification of the A ring (59). 
In mice, NPC1-/-, NPC2-/- and the double mutant showed essentially the same 
phenotype, suggesting nonredundant functions in the same pathway at different steps 
(57). In an in vitro assays using NPC2 and soluble NPC1(NTD), binding and release 
of substrate by both proteins, protein-protein transfer of cholesterol and substrate 
transfer between protein and liposomes were analyzed (58). These experiments 
revealed that the on- and off-rate of NPC2 is much faster than the one of 
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NPC1(NTD). Interestingly, binding and release of cholesterol by NPC1(NTD) was 
accelerated by a factor of approximately 100 in the presence of NPC2, suggesting that 
NPC2 shuttles cholesterol to and/or from NPC1(NTD) and promotes binding and 
release by NPC1(NTD). Based on these findings, two models were proposed in which 
unidirectional egress of unesterified cholesterol out of the E/L system is dependent on 
the cooperation of NPC1 and NPC2. In the first model, cholesterol is bound by NPC1 
and then transferred via NPC2 to a yet unidentified lysosomal cholesterol transporter 
which would insert the substrate into the endosomal membrane. According to the 
second model, it is rather NPC2 that binds cholesterol first and mediates its transfer to 
NPC1, which would integrate the substrate into the membrane. Membrane bound 
cholesterol would then be transported to the ER for further processing (58). 
 
 
 
Figure 3: Topology of AcrB, NPC1, Patched and Scap. The transmembrane helices forming the sterol 
sensing domain (SSD) are framed in white. The extensive loops connecting TM1 with TM2 and TM7 
with TM8 (for NPC1: TM2 with TM3 and TM8 with TM9) are all localized extracellularly or 
luminally. See text for details and references.  
 
Besides in mammalian cells, orthologues of NPC1 were identified in the yeast 
Saccharomyces cerevisiae, the nematode Caenorhabditis elegans and the fruit fly 
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Drosophila melanogaster, where they all seem to be involved in trafficking of lipids 
and derivatives (77,78). 
The closest homolog of NPC1 is NPC1 like protein 1 (NPC1L1). The localization of 
murine NPC1L1 and drosophila NPC1b is restricted to the plasma membrane (PM) of 
small intestine. Human and primate NPC1L1 is found in the PM of small intestine and 
the liver. They accomplish the absorption of food administered cholesterol and can be 
specifically inhibited by the anti-hyperlipidemic drug ezetimibe (79-81). 
The transmembrane helices 3 to 7 of NPC1 bear sequence homology to a sterol 
sensing domain (SSD) found in other RND proteins like the sterol regulatory element 
binding protein (SREBP) cleavage activating protein (Scap), the HMG-CoA reductase 
and Patched (Ptc) (Figure 3) (70,82). However, binding of cholesterol by the SSD 
was only shown for Scap (83,84). 
Scap is predicted to have eight transmembrane helices, from which TM2 to 6 form the 
SSD (85-87) (Figure 3). Scap and SREBP are present as a complex in the membrane 
of the endoplasmatic reticulum (ER). When the cell is deprived of sterols, the 
Scap/SREBP complex is moved via COPII-coated vesicles to the Golgi apparatus. 
There, SREBP is cleaved by the proteases S1P and S2P, releasing the soluble N-
terminus. Processed SREBP enters the nucleus and acts as a transcription factor by 
binding to the sterol regulatory element (SRE), which promotes transcription of genes 
involved in cholesterol uptake (for example low-density lipoprotein (LDL) receptors) 
and biosynthesis (for example HMG-CoA reductase). In the presence of cholesterol, 
the SSD of Scap binds to the transmembrane protein Insig (88,89), which inhibits 
movement of the Scap/SREBP complex to the Golgi apparatus and processing of 
nuclear SREBP (90,91). 
HMG-CoA reductase resides in the membrane of the ER and is the rate controlling 
enzyme in the mevalonate pathway, with cholesterol and other isoprenoids as 
products. Since both substrate (HMG-CoA) and product (mevalonic acid) of the 
reaction catalyzed by HMG-CoA reductase are water soluble, the reason for 
membrane attachment appears to be purely regulatory (92). HMG-CoA reductase has 
seven (93) or eight (94) transmembrane helices, TM2 to 6 form the SSD (85,87,94,95) 
and the catalytic activity is restricted to the cytosolic C-terminus (93). Upon 
accumulation of cholesterol and its precursors, HMG-CoA reductase binds to Insig, is 
then targeted for ubiquitinylation and subsequently degraded by the proteasome (96).  
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The Patched (Ptc) protein is located at the plasma membrane, where it acts as a 
receptor for the morphogenetic signaling peptide Hedgehog (Hh) (reviewed in 
(97,98). Ptc has twelve predicted transmembrane helices, the SSD is formed by TM2 
to TM6 (85,99) (Figure 3). Interestingly, oxysterol derivatives have been suggested to 
influence Ptc activity (100). When Hh is absent, Ptc catalytically inhibits activity of 
its target protein Smoothened (Smo) (60). In the presence of Hh, Smo starts a 
complex signaling cascade ultimately leading to activation of the Ci/GLI family of 
transcription factors (101-103), which control morphogenesis of a variety of tissues 
and organs (97) and proliferation of stem cells in adult tissues (104). 
 
2.4 Tripartite MFP/RND/OMF complexes 
 
The inner membrane located proteobacterial RND proteins associate with two 
accessory proteins for their function in vivo, namely the periplasmic membrane fusion 
proteins (MFPs) and the outer membrane factors (OMFs). They form a tripartite 
complex which allows the effective transport from the outer leaflet of the inner 
membrane directly into the medium (Figure 4). The E. coli genome codes for four 
MFPs (AcrA, AcrE (EnvC), MdtE (YhiU), MdtA (YegM)) and six RNDs (AcrB, 
AcrD, AcrF (EnvD), MdtF (YhiV), MdtB (YegN), MdtC (YegO), MdtBC). Most of 
the MFP and RND components are encoded on the same operon, whereas acrD is 
found isolated on the chromosome. TolC is the only OMF in E. coli, whereas in P. 
aeruginosa, there are five OMFs for nine MFPs and eight RNDs3. Systematic deletion 
of seven known and nine predicted MDR transporters in E. coli demonstrated that the 
tripartite AcrA/AcrB/TolC efflux system is solely responsible for the observed 
intrinsic antibiotic resistance of E. coli wild-type (wt) strains (105). The 
AcrA/AcrB/TolC system is constitutively expressed at a low level. For the other E. 
coli MFP/RND/OMF complexes, increased resistance towards some toxic compounds 
was only detected when the proteins were overexpressed (106). 
                                                 
3 These make up the following tripartite systems: MexA/MexB/OprM, MexC/MexD/OprJ, 
MexE/MexF/OprN, MexX/MexY/OprM, MexJ/MexK/OprM, MexH/I/OpmD, MexV/MexW/OprM, 
TriA/TriB/TriC/OpmH. 
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Figure 4: Schematic representation of tripartite MFP/RND/OMF multidrug efflux system in 
proteobacteria. For proper function in vivo, all three component are needed. The RND protein resides 
in the inner membrane and is the energy module and the substrate specificity determinant coupling the 
influx of protons to the export of noxious compounds. Whether the substrate is garnered from the 
cytoplasm, the inner membrane or the periplasm may depend on the transporter and the chemical 
properties of the substrate. Suggestions for MFP:RND ratio varies between one and four. The 
drug:proton stoichiometry is as yet unknown (based on the original drawing of Andrea Eberle). 
 
2.5 Outer membrane factors (OMFs) - TolC 
 
The tolC locus in E. coli was identified via a mutation causing a phenotype that was 
resistant against the colicin family of bacteriocins (tolerance to Colicins) (107), 
suggesting that TolC acts as an entry pore. Furthermore, TolC deficient strains were 
shown to be highly susceptible to bile salts and dyes. TolC belongs to the family of 
OMF (TC #1.B.17), which spans the outer membrane and protrudes into the 
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periplasm in proteobacteria putatively allowing transport from the periplasm into the 
medium and vice versa.  
TolC is known to interact with other proteins located in the periplasm and inner 
membrane and behaves very promiscuous. In addition to the formation of complexes 
with the RND proteins and the MFPs mentioned above, it has been shown to also 
form complexes with the type I secretion system HlyBD, the primary active (ABC-
type) MDR MacAB and the MFS member EmrAB (108). 
Structures of OMFs of E. coli (TolC) (109), P. aeruginosa (OprM) (110) and Vibirio 
cholerae (VceC) (111) have been solved by X-ray crystallography. OMFs are 
homotrimeric proteins spanning the outer membrane and protruding 100 Å into the 
periplasm. The proteins display a β-sheet domain forming a β-barrel, a periplasmic α-
helical domain, and an equatorial domain. In the β-sheet domain, twelve β-sheets 
form a pore that is inserted into the outer membrane. The equatorial domain divides 
the periplasmic α-helical domain into two sections of approximately equal lengths: an 
outer membrane proximal subdomain in which twelve helices pack to form a hollow 
cylinder, and a distal subdomain where twelve helices form conventional coiled coils. 
Recent crystallographic structures of TolC in space groups lacking threefold 
symmetry revealed that by modulating the curvature of the coiled coils, TolC can 
switch between the open and closed state in a fashion that is reminiscent of the iris 
mechanism of a camera (112) (Figure 5).  
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Figure 5: Crystal structure of TolC. A) Side view of trimeric TolC. The β-barrel domain, which resides 
in the outer membrane, and the two periplasmic α-helical and equatorial domains are depicted. B) and 
C) Top view of the proximal end TolC of the closed (B) and the (partially) open (C) state. Pictures 
were made using pdb coordinate files 1EK9 for (A) and (B) and 2VDD for (C), respectively. 
 
The diameter of the closing aperture varies from 8.5 Å in the closed conformation 
(pdb-ID: 1EK9, (109)) to 20 Å in the open conformation (pdb-ID: 2VDD, (112)). 
Opening and closing of the channel was already suggested by Thanabalu et al., who 
observed that TolC in the HlyB/HlyD/TolC complex is more susceptible to 
proteolytic cleavage when the substrate HlyA was present, implying a substrate 
induced conformational change (113). The opening mechanism of TolC was further 
analyzed by disruption of salt bridges and hydrogen bonds at the very distal ends 
between the coiled coils (114). As a result, TolC was locked in constitutively open 
state, allowing passive influx of the large antibiotic vancomycin (112,115). 
Furthermore, conductance was increased when single channels composed of this 
particular open TolC mutant protein were integrated in black lipid membranes, 
whereas HlyA export and thus assembly with the ABC transporter HlyB and the MFP 
HlyD was unaffected (114). 
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2.6 Membrane Fusion Proteins (MFPs) - AcrA 
 
The membrane fusion protein (MFP, TC #8.A.1.) family was given its name because 
its members are homologous to the paramyxovirus membrane fusion protein involved 
in fusion of the viral envelope and the cell membrane (116). Similarly, MFPs were 
thought to fuse the outer and the inner membrane in proteobacteria, possibly by 
bridging the inner membrane protein with the outer membrane factor (65,116-118). 
This perception has been changed over the years, as more structural information on in 
particular the MFP proteins AcrA and MexA became available. 
The structures of E. coli MFP AcrA and P. aeruginosa MexA have been solved 
(110,119-121). For AcrA deletion of amino acids 313 to 397 was essential to obtain 
crystals (119). The first two MexA structures did not include the N-terminal 27 (120) 
and 24 (110) amino acids and a long C-terminal stretch stretch (283 to 383 (120) and 
302 to 383 (110) in unprocessed MexA, respectively) due to disorder in the crystal 
structure. Very recently, Symmons et al. revealed the missing structural information 
by further analysis of the crystallographic data and averaging of the rigid body 
movement in MexA. MexA and supposedly also AcrA are composed of a β-barrel 
domain, a lipoyl domain, an α-helical hairpin domain and a membrane proximal (MP) 
domain (121) (Figure 6). The N-terminal signal sequence (amino acids 1 to 24) is 
responsible for the translocation of AcrA and MexA into the periplasm and is 
subsequently cleaved producing the mature protein (25 to 397 and 24 to 383 for AcrA 
and MexA, respectively). Both AcrA and MexA are attached to the inner membrane 
via a lipid (palmitoyl-) anchor, which is post-translationally coupled to Cys25 and 
Cys24, respectively. However, since mutants coding for soluble, non-palmitoylated 
AcrA and MexA exhibit a normal resistance phenotype (118,122), the lipid anchor 
appears not to be essential.  
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Figure 6: Crystal structure of MexA. Different domains of MexA are indicated. Due to their 
homology, the structure of the MP domain in AcrA is supposed to be similar. MexA crystallizes as a 
13-mer in which the MP domain of five monomers exhibit the orientation depicted above. In six 
momomers, the MP domain is rotated by approximately 85° along the indicated axis whereas in two 
monomers, this domain is not resolved due to disorder. Picture was made using pdb coordinate file 
2V4D. 
 
In proteobacteria, transporters of the MF-superfamily (EmrAB, (65,123); FarA, (124), 
VceA, (125)) and the ABC family form complexes with MFPs and OMFs. The MFP-
dependent ABC family includes the type I secretion transporter complexes CvaAB-
TolC and HlyBD-TolC (113,126), and the MDR transporter MacAB-TolC (106,127). 
It was shown that upon reconstitution of MacB into proteoliposomes, ATPase activity 
was strictly dependent on the presence of MacA. As Thikonova et al. stated (127), 
this stimulatory effect of MacA is reminiscent of the activity stimulation of loaded 
periplasmic ligand-binding proteins on their cognate transporters. Examples of the 
latter include the maltose- (MalE) and histidine-binding (HisJ) proteins (128). Besides 
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stimulating the ATPase activity of the transporters, periplasmic ligand-binding 
proteins are also responsible for the high-affinity binding of substrates (129,130). 
In firmicutes, the MFPs cannot have the function of connecting the inner membrane 
protein with the OMF, so their role is still elusive. Nevertheless, MFPs have been 
found to be essential factors for ABC transporters in these bacteria. The Gram 
positive MFPs appear to exist in two sizes, full length proteins and internally 
shortened proteins lacking the central 270 residue α-helical region (131). 
Additionally, experiments performed by Elkins and Krishnamoorthy suggest that in 
proteobacteria, MFPs influence substrate specificity: the E. coli MFP AcrE is able to 
substitute AcrA in AcrB-mediated transport for some antibiotics, but not for all (132). 
Similarly, mutations on AcrA affected the substrate specificity of the chimeric 
complex AcrA/MexB/TolC and hence affect growth of cells differentially: A D111N 
and S249N amino acid exchange enhanced resistance towards all drugs tested which 
can be explained by an improved interaction between the non-cognate components of 
the transport complex. Interestingly, substitution of G240 by serine showed 
unchanged MIC values for SDS and erythromycin, but a 16-fold increase towards 
nalidixic acid. A V244M exchange lowered the MIC for SDS, whereas the value for 
nalidixic acid and lincomycin was increased (133). These findings strongly suggest 
that MFPs are functionally more than just a physical linker between the inner 
membrane protein and the outer membrane factor. 
 
2.7 AcrB as a paradigm for Resistance-Nodulation-cell Division (RND) 
superfamily proteins 
 
RND proteins represent the energy module and the substrate specificity determinant 
of the tripartite RND/MFP/OMF efflux system. The most extensively studied RND 
proteins are MexB of P. aeruginosa and AcrB of E. coli. In 1965, the locus coding for 
acrA and acrB was identified (134). Upon mutation of one of these genes, 
susceptibility towards acriflavine was increased (acriflavine resistance protein A and 
B). The inner membrane protein AcrB confers resistance to a variety of chemical 
unrelated compounds. The substrate specificity of AcrB compared to the many other 
MDR proteins is staggering. It includes dyes, bile salts, organic solvents and 
antibiotics of different chemical classes; molecules that are anionic, cationic, 
zwitterionic, aromatic or just aliphatic; chemicals of bulky or planar geometry. Some 
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of the restrictive features might be the size and the hydrophobicity, since to our 
knowledge there has been no report of an AcrB substrate with a molecular weight 
larger than 1000 Da and to be more hydrophilic than logPOW* of -0.34. However, since 
export of membrane lipids and cofactors such as flavonoids is expected to be lethal 
for bacterial cells, additional criteria to discriminate between noxious compounds and 
vital cell constituents must exist, a matter of ongoing research. Like most 
proteobacterial RND proteins, AcrB consists of twelve transmembrane α-helices and 
two extensive periplasmic loops which account for approximately half of the protein’s 
1049 amino acids. The loops connect TM1 with TM2 and TM7 with TM8, 
respectively. The topology of the transmembrane domain – five-plus-one-
transmembrane helices, repeated twice – is also referred to as RND signature (135). 
The repetition of the motif suggests that RND transporters arose as a result of an 
intragenic tandem duplication event (136,137). Indeed, the archaeal RND transporter 
MJ1562 from Methanococcus jannaschii codes for a protein comprising only 372 
amino acids, corresponding to six TMs and one extensive extracellular loop that 
connects TM1 with TM2. Moreover, MexB from P. aeruginosa remains active when 
its N- and C-terminal halves are expressed as two separate proteins (138). 
It appears that the substrate specificity determination is residing in the periplasmic 
loops, which was shown by designing chimeric proteins. Specifically, the two 
extracellular loops of AcrD were replaced by the periplasmic loops of AcrB (139). 
The resulting transporter exhibited a resistance pattern that was typical for AcrB. 
Conversely, when the periplasmic loops of AcrB were replaced by the corresponding 
domains of AcrD, the chimeric protein lost the ability to confer resistance towards 
substrates of AcrB, but the resistance towards aminoglycosides – which are substrates 
of AcrD – was enhanced. 
Domain swapping experiments between MexB and MexY led to similar results (140). 
Here, the periplasmic loops of MexB were combined with the transmembrane domain 
of MexY. Again, the resulting protein conferred resistance towards typical MexB 
substrates, while the cells where susceptible towards MexY specific drugs. 
Additional evidence on the role of the periplasmic domain in substrate specificity 
determination came from a study where six single site mutations causing altered 
substrate specificity were all found to be located on the extracellular loops (141). 
                                                 
4 P is the partition coefficient of a given solvent in an equimolar octanol-water mixture. logPOW of -0.3 
is the experimental partition coefficient of tetracycline (http://www.drugbank.ca/) 
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Crystallographic studies provided further insights on the role of the periplasmic loops 
in substrate recognition and transport (40,41,142). 
 
 
Figure 7: Side view of trimeric AcrB. The monomers are colored in different shades of blue. A) Three 
pore helices located in the central part of the porter domain separate the funnel from the central cavity. 
The different domains are indicated. B) The central cavity is accessible to solvent via vestibules formed 
at the interface of two monomers. Pictures were made using the pdb coordinate file 1IWG. 
 
The first AcrB structure ((143), PDB entry: 1IWG) was based on 3.5 Å X-ray 
diffraction data from crystals containing one unliganded AcrB monomer in the 
asymmetric unit. The trimer therefore contains due to the crystallographic symmetry 
three monomers with exactly the same conformation. Each monomer includes a 
transmembrane domain with twelve TM helices which form a bundle with two central 
helices (TM4 and TM10) in its topological core. On these central α-helices, three 
titratable residues, the D407/D408/K940 triad, were found to be essential for protein 
function (144-146) (Figure 8).  
The periplasmic part – formed by the periplasmic loops described above - extends 70 
Å into the periplasm. It can be further divided into a TolC docking domain which is 
most distal from the membrane plane and a porter domain, formerly known as pore 
domain (Figure 7).  
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Figure 8: Transmembrane domain of trimeric AcrB viewed from the periplasm. D407, D408 and 
K940, three of the four essential charged residues (the fourth being R971 on TM11) of the 
transmembrane domain are depicted. They are located on TM4 and TM10, which are surrounded by 
the remaining helices of the monomer and are referred to as triad. Picture was made using pdb 
coordinate files 1IWG. 
 
The TolC-docking domain is the expected interaction site of the outer membrane 
channel TolC (112,147-149). The TolC docking domain of each monomer 
furthermore exhibits a hairpin-like loop that protrudes into the neighboring monomer, 
which appears to be the main stabilizing factor for the trimeric AcrB complex.  
The porter domain is divided in subdomains PN1, PN2, PC1 and PC2, which are 
coupled by sequential proximity (PN1-PN2, PC1-PC2) or by sharing β-strands to 
form common β-sheets (PN2-PC1, PC2-PN1). The PN1 subdomains are located in the 
centre of the trimer, surrounded by the PN2, PC1 and PC2 subdomains towards the 
periphery. Between the PC1 and PC2 subdomains a cleft is apparent which is 
approximately perpendicular to the membrane plane. In the centre of the trimer, the 
TolC docking domain exhibits a funnel-like structure narrowing to a central pore, 
defined by α-helices (designated pore helices) of the PN1 subdomains of each 
monomer. This pore has a small diameter and therefore does not allow drug passage 
in this conformation (Figure 9). Towards the membrane plane, the central pore leads 
to a central cavity and further to a 30 to 35 Å wide, presumably lipid-filled 
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transmembrane hole defined by the ring-like arrangement of the TM helices of the 
trimer (Figure 8). Three vestibules at the monomer interface located just above the 
membrane plane lead towards the central cavity. It is postulated that substrate might 
access the central cavity via these vestibules (143) (Figure 7). Indeed, there have 
been several reports on AcrB/substrate co-crystals with positive densities in the 
electron density maps derived from (symmetric) R32 crystals that have been 
interpreted as substrate molecules bound to the inner wall of the AcrB central cavity. 
(150-154). From there, large synchronous conformational rearrangements were 
suggested to occur in order to open the central pore, through which substrate would be 
transported into the funnel (153). This mode of action was called elevator mechanism 
since substrate was envisioned to be lifted perpendicular to the membrane plane 
directly from the central cavity via TolC into the media. 
 
Figure 9: Porter domain of trimeric AcrB. A) The porter domain viewed from the periplasm. The PN1, 
PN2, PC1 and PC2 subdomains are indicated. Three α-helices donated by the PN1 domain of each 
monomer define the central pore. At the periphery, a cleft is formed at the interface of the PC1 and 
PC2 subdomains. B) Side view of trimeric AcrB. Pictures were made using pdb coordinate files 1IWG. 
 
In 2006, three groups independently published an asymmetric structure of AcrB 
grown in the monoclinic space group C2 (40,41,142) (2.8 to 2.9 Å), the triclinic space 
group P1 (41) (3.0 Å) and an AcrB structure including bound designed ankyrin repeat 
proteins (DARPins) grown in the orthorhombic space group P212121 (142) (2.5 Å). 
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The DARPin bound AcrB structure was almost identical to the AcrB structures 
crystallized without binder with root mean square deviation (rmsd) of the 
superimposed trimeric structures ≤ 1 Å. The DARPin molecules only bind to the loose 
and the tight conformers, resulting in a ratio of two DARPin molecules per AcrB 
trimer. This stoichiometry was verified by sedimentation velocity experiments, 
suggesting that in solution and probably also in vivo AcrB adopts mainly the 
asymmetric conformation (142). 
 
Within the AcrB trimer, each monomer has a different conformation denoted as loose, 
tight and open (access, binding and extrusion, respectively) (40,41), while the loose 
state is closest to the conformation of the monomers in the symmetric structure (143).  
Compared to the conformation of the symmetric structure, the tight protomer has an 
up-shifted PN1 subdomain, the transmembrane helices are elevated up to 3 Å towards 
the periplasmic part and at the interface of the PN2/PC1 subdomains, a hydrophobic 
pocket is present that is not apparent in the other two conformers (Figure 12). 
Hallmarks of the open monomer are a coil-to-helix transition at the N-terminal part of 
TM8, tilting of the PN1 subdomain including the pore helices towards the 
neighbouring protomer and the PC2 subdomain approaching the membrane plane by 
6.5 Å (Figure 10). Although the pore helices are differently oriented in the 
asymmetric structure as compared to the symmetric structure, the pore diameter is 
similar and hence there does not appear to be an opening of the central pore. Instead, 
conformer specific cavities and tunnels could be identified in the porter domain. In the 
loose conformer, a tunnel (tunnel 2) starts in the PC1/PC2 subdomain cleft 
approximately 15 Å above the membrane plane and protrudes in the direction of the 
pore. In the tight conformer, an additional tunnel (tunnel 1) with an entrance situated 
in a groove formed by TM8 and TM9 at the height of the membrane plane is apparent 
(Figure 11). 
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Figure 10: Main structural differences between the AcrB monomers loose, tight (both in light blue) 
and open (red). A) Side view of the proton relay. In the loose and tight state, D408 and D407 sandwich 
K940 and R971 is oriented towards the triad. The polar side chains of D407, D408, K940 and T978 are 
forming a continuous hydrogen bonded network. Upon transition to the open state, this network gets 
disrupted: K940 bends towards T978 and D407 reorients towards the periplasm. Additionally, R971 
relocates in the direction of the cytoplasm. B) During the transition from tight to open state, there is a 
coil-to-helix transition at the N-terminal end of TM8. As a consequence, the PC2 subdomain is 
repositioned and approaches the membrane plane by 6.5 Å. The N-terminal end of helix 8 and the C-
terminal β-strand of the PC2 subdomain are shown. C) Top view of the triad from the cytoplasm. In 
addition to the drastic reorientation of K940 (as discussed in (A)), a bulging of TM5 towards TM4 and 
TM10 can be observed. The open and the loose monomer are colored in red and blue, respectively. The 
corresponding structural details of the tight momomer are very similar to the loose monomer. The 
pictures were generated by superimposition of the loose and the open monomer. The pdb coordinate 
file 2GIF was used for figures A) and B), and 2J8S for figure C). 
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Due to reorientation of the PN2 subdomain in the tight monomer, a hydrophobic 
pocket at the interface of PN2 and PC1 subdomains is created. This pocket is situated 
close to the end of the tunnel in the tight conformer (defined by the PN1 subdomain of 
the adjacent open monomer) and is rich in aromatic amino acids, a feature that is often 
observed for binding pockets of MDR proteins (39,155-157) (Figure 12). Indeed, 
Murakami et al. detected electron densities for the AcrB substrates minocycline and 
doxorubicin in the hydrophobic pocket. By using a brominated derivative of the 
former compound (9-bromo-minocycline), they unambiguously could assign the 
position of this substrate within the binding pocket (40) due to the anomalous signal 
produced by the bromine atom in the X-ray diffraction experiment. 
 
 
Figure 11: Visualization of tunnels in the porter domain of the different monomers. A) In the loose 
monomer, tunnel 2 leads from the entry situated in the cleft about 15 Å above the membrane plane 
towards the centre of the periplasmic porter domain. B) An additional tunnel (tunnel 1) is apparent in 
the tight conformer. This tunnel starts at the height of the membrane plane and joins tunnel 2 near the 
binding pocket, which is open in the tight conformer. C) Due to dramatic reorientation of the 
subdomains and the coil-to-helix transition at the N-terminal end of TM8, both lateral tunnels are 
closed in the open conformer. Instead there is a new tunnel (tunnel 3) which leads from the collapsed 
binding pocket to the funnel in the centre of trimer. The figures were made using pdb coordinate file 
2J8S. Tunnels were calculated by the program Mole (158). 
 
In the open monomer, the lateral periplasmic entrance of the tunnels observed in the 
loose and tight conformations are closed due to the coil-to-helix transition of TM8, 
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whereas another tunnel (tunnel 3) is created due to tilting of the pore helix (PN1 
subdomain). The latter tunnel leads from the now collapsed binding pocket to the 
funnel located in the centre of the AcrB trimer.  
 
Figure 12: Binding pocket in different monomers of the AcrB trimer. At the interface of the 
subdomains PN2 and PC1, a hydrophobic binding pocket is located close to the end of tunnel 1 and 2. 
The binding pocket is open only in the tight monomer. Picture was made by using pdb coordinate file 
2GIF. 
 
Substrate transport by AcrB was postulated to be accomplished via functional rotation 
in which each monomer changes its conformation in a concerted fashion (40,41). One 
transport hypothesis assumes the substrate to be garnered from the outer leaflet of the 
inner membrane. It might enter the loose monomer via the TM8/TM9 groove or via 
tunnel 2 approximately 15 Å above the membrane plane. While it is not clear how 
hydrophobic compounds might enter tunnel 2 once these have been partitioned in the 
inner membrane, several groups provided structural data of symmetric AcrB (where 
all the monomers adopt the loose conformation) based on 3.2-3.8 Å data with 
presumably bound AcrB substrates in the tunnel 2 region (151,159). High resolution 
(2.5 Å) data describing the asymmetric trimer show clear densities in the TM8/TM9 
groove of the loose monomer, which has been attributed to the highly concentrated 
detergent and AcrB substrate n-dodecyl-β-D-maltoside (142). Upon conformational 
change from the loose to the tight state, tunnel 1 appears and might provide one of the 
pathways for substrates towards the hydrophobic pocket which accommodates the 
substrate molecule. Structural flexibility within the trimer (160,161) suggests that the 
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loose and even tight conformational states might be adoptable in the absence of 
substrates and that substrate binding to the hydrophobic pocket specifically stabilizes 
the tight conformation. This might also present an alternative role for tunnel 2 in these 
conformations as an exit pathway for compounds which are not substrates of the 
pump (Figure 11). In analogy with the binding change mechanism (162), the 
conversion of the tight monomer to the open monomer is energy consuming and 
subject to bi-site activation i.e. only occurs upon binding of substrate to the 
neighboring monomer (163). 
Upon transition from the tight to the open state, the binding pocket closes again; 
substrate is squeezed out and follows a newly formed tunnel (tunnel 3) to the funnel, 
and is from there finally extruded into the media via TolC. 
In summary, upon conformational change from loose to tight to open and back to 
loose, an alternating access tunnel is formed through which substrates are transported 
from the outer leaflet of the inner-membrane towards the outside medium. The mode 
of action is suggested to be based on occlusions migrating from the lateral entrance(s) 
to the central funnel and is reminiscent of a peristaltic pump. 
To test the proposed conformational cycling in vivo, subdomains that undergo 
substantial rearrangement during cycling were locked by the introduction of disulfide 
bonds (160,161). As could be demonstrated by tracing the efflux of a fluorescent 
substrate, formation of disulfide bonds significantly decreased AcrB mediated 
transport. When the disulfide bonds were broken by the addition of the reducing 
reagent dithiothreitol (DTT), transport activity was restored, which was in strong 
support of the functional rotation mechanism (160). Even more convincing, Takatsuka 
and Nikaido designed a functional covalently linked AcrB trimer, which could be 
inactivated by the introduction of a mutation in the proton relay network (D407A) or 
by disulfide formation in only one of the protomers (164). These results are in 
accordance with the proposed functional rotation mechanism. 
As a secondary active transporter, AcrB couples the efflux of substrate to the influx of 
protons from the periplasm to the cytoplasm. Besides the four essential charged 
residues D407, D408, K940 and R971, T978 is also thought to be involved in 
mediating passage of the proton through the transmembrane domain (145). Therefore, 
these five residues are denoted as proton relay. Indeed, the observed alterations in the 
orientation of these residues in the different states of the functional rotation might be 
indicative for protonation and deprotonation events: K940 is sandwiched between 
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D407 and D408 in the loose and tight states, but gets reoriented towards T978 in the 
open state; R971 is oriented towards D407 in the loose and tight state, but points in 
the cytoplasmic direction in the open monomer; D407 is oriented towards the 
cytoplasm in the loose and tight state, but bends towards the periplasm in the open 
state. Furthermore, the N-terminal end of TM8 in the loose and tight monomers is 
marked by Pro874, but gets elongated by four full turns in the open monomer and a 
bulging of TM5 towards TM4 and TM10 in the open conformation can be observed. 
How these conformational changes are levered to the porter domain and cause the 
large conformational changes observed there is subject to ongoing research. 
 
 
2.8 Tripartite AcrA/AcrB/TolC complex 
 
To date, there is no structure of the complete assembled AcrA/AcrB/TolC complex or 
of its homologues available. However, models have been described on the interaction 
between the components of the tripartite complex which are based on biochemical 
studies including co-purification, crosslink studies, the design of chimeric proteins, 
isothermal titration calorimetry (ITC) and crystallographic structure-driven in silico 
docking. 
In one study, the interaction between the components of the tripartite 
MexA/MexB/OprM complex in P. aeruginosa was analyzed by a pull-down assay 
tagging only one of the subunits (165). In the presence of all three components, 
MexA, MexB and OprM could be co-purified independent of which subunit was 
tagged, suggesting tight association of the components in the trimeric complex. 
Additionally the bi-partite MFP/OMF complex MexA/OprM could be co-purified in 
the absence of MexB (165), whereas co-purification of the bi-partite RND/MFP and 
RND/OMF complexes failed. In another study the physical proximity between AcrA 
and AcrB in absence of TolC (149,166,167) and between AcrB and TolC in absence 
of AcrA (148,166) was shown in vivo by using the crosslinker 
dithio(succinimidylpropionate) (DSP). Physical interaction between AcrA and TolC 
as well as between AcrA and AcrB was demonstrated by ITC, whereas there appeared 
to be no measurable interaction between AcrB and TolC (166). 
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To locate the interaction sites of the MFP MexE with its cognate RND and OMF, a 
chimeric MexE/MexA fusion protein was designed where the α-helical hairpin 
domain originated from MexA (168). This mosaic protein could be shown to form a 
functional complex with MexF and OprM, the cognate OMF of MexA, but lost its 
ability to interact with OprN, the cognate OMF of MexE. Similarly, the complex 
AcrA/AcrB/OprM is functional when the α-helical hairpin domain of AcrA is 
replaced by the corresponding domain of MexA (169). 
 
Figure 13: Interaction surface between TolC and AcrA. Four single cysteine mutants of TolC could be 
cross-linked to wt AcrA by using bi-functional cross-linking agents. Reciprocally, eight single cysteine 
mutants of AcrA could be cross-linked to TolC. The positions of the mutated residues are indicated 
with spheres in the wt structure of the two proteins. The monomers of trimeric TolC are colored in 
different shades of yellow. Coordinate file of TolC: 2VDD, Coordinate file of AcrA: 2F1M. 
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The interaction surface between AcrA and TolC was investigated in detail by cysteine 
scanning of both proteins (170). Crosslink experiments followed by co-purification 
revealed that AcrA contacts TolC at the outer surface of the channel between the tip 
of the closing aperture and the equatorial domain. For AcrA, residues of the helix α1 
of the α-helical hairpin domain exhibiting appropriate orientation are involved in 
contact formation (Figure 13).  
The interaction between the RND and MFP component was analyzed by construction 
of chimeric proteins, ITC and crosslink studies. Domains of AcrA were replaced by 
the corresponding domains of the AcrA paralogue YhiU, which is unable to form a 
functional complex with AcrB (132). Minimal Inhibitory Concentration (MIC) assays 
allowed to distinguish between active and non-active chimeras and revealed that 
interaction between AcrA and AcrB is mediated by the protease sensitive domain 
(119) between residues 290 and 357. This stretch roughly corresponds to the MP 
domain of MexA (121) and had to be removed in AcrA to allow crystal formation 
(110,119,120). CD spectroscopy revealed that the C-terminal part of AcrA is largely 
unordered (but not unfolded). However, ITC analysis indicated strong association 
with AcrB, whereas no interaction between the AcrB and the N-terminal half of AcrA 
could be detected (166). 
The lack of structural information on the C-terminal domain of MFPs (i.e. AcrA and 
MexA) was for long time the main obstacle in building an assembled model of a 
trimeric MFP/RNF/OMF complex. Different stoichiometric ratios between 
MFP:RND:OMF were proposed, i.e. 4:1:1 (110), 3:1:1 (120), 2:1:1 ((110,169)) and 
1:1:1 (170). The latter suggestion was found by two molecular docking approaches to 
be the only ratio that satisfies the restriction revealed by cysteine scanning 
experiments (121,170) (Figure 14). Furthermore, a leaky mutant of TolC was 
crystallized exhibiting a novel asymmetric conformation in a partly open state (112). 
In each TolC monomer, a shallow external groove extending from the closing 
aperture to the equatorial domain was identified. Since this area interacts with AcrA 
as was shown by crosslink studies (170), Bavro et al. suggested that three grooves of 
trimeric TolC accommodate one AcrA molecule each. Unlike previous suggestions, 
crosslink studies between AcrA and AcrB revealed that the contact surface of the two 
proteins is located on the PN2 subdomain of AcrB rather than in the cleft situated 
between the PC1 and PC2 subdomain. 
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Figure 14: Putative assembly of the AcrA/AcrB/TolC complex. AcrB and TolC reside in the inner and 
outer membrane of Gram-negative bacteria, respectively. AcrA (red) functions as an adapter and 
connects AcrB (blue) with TolC (yellow). A ratio of 1:1:1 of the three proteins was found to be the 
most probable stoichiometry based on two molecular docking approaches considering the results from 
cysteine crosslink studies (121,170). AcrA might control opening and closing of the distal end of TolC 
and transduce the energy generated by AcrB to the OMF. This would allow TolC to convey substrate 
unidirectionally into the outer space. 
 
Since AcrB is postulated to undergo a functional rotation (40,41,160), the interaction 
between each AcrB monomer and its affiliated AcrA molecule would be 
nonequivalent. Hence, the subtle conformational changes observed in TolC would be 
caused by induced fit interactions between AcrA and TolC. Rather than just being an 
rigid adapter, AcrA would actively transduce the energy generated by AcrB and 
induce the coordinated substrate transport through TolC. Similar to the tunnels 
observed in a single AcrB protomer during functional rotation (40,41), TolC is 
probably not a rigid hollow cylinder but changes its diameter by conformational 
change of each monomer, thereby pushing substrate unidirectionally from the closing 
aperture into the media (163,171,172). 
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2.9 Multispecificity 
 
AcrB is known to transport a plethora of structurally and functionally unrelated 
compounds. This broad substrate specificity, a common feature for MDR transporters, 
contrasts dramatically with the narrow chemical specificity of the vast majority of 
ligand-binding proteins and the tight interaction between enzymes and their cognate 
substrates. Therefore, alternative transport mechanisms as how to expel drugs from 
the cell interior without an intermediate binding step were discussed, including 
formation of discontinuities in the lipid bilayer and „slippery“ protein-lipid interfaces 
(29). 
The first structural data available for a multidrug binding protein in complex with one 
of its multiple substrate was from a truncated version of BmrR (BRC) binding 
tetraphenylphosphonium (TPP) (155). BmrR is a soluble B. subtilis regulator of the 
MerR family that activates transcription of Bmr, an MDR transporter of the MF 
superfamily (173). BmrR is known to be induced by the same chemical compounds 
that the transporter Bmr confers resistance to. Binding of substrate by BmrR was 
shown to take place in a pocket that is partly solvent-inaccessible in the apo form. 
Binding is mediated by stacking interactions with aromatic residues, van der Waals 
contacts with multiple hydrophobic side chains and neutralization of the positive 
charge by a glutamate. 
In 2001, the crystal structures of six QacR/drug complexes were published by 
Schumacher et al. (QacR in complex with rhodamine 6G (R6G), ethidium, 
dequalinium, crystal violet, malachite green and berberine, respectively) (39). QacR 
of Staphylococcus aureus regulates the transcription of the MFS transporter QacA and 
is a repressor of the TetR family (174). Like BmrR, QacR is induced by the same 
chemical compounds that its target gene (qacA) confers resistance to. QacR consists 
of nine α-helices, three of which form the DNA binding domain, the remaining six 
form a binding/dimerization domain. The structures were in agreement with the 
stoichiometry obtained by biochemical experiments of one drug molecule per QacR 
dimer. In the drug free monomer, an internal cavity of 400 Å3 was detected. Y92 
plays an essential role in formation of the protein hydrophobic core. This residue is 
located on a coil and its aromatic side chain protrudes into the pocket, filling the space 
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of the collapsed cavity together with two structured waters. In the substrate loaded 
monomer, the Y92 containing coil undergoes a coil-to-helix transition. As a result, 
Y92 is expelled from the pocket and accommodates a position towards the solvent 
region. Additional conformational rearrangements lead to a triplication of the volume 
of the cavity. These events are thought to be the trigger for the conformational 
changes in the DNA-binding domain necessary for the dissociation of the dimer from 
the DNA.  
 
 
Figure 15: R6G- and ethidium binding pocket in QacR. The two substrates R6G (yellow) and 
ethidium (blue) interact with distinct residues of the QacR binding pocket (colored orange and blue, 
respectively). The residues involved in the formation of polar, stacking and van der Waals interaction 
are depicted. The positive charge of the two substrate molecules is compensated by acidic glutamates 
E90 and E120. Picture was made by using the pdb coordinate files 1JUS (QacR/R6G) and 1JTY 
(QacR/ethidium). 
 
The monovalent substrates R6G and ethidium were found to occupy different areas 
within the binding pocket. The large internal cavity was therefore interpreted as two 
separate binding pockets, termed ethidium- and R6G pocket. They are partially 
overlapping yet distinct (Figure 15). Key residues in the R6G pocket are the aromatic 
residues W61 and Y93, in between of which R6G is stacked with the shortest 
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interatomic distance (SID) between the residues and the drug being 3.5 Å. The polar 
residues Q64, Q96 and T89 also interact with R6G, with an SID of 3.9, 3.4 and 3.9 Å, 
respectively. E90 neutralizes the positive charge of R6G, the carboxilic oxygen being 
4 Å away from the formal positive charge of R6G. The acidic residues E57 and E58 
are also part of the R6G pocket, but do not interact with the drug.  
Hallmark of the ethidium pocket are the aromatic residues Y103 and F162 which 
sandwich ethidium with an SID of 3.3 and 3.7 Å, respectively. I99 and I100 make van 
der Waals contacts with the drug (SID = 3.4 and 3.7 Å, respectively), the acidic E120 
compensates for the formal positive charge of the phenanthridinium ring (SID = 4.0 
Å) and Q96 is within hydrogen bonding distance (SID = 2.9 Å) to one of the amine 
groups of the ethidium ring system. Upon rotation of the side chain, Y123 can make 
stacking interactions with ligands bound by either the R6G- or the ethidium binding 
pocket.  
Berberine is a planar monovalent cationic drug and gets bound in the R6G pocket. 
The anthracene ring is stacked in between W61 and Y93 with an SID of 3.6 and 3.1 
Å, respectively. The positive charge gets compensated by E57 and E58 (SID = 5.6 
and 4.9 Å, respectively). At the other end of the drug molecule, Y123 undergoes 
stacking interactions (SID = 3.4 Å) and N157 is within hydrogen bonding distance 
(SID = 3.1 Å) to the dioxolane ring. 
The bivalent substrate dequanilium consists of two positively charged 
aminomehtylquinolinium groups that are linked by a 20.6 Å long decamethylene 
linker. Consequently, this molecule spans the entire internal cavity and its two 
positive charges are neutralized by glutamates of both the ethidium- and the R6G 
pockets. Crystal violet and malachite green, two molecules with propeller-like 
geometry, are bound in between the two pockets. Hence, QacR is flexible enough to 
bind mono- and bivalent cationic drugs and can cope with planar chemicals as well as 
with bulky propeller-like substances (Figure 19).  
In 2004, Schumacher et al. published the structure of the binary complex 
QacR/proflavine and the ternary complex QacR/ethidium/proflavine. Additionally, 
the binding affinities of QacR for ethidium and proflavine were determined to be 42 ± 
11 and 186 ± 25 µM (156).When both substrates were added simultaneously, the 
binding affinity for proflavine was not affected (KD = 35 ± 4 µM) whereas the affinity 
for ethidium decreased (KD = approx. 1000  µM). This observation was reflected by 
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comparing the crystal structure of the ternary QacR/ethidium/proflavine complex with 
the corresponding binary complexes: whereas proflavine maintained its location in the 
R6G binding pocket, the position of ethidium was shifted but still accomplished by 
the same residues.  
 
 
Figure 16: Different orientations of ethidium in the QacR binding pocket. Compared to the binary 
QacR/ethidium structure, the position of ethidium in the ternary QacR/ethidium/proflavine complex is 
rotated by approximately 15° along the axis perpendicular to the ring system of ethidium. In this new 
position, ethidium is engaged in favorable van der Waals interactions with the second substrate 
proflavine. Ethidium and proflavine  of the ternary complex are colored green and yellow, respectively. 
The binary complex is shown in white. Picture was made using pdb coordinate files 1QVU 
(QacR/ethidium/proflavine) and 1JTY (QacR/ethidium). 
 
The interatomic distances between ethidium and the binding pocket residues Q96, 
I100, Y103 and F162 remained constant within ± 0.2 Å, whereas the distance between 
ethidium and I99 was elongated for 0.8 Å. Y123, which was shown to be involved in 
binding of proflavine and ethidium in the binary complexes, adopted the conformation 
observed for the QacR/proflavine binary complex. In this position, it can still form 
stacking interactions with ethidium. However, the distance between the positive 
charge of ethidium and the neutralizing E120 was elongated from 4.0 Å to 5.0 Å. 
Thus, most stacking interactions were maintained, probably at the expense of the 
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charge-charge interaction. Furthermore, comparison of the ternary and binary 
complexes demonstrated that by rotation of aromatic side chain residues along their 
Cα-Cβ bonds,  substrate can slide inside the pocket while the stacking interactions are 
maintained (Figure 16). 
 
In the same year, Murray et al. (157) published the structure of QacR in complex with 
the bivalent substrates hexamidine and pentamidine. As dequalinium, they belong to 
the chemical class of diamidines, but differ in the length of the alkyl chain linker 
(Figure 19). Hexamidine binds to QacR in a manner similar to dequalinium, spanning 
both the R6G- and ethidium pocket and involving a similar set of binding residues. In 
contrast, pentamidine is twisted and oriented inside the QacR binding pockets in a 
novel fashion. One benzamidine moiety resides in the R6G pocket, and the charge is 
neutralized by E63 outside the common binding pocket. The other benzamidine ring 
protrudes into the core of the protein, interacting with residues which so far were not 
accounted to be part of the binding pocket.  
 
Figure 17: Location of pentamidine in the binding pocket. Pentamidine is twisted inside the QacR 
binding pocket and one benzamidine ring interacts with residues that neither belong to the R6G- nor 
the ethidium binding pocket. Remarkably, the positive charge of this moiety is compensated by 
negative dipoles of polar residues and by cation-π interaction rather than by a formal negative charge. 
Pentamidine is shown in pink. For comparison, R6G and ethidium are shown in yellow and blue, 
respectively. Picture was made by using the pdb coordinate files 1RKW (QacR/pentamidine), 1JUS 
(QacR/R6G) and 1JTY (QacR/ethidium). 
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Strikingly, the positive charge of the fully buried benzamidine moiety inside this 
pocket is not compensated by a formal negative charge, but rather by the two negative 
dipoles of the hydroxyl oxygens of Y127 and S86, the carboxamide oxygen of N157, 
the carbonyl oxygen of A153 and a cation-π interaction with Y82 (Figure 17).  
 
Although E58 compensates the positive charge of berberine in the QacR/berberine 
structure (39), substitution of E57 or/and E58 in the multidrug binding pocket of 
QacR counterintuitively increased the binding affinity of QacR for this cationic drug 
(KD of wt QacR, QacR_E57Q, QacR_E58Q and QacR_E57Q_E58Q = 2.86 ± 0.62, 
1.39 ± 0.15, 0.72 ± 0.08 and 0.32 ± 0.15 µM) (175). The single mutant QacR_E58Q 
was amenable for crystallization studies and revealed another binding mode for 
berberine: rather than neutralization of the positive charge of berberine by 
reorientation of nearby acidic E57, the drug rotates 180° along its long axis (Figure 
18).  
 
Figure 18: Different location of berberine in the binding pocket of wt and E58N mutant QacR. 
Compared to the position in the wt protein, berberine is rotate 180° along its long axis in the binding 
pocket of the QacR_E58N mutant protein. The QacR/berberine complex is shown in cyan and green, 
respectively. For comparison, the QacR_E58N/berberine complex is shown in white. Picture was made 
by using the pdb coordinate files 3BTI (QacR_E58N/berberine) and 1JUM (wt QacR/berberine). 
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In this position, the charge at the pyridinium nitrogen gets compensated by the 
hydroxyl side chain of S86 (interatomic distance 3.8 Å) and by improved cation-π 
interactions of the entire molecule with W61 and Y123 (Figure 18). 
The crystal structures of QacR/drug complexes impressively demonstrated enormous 
flexibility in ligand binding which might be exemplary for all MDR proteins. So far, 
densities of ten different compounds could be shown to bind in the extensive QacR 
binding pocket. The substrates differ in their chemical structure (planar vs. propeller-
like) as well as in their valence (no charge vs. trivalent) (Figure 19). A key feature for 
the vast plasticity of binding pockets of MDR proteins seems to be chemical 
redundancy. This allows a bound ligand to be shifted or rotated upon binding of 
additional substrate molecules or mutation of an alleged essential residue. It also may 
account for the fact that MDR proteins can bind to and transport substrates that the 
organism has never been exposed to before. 
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Figure 19: Co-crystallized substrates of QacR. At the moment of writing, QacR was crystallized in the 
presence of the ten substrates shown above. Note the different valence and geometry of these drugs. 
CGQ: 3-[C-[N'-(3-carbamimidoyl-benzylidenium)-hydrazino]-[[aminomethylidene]aminium]-
iminomethyl]-benzamidium. 
 
 
2.10 Proton translocation 
 
AcrB utilizes the proton motive force to energize the extrusion of its cognate 
substrates from the cell into the medium (28,176,177). The transmembrane domain of 
AcrB harbors four functionally essential charged residues that are conserved 
throughout the HAE1 family: D407, D408, K940, and R971 (145,146,178). Another 
highly conserved transmembrane residue, T978, is in hydrogen bonding distance from 
D407 in the loose and tight monomer and with K940 in the open monomer. However, 
when T978 was replaced by valine, isoleucin, leucine or asparagine, the relative 
2. Introduction 
45 
 
activity of these mutants remained 40 to 60% as revealed by drug susceptibility assays 
(145).  
 
Figure 20: Analogy between the active center of bacteriorhodopsin (BR) and the proton relay of AcrB. 
A) In the ground state of BR, the ε-amino group of K216 (nitrogen atom of the protonated Schiff-
base) is located between D212, D85 and in vicinity to T89. Arg82 is located in the hydrated 
extracellular halfchannel downstream of the proton translocation pathway close to the membrane-
extracellular interface. Upon photoisomerisation of the retinal chromophore, the Schiff base becomes 
deprotonated and the NZ vector bends away from the aspartates. In the M phase of the photocycle, 
R82 is reoriented away from the Schiff-base towards the membrane-extracellular interface. B) In a 
similar way to K216 in BR, K940 of AcrB is situated between D407 and D408 in the loose and tight 
state. Protonation and deprotonation events are thought to cause reoriention of K940 towards T978. In 
analogy to R82 in BR, R971 in AcrB is located in a half-channel close to the membrane-water 
interface. R971 is oriented towards the proton relay in the tight state and towards the cytoplasm in the 
loose and tight state. Picture was made using pdb coordinate file 1M0L for BR and unpublished 
structure for AcrB, respectively. 
 
In the asymmetric structure of AcrB, the four above mentioned essential residues 
D407, D408 K940 and R971 have distinct different conformations in at least one of 
the three conformers loose, tight and open (40,41) (Figure 10). Mutagenesis and 
structure suggest that proton translocation is mediated by these titratable residues. 
Recently, D408 has been shown to be a titratable residue within AcrB with a 
measured apparent pKa of 7.4 (179). Up to date, the progression of the protonation 
and deprotonation events is speculative and awaits further examination. The active 
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center of the archeal integral membrane protein bacteriorhodopsin (BR), a light driven 
proton pump intensively studied since its discovery in the early seventies (180), is 
composed of a set of similar residues (D, K, R) as the proton relay of AcrB (Figure 
20). Additionally, these residues display an analogous geometry in both proteins. It is 
therefore tempting to look for structural and functional similarities in the proton 
transfer pathway between AcrB and the well characterized bacteriorhodopsin.  
BR is a rhodopsin-like protein found in the purple membrane of Halobacterium 
halobium. It was shown to be a light-driven proton pump that is not forming 
functional or structural complexes with other energy-transducing proteins. BR 
generates an electrochemical gradient of protons resulting in a proton motive force of 
-250 mV, which corresponds to a difference of four pH units between the intra- and 
extracellular space (181). BR has seven transmembrane domains and serves as model 
for the G-protein-coupled receptors (GPCRs). The overall architecture of BR is that of 
two half-channels, a cytoplasmic and an extracellular one, separated about in the 
middle of the membrane by the retinal chromophore. The connection between this 
prosthetic group and the K216 of the (holo) enzyme is accomplished via a Schiff base 
linkage (Figure 21). 
In the extracellular half-channel, ordered waters and side chain residues form an 
extensive hydrogen-bonded network, the dynamic properties of which were revealed 
for many steps of the pumping process by NMR, crystallographic and electron 
microscope structure analysis. 
In contrast to the extracellular half-channel, the cytoplasmic half-channel contains 
mainly hydrophobic side chain residues and lacks the defined network of ordered 
waters. Therefore, it remains elusive how the protons are transferred from the 
cytoplasmic surface to the Schiff base (Figure 21). 
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Figure 21: Crystal structure of bacteriorhodopsin in the resting state. The retinal, residues important 
for proton translocation and structured waters in the extra- and intracellular half-channel are shown. 
The helices are denoted (A-G). Y185, Y57, helix B and N-terminal part of helix C are omitted for 
clarity. Drawn from pdb coordinate file 1C3W. 
 
During the transport of a proton across the lipid bilayer, BR adopts the main 
conformational states denoted as resting state, K-, L-, M-, N- and O- states and 
numerous substates which were investigated in detail by means of fourier transform 
2. Introduction 
48 
 
infrared (182-184) and Raman spectroscopy (185,186), solution-state (187) and solid-
state (188-190) NMR, X-ray (191-194) and electron spectroscopy (195), using 
different mutants, varying pH conditions and illumination of BR at different 
wavelengths. 
The interpretation of these data has lead to a model for proton transport by BR 
(181,196,197). In brief, the energy for the pumping process of a proton against the 
proton gradient across the lipid bilayer is provided by the absorption of a photon by 
the chromophore and is initially stored in the strained 13-cis,15-anti configuration of 
the retinal in the K intermediate. As the distortion of the retinal and its protein 
surrounding gradually decreases, the energy is released and transferred in a selective 
and timed way to the protein, resulting in reorientation of key residues, repositioning 
of waters and alteration of pKa of charged residues inside the membrane. This allows 
the unidirectional transport of protons from the cytoplasm to the extracellular site.  
In the resting state (BR), retinal is present in the all-trans configuration, the NZ 
vector5 of the protonated Schiff base pointing towards the extracellular site. In the 
extracellular half-channel, the Schiff base donates a hydrogen bond to ordered water 
W402, which in turn donates a hydrogen bond to ionized D85 and D212. D85, which 
will be protonated in the first steps of subsequent states, is further hydrogen bonded 
with T89 and via two ordered waters (W401 and W406) with R82. D212, which 
seems to remain charged throughout the entire cycle, is hydrogen bonded with the 
phenolic hydroxyl group of Y185 and water W406. A second chain of hydrogen 
bonds connects D212 to R82 via Y57 and water W407 (192,198,199). Finally, E194, 
E204, S193 and four ordered waters (W403-W405, W420) complete the network of 
hydrogen bonds towards the extracellular surface (Figure 21). 
Upon absorption of a photon, the retinal isomerizes in the K (and L) state from all-
trans to a strained 13-cis,15-anti configuration, the NZ vector of the Schiff base 
gradually reorienting towards the cytoplasmic half-channel. This triggers 
deprotonation of the Schiff base and protonation of D85 during the transition from L 
to M state. The degree of distortion of the retinal as well as whether W402 is involved 
in proton transfer from the Schiff base to Asp85 is still debated (200). Protonation of 
Asp85 leads to disruption of the hydrogen-bonded network of waters in the 
extracellular half-channel, resulting in the movement of R82 toward the extracellular 
                                                 
5 the vector originating at the nucleus of the nitrogen atom pointing in the direction of the free electron 
pair and the proton in the deprotonated and protonated Schiff base, respectively 
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proton release group (E204, E194 and ordered waters) whereupon a proton is released 
at the extracellular surface (192,201,202). The biphasic titration behavior of D85 in 
non-illuminated bacteriorhodopsin indicates that the proton that is released into the 
extracellular space neither originates from D85 nor from Schiff base directly (201). It 
is rather assumed that the proton derives from a putative proton release site, probably 
a H5O2+ cluster situated around E204 and E194 (203,204).  
Reprotonation of the Schiff base during the transition from the N to O state occurs 
from the intracellular space and presumably involves the proton donor D96, which is 
situated approximately in the middle of the inner half-channel. In the resting state, 
there is no obvious pathway of the proton neither from the cytosol to D96 nor from 
D96 to the Schiff base due to a lack of polar and charged residues and the absence of 
a continuous file of waters (Figure 21). However, by illumination of a E204N BR 
mutant crystal, a late M state was simulated in which the Schiff base is deprotonated 
and D85 is protonated (1.9 Å resolution, nearly full occupancy, i.e. ≥ 93% of all 
molecules within the crystal adopted the late M state conformation). In this step of the 
photocycle, electron densities for two additional water molecules could be detected in 
the surrounding of D96. These are thought to lower the pKa of D96 due to hydration 
and partially fill the gap between D96 and the Schiff base (205). 
A similar intermediate was observed with an illuminated wt crystal diffracting to 2.25 
Å and an observed occupancy of 35% (206). An even larger chain of hydrogen 
bonded waters could be detected which extends from D96 within 5.8 Å of the Schiff 
base. 
By illumination of the mutant V49A BR crystal (diffracting to 1.62 Å), a late N 
intermediate could be obtained at 37% occupancy where both the Schiff base and D96 
are (re)protonated. This structure revealed a single-file hydrogen bonded chain of 
waters, extending from D96 to the retinal Schiff base (194). In this intermediate, 
retinal adopts a relaxed 13-cis,15-anti configuration and the NZ vector of the Schiff 
base points towards the cytoplasmic half-channel (Figure 22). 
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Figure 22: Water molecules in the cytoplasmic half channel of the bacteriorhodopsin V49A mutant. 
The inset shows the continuous file of water molecules (colored blue) between D96 and the Schiff base 
in the N state of the photocycle. The structure of the all-trans retinal of the resting state is shown in 
orange. The side chain of mutated V49 would protrude between the water molecules 505 and 506. For 
comparison, the structure of wt bacteriorhodopsin in the resting state is shown on the left. Figure 
prepared with pdb coordinate files 1C3W and 1P8H for wt and V49A mutant BR, respectively. 
 
Trials to obtain a crystal structure of an early N intermediate, in which D96 is 
deprotonated, were unsuccessful. It is also unknown how the cytoplasmic half-
channel rearranges to allow for the transfer of the proton from the cytoplasmic surface 
to D96. However, two water molecules were identified (W520 and W504) at the 
cytoplasmic surface and close to D96 which might be the first and last members of a 
continuous chain, formed as a result of protein conformational fluctuation in the N 
state (194,207). 
In the O intermediate, D96 is reprotonated from the cytoplasm and the retinal is 
reisomerised to a twisted all-trans configuration (208). 
The resting state of the photocycle is recovered by deprotonation of D85. The proton 
is thought to be passed on to the empty proton release site. Finally, the negatively 
charged D85 allows the retinal to adopt a relaxed all-trans configuration 
(202,209,210). 
To prevent a futile cycle, it has to be ensured that the Schiff base is reprotonated from 
the cytoplasmic site and not by D85. This can be accomplished either by physical 
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separation of the protonated D85 and deprotonated Schiff base or by increasing the 
pKa of D85 in the N and O states. The former hypothesis could be accomplished by 
the reorientation of NZ vector of Schiff base upon deprotonation either due to 
curvature of the retinal polyene (211) or due to the weak electrostatic interaction 
between protonated D85 and the Schiff base (189,212). According to Royant et al., it 
is rather D85 that makes the move towards the Schiff base in the L state and then 
moves again away from the Schiff Base in the M state, induced by bending of helix C 
(Figure 21) (213). The latter hypothesis is based on the assumption that upon proton 
release to the extracellular side, which happens concomitantly to protonation of D85, 
the pKa of D85 rises due to the disrupted extracellular hydrogen-bonded network. 
This disqualifies D85 as a proton donor for the Schiff base and puts D96 located in 
the cytoplasmic half-channel forward as candidate proton donor to the Schiff base.  
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3. The all-tight conformation of AcrB trimer is in support of 
bi-site activation of drug transport 
 
This section contains a manuscript describing experiments, results and interpretations 
of the findings obtained for the characterization of the AcrB binding pocket mutants 
AcrB_F610A, AcrB_V612F and AcrB_F610A_V612F. 
 
My contribution to this work was the construction of the E. coli BW25113 ∆acrB 
strain, the production of the plasmids containing mutant AcrB, performing the 
phenotypical experiments, protein overexpression, purification crystallization and 
crystallographic data collection. 
 
Processing and refinement of crystallographic data was executed by me with 
substantial support of Prof. Dr. Klaas Martinus Pos. 
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Abstract 
AcrA/AcrB/TolC is the major efflux protein complex in Escherichia coli extruding a 
vast variety of antimicrobial agents from the cell. The asymmetric structure of the 
trimeric inner membrane component AcrB implies functional rotation in analogy to 
the functional rotation observed for the F1Fo ATPase. In one of the monomers, bound 
substrate could be detected in an internal cavity formed by hydrophobic and aromatic 
residues. Here we report the phenotypical and structural effect of substituting the 
binding pocket residues F610 and/or V612 with alanine and phenylalanine, 
respectively. Except for the antibiotic linezolid, single amino acid exchange generally 
resulted in reduced growth of bacterial cells. Interestingly, resistance could be 
partially restored upon introduction of the second mutation. The structure of the 
AcrB_V612F mutant was solved at 2.2 Å in presence and absence of DARPins. The 
protein exhibited a novel conformation in which all monomers adopt the tight state 
presumably representing an intermediate step during functional rotation. Additionally, 
the location of bound substrate was found to be shifted compared to the wild-type 
protein, highlighting the remarkable flexibility of AcrB to comply with severe 
changes in the binding pocket. 
 
 
Introduction  
The three component AcrA/AcrB/TolC multidrug resistance (MDR) pump provides 
the E. coli cell with the necessary means to protect it against a wide range of noxious 
compounds (1). AcrB resides in the inner membrane and is the energy transducing 
and substrate specificity determinant (2-6). AcrA is the adapter component which 
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associates the inner membrane pump with the TolC outer membrane channel (7,8). 
Importantly, all three components are necessary to obtain the MDR phenotype (3,4,8). 
Despite its wide range of substrates, which includes dyes, detergents, bile salts, 
organic solvents and antibiotics of different chemical classes, some restrictive features 
appear to be size and hydrophobicity. Substrates of AcrB have not been reported to 
exceed a molecular weight of 103 Da or to be more hydrophilic than logPOW of -0.31. 
AcrB seems therefore to prefer hydrophobic substrates including polar or charged 
moieties, but is also able to transport small organic compounds like hexane and octane 
(9).  
Substrate specificity was found to be localized in the periplasmic porter domain of 
AcrB (6). Both biochemical and structural studies point towards a region consisting of 
a cluster of phenylalanines responsible for substrate binding (10-14). Recent 
published structures of AcrB showed an asymmetric homotrimer with the monomers 
in the distinct states loose (L), tight (T) and open (O). The substrate binding pocket 
appears to be widened in the tight state where binding of minocycline and doxorubicin 
was shown (11). In analogy with the functional rotation of the α/β-subunits of the 
F1Fo ATPase leading to synthesis of ATP (15,16), a similar catalytic mechanism was 
postulated for AcrB leading to drug export (11-13). In short, the hypothesis states that 
within the asymmetric trimer, the monomers can adopt any of the conformational 
states L, T and O. The process is dependent on the concerted cycling of the monomers 
through the states L, T, O and back to L, which is the essence of the functional 
rotation. In the L conformation, substrates are recruited for transport towards the 
binding pocket from the periplasmic space and/or the membrane. Tunnels lead 
towards the periplasmic binding site in the T conformation and substrate gets tightly 
bound. Upon conformational change towards the O state, the substrate is released 
from the binding pocket and exits AcrB via the trimeric funnel towards the TolC 
tunnel. The tunnels towards and from the hydrophobic binding pocket are lined with 
hydrophilic side chains through which hydrophobic substrates are transported (11,12).  
During a complete functional rotation, occlusions and constrictions inside the 
dynamic tunnel system seem to propagate from the lateral opening towards the central 
                                                 
1 P is the partition coefficient of a given solvent in an equimolar octanol-water mixture. logPOW of -0.3 
is the experimental partition coefficient of tetracycline (http://www.drugbank.ca/). 
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funnel driving the transport of substrate. Hence this mechanism was dubbed 
“peristaltic pump mechanism” (12,17). 
The functional rotation mechanism suggests interdependence of the monomers, which 
means that if one of the monomers within the trimer has a lethal mutation, the whole 
trimer is inactive. Recently, this has been impressively shown to be the case by 
Nikaido and co-workers by the use of a covalently linked AcrB trimer (18). Two 
crystallographical distinct structures are known up-to-date: the symmetric LLL (all 
loose) conformation (19) and the asymmetric LTO conformation (11-13). Most of the 
published structures are in the symmetric conformation but show a marked deviation 
between each other (19-25). However, it has been discussed whether the symmetry for 
some of these structures is due to crystallographic “artifacts” like an induced 
conformation due to crystal contacts or even the presence of twinning inside the 
crystals (12). On the other hand the LLL conformation might represent the “resting 
state” e.g. in the absence of substrate (21) with structural flexibility necessary for 
substrate acquisition. Other structures show the AcrB trimer in the asymmetric LTO 
state (11-13) with binding of substrates in the T conformer (11). Whether the apparent 
“substrate-free” preparations are indeed without substrates is ambiguous since the 
solubilizing and stabilizing detergents used in the preparation of the crystals are all 
substrates of AcrB. These detergents might not be visible in the electron density maps 
in or near the minocycline/doxorubicin binding area due to multiple conformational 
binding of the ligand (11,12,26).  
In theory different combinations of the three monomeric states within the AcrB trimer 
are plausible, especially since the binding change mechanism (15,16) postulates a bi-
site activation of the transporter for catalysis (17,27). I.e. before the AcrB substrate 
can be released from the T monomer by conversion to the O monomer, a second 
substrate has to be bound to the adjacent monomer. Structural flexibility within the 
trimer (28,29) suggests that multiple L and T conformational states (LLT or LTT) 
might be present in the AcrB trimer. Upon high substrate concentration or in the case 
of altered biophysical properties of the protein, even a TTT (all tight) trimer 
conformation might be plausible (27). We describe here a structure of AcrB in a novel 
TTT conformation for the AcrB binding pocket mutant V612F. The latter mutation 
was previously shown to alter the antibiotic efflux profile for the AcrB homologue 
YhiV (10).  
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AcrB_V612F crystallizes as a symmetric trimer with every monomer in the T 
conformation. Moreover, this trimeric conformation could be obtained in the presence 
and absence of the AcrB substrate minocycline. The position of bound minocycline in 
the binding pocket of the V612F mutant has been shifted compared to the location in 
the binding pocket of the wild-type (wt) T monomer (11). This highlights the great 
flexibility of the binding pocket to adapt to severe changes in the ligand-binding side 
chains, and is reminiscent to the observation made previously for the drug binding 
protein QacR (30).  
 
Results 
A single V610F mutation in the YhiV homologue of AcrB resulted in a 16-fold 
increase of resistance towards linezolid and a eight-fold increase towards tetracycline, 
whereas the mutants where more susceptible towards the macrolide antibiotics 
erythromycin, clarithromycin and azithromycin (10). In AcrB, the corresponding 
V612 is part of the hydrophobic binding pocket (11-13) of the tight monomer 
consisting of six phenylalanines, two valines, two isoleucines and a tyrosine. As has 
been shown recently (11), co-crystallization of the AcrB substrates minocycline and 
doxorubicin visualized the presence of these substrates inside the binding pocket.  
We substituted V612 with phenylalanine in plasmidial encoded AcrB and tested the 
phenotypic impact of this mutation in an E. coli BW25113 ∆acrB background (28). A 
similar change of substrate preference was observed as described for the AcrB 
homologue YhiV (10) (Table 1). 
5 
3. The all-tight conformation of AcrB trimer is in support of bi-site activation of drug transport 
 
Table 1: Drug susceptibility of E. coli BW25113 ∆acrB expressing wt and mutant AcrB 
  
MIC (µg ml-1) 
 
mutation 
R6G berb clarithro oxa eth lin erythro 
D407N 
_D408N 
8 64 <4 2 8 8 2-4 
wt 128 1024 64 128 128 128 64 
V612F 16 128 16 64 32-64 256 16 
F610A 16 512 8 32-64 64-128 64-128 8 
F610A 
_V612F 
64 512 16-32 64 128 256 16-32 
abbreviations: MIC, minimal inhibitory concentration; R6G, rhodamine 6G; berb, berberine; clarithro, 
clarithromycin; oxa, oxacillin; eth, ethidium; lin, linezolid; erythro, erythromycin 
 
Seven compounds that belong to different chemical classes and that are known AcrB 
substrates were tested (i.e. the dyes rhodamine 6G (R6G) and ethidium, the plant 
alkaloid berberine, the macrolides clarithromycin and erythromycin, the β-lactam 
antibiotic oxacillin and the oxazolidinone antibiotic linezolid). With the exception of 
linezolid (two-fold increase of the minimal inhibitory concentration (MIC)), 
AcrB_V612F conferred less drug resistance to the tested compounds than wt AcrB, 
with oxacillin resistance being least affected. Apart from intrinsic differences between 
AcrB and YhiV, the reason for the less pronounced effect of the phenylalanine to 
alanine substitution seen in our measurement could be the mildly decreased 
expression level of AcrB_V612F compared to the wt protein (Figure 1). 
 
 
 
Figure 1: Western blot analysis of cell extracts obtained from E. coli BW25113∆acrB cells coding for 
wt and mutant AcrB. Expression level of AcrB_V612F (lane 3), AcrB_F610A (lane 4) and 
AcrB_F610A_V612F (lane 5) are mildly decreased compared with wt AcrB (lane 1), As a control, E. 
coli BW25113∆acrB was complemented with the expression vector (lane 2). Molecular size marker is 
indicated in kDA on the left. 
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To obtain structural information on the change in substrate specificity, we crystallized 
an AcrB_V612F/DARPin complex and surprisingly obtained crystals in a hitherto 
unreported crystal form I23. 
 
Novel all-tight conformation of AcrB 
For structure determination of AcrB, we standardly used Designed Ankyrin Repeat 
Proteins (DARPins) in order to obtain high-resolution AcrB/DARPin co-crystals. 
DARPins are specific, high-affinity binding proteins selected by in vitro ribososome 
display using a DARPin library (31,32). DARPin clone 1108_19 was shown to bind 
specifically to the loose and tight monomer (but not to the open monomer) of trimeric 
AcrB in its asymmetric conformation, yielding a DARPin:AcrB stoichiometry of 2:3 
(13). These specific DARPin molecules allowed for new crystal contacts to be formed 
and appear to stabilize the specific asymmetric conformation of AcrB augmenting the 
crystallization process. 
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Figure 2: Superimposition of the porter domain of AcrB_V612F (yellow) onto the porter domain of the 
asymmetric structure of wt AcrB (2GIF). The loose, tight and open monomer of wt AcrB are colored 
blue, grey and red, respectively. In the AcrB_V612F structure, minocycline (green) is found in the 
binding pockets between subdomains PN2 and PC1 of each monomer. In the insets, key residues of the 
binding pocket and residues that help to coordinate minocycline are depicted as spheres.  
 
The structure of the V612F AcrB mutant/DARPin complex was solved at 2.2 Å from 
cubic crystals (space group I23) grown in presence and absence of the substrate 
minocycline. A three-fold symmetry axis runs through the center of the AcrB trimer 
reminiscent to the symmetric AcrB trimer structure derived from the R32 crystal form 
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(19,33,34) (Table S1). An improved structure of the wt AcrB/DARPin complex 
(Eicher et al., unpublished data) was used as a search model for molecular 
replacement. The asymmetric unit of the V612F/DARPin co-crystal consists of a 
stoichiometric complex. The V612F monomer exhibits the typical features of the 
AcrB monomer in its tight conformation and includes a bound minocycline molecule 
in the designated binding pocket (11-13).  
This observation is in accordance with the small root mean square deviation (RMSD) 
between the AcrB_V612F chain and the AcrB wt monomer (pdb entry: 2GIF) in the 
tight conformation (Table S1).  
As apparent from the space group symmetry there is one additional DARPin molecule 
per AcrB_V612F trimer compared to the asymmetric wt AcrB/DARPin P212121 
structure (pdb entry: 2J8S). Although the number of contacts facilitating the single 
AcrB_V612F/DARPin interaction are maintained by virtually the same side chain 
residues as in the wt tight monomer AcrB/DARPin complex (Table S2), the total 
number of salt bridges and H-bond interactions in the trimeric AcrB/DARPin 
assemblies differ substantially due to the unequal AcrB:DARPin stoichiometry in the 
two structures. 
To test whether this novel conformation of AcrB_V612F is an artifact due to binding 
of the DARPins, we crystallized the protein in the absence of the high affinity binding 
molecules. Crystals grew in the presence and absence of the substrate minocycline 
diffracting to 2.8 Å and belonging to the space group P321 (Table S1). To solve the 
structure, the same steps were performed as described for the AcrB_V612F/DARPin 
complex. The asymmetric unit of the crystal consists of one AcrB monomer in the 
tight conformation and shows little deviation to the structure obtained in presence of 
the DARPin molecules (RMSD = 0.43 Å) (Table S1). The P321 crystals were grown 
at the same conditions where wt AcrB forms the asymmetric C2 crystal (12). 
Surprisingly, no condition was found to promote growth of crystals of AcrB_V612F 
exhibiting the all loose confirmation, the state that is predominantly found for AcrB 
wt protein. 
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Differences between the tight conformer of the wt AcrB and AcrB_V612F 
The largest deviations between the tight conformation of the symmetric I23 V612F 
structure and the asymmetric wt AcrB C2 structure monomer are observed in the 
loops connecting the PN1 with the PN2 subdomain (RMSD of Cα atoms ≥ 3.5 Å) and 
the PC1 with the PC2 subdomain (RMSD ≥ 4.7 Å), at the N-terminal end of the 
cytosolic α-helix (Iα) (RMSD ≥ 6.4 Å) and in the PC1 subdomain (RMSD ≥ 3.2 Å) 
(Figure 3). 
Figure 3: Differences between the tight conformer of wt AcrB and AcrB_V612F. A) Side view of the 
AcrB_V612F trimer. The monomers are colored in different shades of yellow. Stretches which deviate 
significantly between the wt and AcrB_V612F structure (rmsd ≥ 2.38 Å) are colored blue and 
highlighted with circles. B) Top view onto superposed pore domain of AcrB_V612F (yellow) and tight 
conformer of wt AcrB (white). Minocycline bound by AcrB_V612F is colored green and F612 is 
shown in stick representation. Subdomains are indicated. C) Superimposition of the transmembrane 
domain of AcrB_V612F (yellow) and wt AcrB (white). There is little deviation between the two 
structures in this domain except for the N-terminus of the cytosolic α-helix (Iα). Number of 
transmembrane helices are indicated. For wt AcrB, the pdb coordinate file 2GIF was used. 
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The two aforementioned loops are located in the porter domain of AcrB and partially 
line tunnel 1 in the tight conformer of wt AcrB (Figure 4). This tunnel connects the 
inner membrane with the open binding pocket and is continuous in the structure 
published by Sennhauser et al. (pdb coordinate file 2J8S, (13)), whereas the side chain 
of F563 protrudes into this tunnel in another structure (17) and was hence postulated 
to act as a gating residue. In AcrB_V612F, the side chain of F563 adopts the same 
conformation as in 2J8S, but the tunnel is occluded by the side chains of S561, L674 
and T676. The latter two residues are located on the PC1-PC2 connecting loop and 
seem to be involved in gating of tunnel 1 as well (Figure 4). 
 
 
Figure 4: Visualization of the tunnels in the porter domain of AcrB_V612F. In the tight conformer of 
wt AcrB, occlusions and cavities form tunnel 1 and 2 (green surface) connecting the binding pocket 
with the inner membrane and the periplasm, respectively. Tunnel 1 is occluded by the residues 561, 
674 and 676 in AcrB_V612F as depicted in the inset. 
 
Adaptability of the altered AcrB_V612F binding pocket 
AcrB binds and transports a broad spectrum of chemically unrelated compounds. 
Among the many substrates tested in co-crystallization trials, only doxorubicin and 
minocycline could be identified in the binding pocket of the tight monomer of the 
asymmetric AcrB wt structure (11). Structural analysis of the AcrB_V612F/DARPin 
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complex co-crystallized in the presence of minocycline revealed binding of 
minocycline by virtually the same side chain residues as observed in the tight 
monomer of the wt AcrB, but the substrate position has been shifted by approximately 
2.1 Å along its longitudinal axis (Figure 5).  
 
 
Figure 5: Shifted position of minocycline in the binding pocket of AcrB_V612F compared to its 
location in the wt AcrB tight monomer binding pocket (pdb entry: 2DRD). The structure of the binding 
pocket region of AcrB_V612F (yellow) and wt AcrB (grey) co-crystallized with minocycline are 
superimposed. Residues involved in the binding of minocycline are designated. F615 is omitted for 
clarity. 
 
In the new substrate location the polar tertiary amine nitrogen (N1) of minocycline is 
about 0.8 Å nearer to the carboxylate side chain of E273 (new distance of 4.6 Å) and 
the amide side chain of N274 is approximately 0.6 Å closer to the amide nitrogen 
(N2) of minocycline, allowing the formation of a hydrogen bond. On the other hand, 
the ring system of minocycline was 1.5 Å further apart from F178 presumably 
weakening the π-π interaction (Table 2) (Figure 5). Despite considerable efforts we 
were until now not successful in co-crystallization of AcrB_V612F/DARPin with 
other known AcrB substrates besides minocycline. 
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Table 2: Distance between minocycline and binding pocket residues of wt and AcrB_V612F  
  
 distance 
residues wt AcrB 
(pdb ID: 2DRD) 
AcrB_V612F 
E273 (OE1) - MIY (N1) 5.40 4.58 
N274 (OD1) – MIY (N2) 3.64 3.08 
F178 (CD2) – MIY (C12) 3.10 4.58 
 
 
Substitution of F610 with alanine rescues the V612F mutant 
A systematic alanine scanning approach on the phenylalanine residues inside the 
AcrB binding pocket revealed the insensitivity of single alanine substitution with 
regard to the efflux capability of the AcrB pump. Nevertheless, a F610A substitution 
was shown to have considerable effect on the capacity to confer resistance towards a 
range of toxic compounds (14). The substituted phenylalanine residue is located in 
spatial vicinity of the valine at position 612 (Figure 2 and Figure 5). We 
hypothesized that the bulky F610 side chain might be causing part of the reduced 
activity observed in the V612F mutant and introduced a F610A substitution in the 
latter mutant. 
Interestingly, the second mutation (F610A in AcrB_V612F or V612F in 
AcrB_F610A) caused an improvement on the capability to confer drug resistance 
(Table 1). The MIC values for the double mutant were either elevated to the level of 
the less affected single mutant (i.e. in the case of berberine and oxacillin) or even 
higher (in the case of R6G, clarithromycin, ethidium, erythromycin). Linezolid 
resistance, however, remained two-fold elevated compared to wt AcrB, despite 
introduction of the second (F610A) mutation.  
 
 
Mutations in the binding pocket inhibit efflux of N-phenylnaphthylamine (NPN)  
To further investigate the impact of the mutations in the binding pocket on activity of 
the protein, cells producing AcrB_F610A, AcrB_V612F and AcrB_F610A_V612F 
were subjected to NPN fluorescence spectroscopy (Figure 6). NPN integrates readily 
in the inner membrane of de-energized bacterial cells where it gives rise to a strong 
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fluorescent signal. NPN is a cognate substrate of AcrB and its efflux can be followed 
in real time as quenching of the fluorescence upon re-energization of the cells (35,36). 
Both the initial efflux rate and steady-state fluorescence quenching for the 
AcrB_F610A and AcrB_V612F single mutants were considerably diminished as 
compared to the wild-type. The efflux of NPN was, however, improved upon 
introduction of the second mutation (yielding AcrB_F610A_V612F), but well below 
the level observed for the cells expressing wt AcrB. This is in accord to the results 
obtained with MIC experiments, where the F610A mutation rescues in part the 
activity of the AcrB_V612F mutant and vice versa. 
Cells expressing AcrB_D407N_D408N served as negative control. In this mutant, 
efflux of NPN is completely inhibited as has been shown before (28,36). 
 
 
Figure 6: NPN efflux in E. coli BW25113 ∆acrB harboring plasmid encoding wt and mutant acrB. 
Cells were energized at t=0 and efflux of substrate was followed as decay of the fluorescence signal. 
Cells producing AcrB_F610A, AcrB_V612F and AcrB_F610A_V612F are still able to accomplish 
efflux of NPN, although to a lesser degree than cells harboring wt acrB. The nonfunctional 
AcrB_D407N_D408N mutant was used as a negative control. au, arbitrary units.  
 
 
Discussion  
Recent structural studies show that homotrimeric AcrB can adopt different monomer 
conformations representing the consecutive states L, T and O in an allosteric 
functional rotation transport cycle. Trimeric AcrB has been crystallized in the 
symmetric “all loose” (LLL) (19) and the asymmetric LTO state (11-13).  
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It has been discussed (17,27) whether the LTO conformation represents the lowest 
energy form of the AcrB trimer, since in vivo cross-link studies (28,37) point towards 
the presence of this conformation rather than the LLL form. Moreover, addition of 
DARPins to solubilized AcrB appears to stabilize the asymmetric LTO only while in 
absence of these ligands, the LLL form can be readily and predominantly crystallized. 
Additionally, the LTO state seems to be the most abundant conformation of wt AcrB 
in soluble detergent extracts based on analytical ultracentrifugation experiments in the 
presence of DARPins (13). However, during functional rotation of the protein, 
trimeric AcrB is anticipated to exist in intermediate states (17), a hypothesis that is 
supported by quantitative cysteine cross-link experiments (28). 
Here we describe a novel “all tight” (TTT) conformation of trimeric AcrB. This 
structure was obtained in crystallization trials with AcrB_V612 in the presence and 
absence of DARPins. Addition of minocycline facilitated crystallization but was not 
essential to obtain this conformation. 
 
In analogy to the binding change mechanism for the F1Fo ATPase, conversion of one 
monomer from the tight to open state and thus release of substrate is thought to be the 
energy requiring step (15,16). Furthermore, the T to O transition within the LTO 
trimer is postulated to occur only when a second substrate has bound to the adjacent 
loose monomer. This in turn promotes conversion of loose to tight conformation, 
resulting in a TTO intermediate of trimeric AcrB. Then the O monomer would change 
to the L conformation, resulting in an intermediate TTL state. In the final step, the T 
monomer would release the bound substrate and change to the O state, which 
completes the transport cycle and restores the LTO (OLT) state (Figure 7). 
Based on the observation that AcrB_V612F failed to crystallize in either the LLL or 
the LTO state, we conclude that this amino acid substitution increases the probability 
of the monomers to adopt the T conformation. Indeed, when the V612F mutation was 
introduced in silico into the collapsed binding pocket of the loose or open monomer, 
the side chain of F612 collides in any possible orientation with one or several of the 
binding pocket residues I626, I276, I277, F610 and F615. However, since the protein 
is functionally still active and in case of linezolid the MIC was even increased, 
functional rotation does not seem to be impeded by the V612F mutation. Some 
structural rearrangements are thus necessary for the AcrB_V612F mutant to adopt L-  
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Figure 7: Schematic representation of the AcrB binding change mechanism. The conformational states 
loose (L), tight (T) and open (O) are colored blue, yellow and red, respectively. Substrate 
(minocycline) is displayed in green and is located close to the lateral entrance of the tunnel system in 
the loose monomer, bound tightly in the binding pocket of the tight monomer and is extruded from 
AcrB in the open monomer. The putative protonation state of D407 and D408 are indicated for the 
different conformations (H+ and -, respectively). Structures of conformations which have been 
crystallized thus far are represented larger than the other putative intermediate states. The TTT state is 
expected to be predominantly present in the AcrB_V612F mutant.  
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or O- like states which are probably energetically less favorable than the 
conformations in wt AcrB. As a consequence, T is the preferred state for 
AcrB_V612F. Parameters such as high substrate concentration are considered to shift 
the balance in wt AcrB towards the T state as well, especially since the energy needed 
for the transition from O to L or L to T presumably is low. 
 
Since there is no structural information on the binary AcrB/drug complexes for the 
substrates tested in the MIC experiments, it remains speculative whether and how 
these molecules are adapted in the AcrB binding pocket. However, some 
interpretation can be done based on the effect of the mutations on the MIC values. For 
example, the R6G MIC value is decreased severely in the two single mutants F610A 
and V612F, whereas for other substrates (e.g. oxacillin, ethidium and linezolid) the 
effects are less severe or even, in the case of linozolid, beneficial. This appears to 
exclude a general constraint on transport based on hindrance of conformational 
changes and might be an argument for a specific effect on substrate binding inside the 
binding pocket. One explanation might be therefore that in the AcrB_V612F mutant, 
the two bulky phenylalanine residues (F610 and F612) might prohibit access to the 
entire binding pocket and thereby hinder e.g. R6G to adopt its favored position 
(Figure 8). 
The decrease of MIC values in the AcrB_F610A mutant might be explained by the 
reduced opportunities for substrates to interact via favorable π-π or cation-π 
interactions. In the AcrB_F610A_V612F double mutant, the access to the entire 
binding pocket might be re-established due to the F610A mutation and the 
phenylalanine at position 612 might compensate for the loss of F610. This would 
allow the altered binding pocket to accommodate e.g. R6G in a similar fashion as the 
wt protein does. Similar considerations may explain the phenomenon for the other 
drugs tested by MIC experiments except for linezolid. The MIC of this drug improved 
upon introduction of phenylalanine at position 612, but hardly changed when the 
phenylalanine at position 610 was removed. We therefore hypothesize that linezolid is 
bound differently compared to the other drugs tested and that the interaction of this 
substrate with the F610 and V612 residues is weak. 
 
 
17 
3. The all-tight conformation of AcrB trimer is in support of bi-site activation of drug transport 
 
Figure 8: Volume reduction of the AcrB binding pocket by the V612F mutation. The structure of the 
binding pocket of the tight conformer is shown for wt AcrB (A) and AcrB_V612F (B). Whereas the 
entire binding pocket of wt AcrB is accessible (A), the bulky side chain of F612 protrudes into the 
pocket and restricts entry in the mutant protein (B). Note that in AcrB_V612F, the side chains of F628 
(colored red) and F615 exhibit different orientations. For wt structure, pdb coordinate file 2GIF was 
used. 
 
The flexibility of MDR proteins in accommodating different substrates in their 
binding pockets was impressively demonstrated for the transcription regulator QacR. 
QacR is a soluble repressor of the TetR family and binds to the same substrate as its 
target gene qacA confers resistance to (38-40). To date, ten crystal structures were 
published showing QacR in complex with different substrates (41-43). Furthermore, 
QacR is rather promiscuous and is even capable of binding the same substrate in 
different positions. QacR was crystallized as binary complex with ethidium (43) and 
as ternary complex with ethidium and proflavine (42). In the 
QacR/proflavine/ethidium structure, binding of ethidium is essentially maintained by 
the same residues as in the binary structure. Rather than to clash with the second 
substrate, the position of ethidium was rotated approximately 15° along the axis 
perpendicular to its ring system and the two substrates are now engaged in favorable 
van der Waals interactions. 
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In another study, E58 of QacR was mutated to glutamine (30). This residue was 
shown to compensate for the positive charge of the substrate berberine in the wt 
structure. However, binding affinity counter intuitively increased for the mutant 
protein. Structural analysis of this mutant revealed that berberine is bound in an 
alternative fashion: it was rotated approximately 180° along its longitudinal axis. To 
avoid steric clash, Y123, which formed van der Waals contacts with the non-aromatic 
1,3-dioxolane ring of berberine in the wt structure, rotated along its Cα-Cβ bond, to be 
now engaged in favorable π-π interactions with the aromatic benzene ring of 
berberine. Furthermore, berberine and W61 are oriented parallel to each other and the 
overlapping area of the two ring systems has been enlarged due to the new position of 
the drug molecule. This improves aromatic stacking interactions and allows cation-π 
interaction with the pyridinium nitrogen of berberine (30). 
The situation in AcrB_V612F is quite similar: the position of minocycline within the 
binding pocket is shifted for about 2.1 Å relative to its location in wt AcrB. The 
molecule in its original position would have had a distance from the F612 side chain 
of only 2.0 Å, which would have resulted in a sterical clash between the bulky side 
chain of F612 and the dimethylamino-phenol ring of minocycline. As mentioned 
earlier, the polar interactions between the drug and residues E273 and N274 were 
improved by the dislocation of minocycline, whereas the π-π interaction between the 
dimethylamino-phenol ring and the aromatic side chain of F178 got impaired  
(Table 2). 
These results underline the flexibility of the AcrB binding pocket. Not only is it able 
to bind a variety of chemically unrelated substrates, but it can also compensate for 
mutations and – at least in the case of minocycline – accommodate substrate in 
different locations inside the binding pocket. 
The all-tight structure is the second conformational state of trimeric AcrB that was 
crystallized in the presence of DARPins (13). The asymmetric structure of wt AcrB 
and the symmetric all-tight conformation of AcrB_V612F were both obtained in the 
presence and absence of these high affinity binders. Since the deviation between the 
liganded and unliganded structure is very small for both conformations, the DARPin 
molecules appear not to impose a non-native confirmation, but rather stabilize an 
existing conformational state, which helps to improve crystal formation and crystal 
diffraction.  
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Materials and methods 
 
Bacterial strains, plasmids and growth conditions 
E. coli DH5α (44) was used as host for cloning procedures. E. coli BW25113 ∆acrB 
(28) served as background for MIC determination and NPN efflux experiments. E. 
coli C43 (DE3) (45) harboring pET24acrB_V612F was used for protein 
overexpression. LB medium and LB agar (46) were used for routine bacterial growth 
at 37°C. Terrific broth (47) was used for protein overexpression. Kanamycin 
(Applichem) was applied at 50 µg ml-1 (Kan50). 
 
Site directed mutagenesis 
pET24acrBHis (33) served as a template for site-directed mutagenesis. By using the 
Quikchange protocol (Stratagene), amino acid substitution was achieved with 5’ 
phosphorylated primers. Insertion of mutation was verified by sequencing 
(Microsynth, Balgach, Switzerland). 
 
Western blot analysis 
Cultures of E. coli BW25113 ∆acrB carrying pET24acrBHis with and without 
additional mutations were grown over night in LB Kan50 (5 ml). The pellet of 1.0 ml 
culture was resuspended in SDS-PAGE loading buffer (0.1 ml * OD600 of the 
harvested culture) supplemented with 2% (v/v) β-mercaptoethanol and boiled for 5 
min. The samples (15 µl) were subjected to SDS-PAGE (48) and blotted onto 
nitrocellulose membrane (49). AcrB and its mutant derivatives were immunodetected 
with anti-AcrB rabbit antibodies (Neosystem) at a 1:104 dilution. Bound 
immunoglobulins were probed with mouse anti-rabbit antibody coupled to horseradish 
peroxidase and visualized using the enhanced chemiluminescence ECL system 
(Pierce). 
 
Drug susceptibility assays 
E. coli BW25113 ∆acrB carrying pET24acrBHis with and without additional mutations 
were subjected to MIC experiments as described earlier (28). In brief, 96-well 
microtiter plates (Thermo-Fisher Scientific) containing LB Kan50 and the indicated 
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drugs were prepared by two-fold serial dilution. The plates were inoculated 1:100 
with precultures grown until a cell density of OD600 of 0.6. After incubation for 22 
hours (37°C, 160 rev min-1) the OD600 was determined. The smallest concentration 
that inhibited growth above the turbidity visual detection limit (OD600 of 0.58) was 
considered to be the MIC. 
Each assay was repeated at least twice and in each experiment the plates were 
prepared in duplicates. On each plate, the strains at any drug concentration were 
present twice. 
 
N-Phenylnaphthylamine (NPN) efflux assay 
The clearance of NPN from the bacterial membrane by the AcrA/AcrB/TolC efflux 
pump was analyzed by following the decrease in the fluorescence signal (35,36). The 
same strains and plasmids as described for the MIC experiments were used and the 
protocol described by Seeger et al. (28) was applied. 
 
Crystallization of AcrB_V612F in presence and absence of DARPins 
Overexpression and membrane preparation of AcrB_V612F was carried out as 
described previously (12,33). Overexpression and purification of DARPin clone 
1108_19 (13) was accomplished as described by Binz et al. (32). For crystallization of 
AcrB_V612F in absence of DARPins, purification and crystallization was carried out 
with cyclohexyl-n-hexyl-β-D-maltoside as detergent according to Seeger et al. (12). 
Crystals were grown by the hanging drop vapor diffusion method at 0.1 M citrate pH 
4.6, 5% polyethylene glycol (PEG) 400, 16-21% PEG 300, 8-11% glycerol. To 
crystallize the AcrB_V612F/DARPin complex, the method described by Sennhauser 
et al. (13) with n-dodecyl-β-D-maltoside as detergent was applied. Unlike the wt 
protein, AcrB_V612F precipitated during buffer exchange from Tris-HCl to HEPES, 
which could be avoided when HEPES was replaced by KPi buffer. Crystals were 
grown in presence and absence of 2 mM minocycline (Sigma-Aldrich) by the hanging 
drop vapor diffusion method at 0.1 M acetate buffer pH 4.5, 3-7% PEG 200, 15-25% 
PEG 400, 0.15 M MgCl2, 0.15 M NaCl.  
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X-ray diffraction dataset analysis and refinement procedure 
Datasets of I23 and P321 crystals were collected at the beamline X06SA of the Swiss 
Light Source (Paul Scherrer Institut, Villigen, Switzerland) (wavelength 1.0 Å and 
0.9762 Å). Data reduction was done with the XDS package (50). The structures were 
solved by molecular replacement using MOLREP (51) or PHASER (52). Refinement 
was performed with the program REFMAC5 (53) using rigid body refinement 
followed by restrained refinement with TLS restraints. Model rebuilding was 
performed using the program COOT (54), tunnels were calculated using CAVER (55) 
and MOLE (56). Figures were created using Pymol (http://pymol.sourceforge.net/). 
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Table S1: Crystallographic data and refinement 
     
  AcrB_V612F/DARPin 
& minocycline 
 AcrB_V612F 
     
Data collection     
space group  I23  P321 
     
Cell dimensions     
a (Å)  227.46  134.41 
b (Å)  227.46  134.41 
c (Å)  227.46  190.97 
α (°)  90.00  90.00 
β (°)  90.00  90.00 
γ (°)  90.00  120 
     
Resolution (Å)  2.20  2.80 
     
Rmeas (%)  116.9  143.5 
I/σI  3.97  1.87 
Completeness (%)  79.1  97.8 
redundancy  22.82  10.62 
     
Refinement     
trimer model  unpublished  AcrB_V612F/DARPin 
& minocycline 
program  PHENIXa,b & REFMAC5c  PHENIXa,b & REFMAC5c 
     
Resolution (Å)  29.87 - 2.20  49.69 - 2.80 
No. of reflection  98553  49614 
     
Rwork  18.97  25.85 
Rfree  22.17  28.26 
No. atoms     
macromolecule residues  9152  7937 
solvent residues  1013   
     
B-factors     
macromolecule  39.3  56.9 
solvent  43.5   
overall  39.7  56.9 
RMS deviations     
bond length (°)  0.007  0.007 
bond angles (Å)  1.1  1.0 
     
RMS deviation to 2J8S 
(Å)d 
    
loose  2.34  2.32 
tight  1.11  1.07 
open  2.77  2.80 
     
RMS deviation between      
AcrB_V612F/DARPin 
and AcrB_V612F (Å)d 
                               0.43 
     
a: (1) 
b: (2) 
c: (3) 
d: calculated with the program superpose (3) 
 
  
Table S2: Distance between AcrB monomer and DARPin molecule in wild-type (wt) AcrB and AcrB_V612Fa 
   
AcrB_V612F / DARPin complex  wt AcrB/DARPin complex (pdb ID: 2J8S) 
       
 
chain Db 
 
chain Bc 
 
dist. (Å) 
 distance (Å) between corresponding 
atoms of chain Db and Bc, resp. 
 distance (Å) between corresponding 
atoms of chain Eb and Ac, resp. 
      
ARG 23 (NH2) ASP 723 (O) 2.94  3.24  3.16 
TYR  56 (OH) TYR 811 (O) 3.52  3.71  3.54 
ASN 112 (ND2) SER 807 (O) 2.73  2.66  2.55 
LYS 144 (NZ) SER 805 (O) 2.83  3.14  2.97 
LYS 144 (NZ) SER 802 (O) 2.75  2.64  2.58 
LYS 147 (NZ) GLU 734 (OE2) 2.62  3.69  2.76 
TYR 56 (OH) TYR 811 (N) 2.97  3.08  3.00 
THR 78 (OG1) TRP 809 (NE1) 2.91  n.a.  2.83 
ASN 112 (OD1) SER 807 (N) 3.17  3.28  n.a. 
LYS 147 (NZ) GLU 734 (OE1) 3.57  n.a.  3.73 
ASP 13 (OD2) LYS 659 (NZ) n.a  3.23  n.a. 
ARG 23 (NH2) GLU 722 (OE2) n.a.  3.94  n.a. 
VAL 46 (O) TRP 809 (NE1) n.a.  n.a.  3.27 
ASP 44 (OD2) TYR 811 (OH) n.a.  3.03  n.a 
       
 
chain Db 
 
chain B’,d 
 
dist. (Å) 
 distance (Å) between corresponding 
atoms of chain Db and Ac, resp. 
 distance (Å) between corresponding 
atoms of chain Eb and Cc, resp. 
       
ILE 154 (O) ARG 263 (NH2) 2.85  3.61  3.2 
ASN 155 (O) ARG 263 (NH1) 2.78  n.a.  2.76 
ASN 155 (O) ARG 263 (NH2) 3.01  2.8  n.a. 
ASN 156 (OD1) LYS 248 (NZ) 2.79  2.62  n.a. 
       
# of contacts  14  14  12 
∆iGe (kcal/mol)  -6.1  -5.7  -3.5 
total # of contacts  42  26 
total ∆iGe (kcal/mol)  -18.3  -9.2 
 
a: calculated at PISA webservice (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html), (4) 
b: DARPin molecule 
c: AcrB molecule 
d: B’ is the symmetry related protomer of B, corresponds to A in 2J8S 
e: solvation free energy upon formation of interface
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Abstract 
 
The tripartite AcrA/AcrB/TolC complex extrudes structurally and functionally diverse 
chemical compounds and is the major multidrug efflux pump in Escherichia coli. 
AcrB is a trimeric integral inner membrane protein and is both the substrate 
specificity and energy module of the complex. The recently published asymmetric 
structure of AcrB implies transport of substrate in the soluble domain by functional 
rotation of the monomers in a connected and concerted fashion through the three 
different conformations loose, tight and open. The rather large conformational 
changes in the porter domain are thought to be energized by protonation and 
deprotonation of four essential charged residues that form the proton relay network 
and reside in the transmembrane domain. To gain insight into the functional rotation 
mechanism, we crystallized wild-type and proton relay network mutants of AcrB in 
the presence of Designed Ankyrin Repeat Proteins (DARPins) and solved the 
structures at resolutions of 2.0 - 3.0 Å. The presence of ordered waters exhibited by 
the high resolution structures allowed us to deduce a pathway for proton-transfer from 
the periplasm to the cytoplasm. Based on the different orientations of the proton relay 
network residues and dynamic conformational changes of the transmembrane helices 
in the different monomers of wild-type and mutant AcrB, we propose a detailed 
model for protonation and deprotonation events during functional rotation. 
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Introduction 
 
Organisms of all phyla express genes encoding multidrug-resistance (MDR) pumps to 
clear the cell interior from noxious compounds. For some bacteria, up to 18% of all 
the transport proteins encoded are putative MDR transporters, which can be classified 
on basis of their sequence homology to five families (1,2). ATP binding cassette 
(ABC) transporters are predominantly found in eukaryotes, whereas putative MDR 
transporters from major facilitator (MF) and resistance-nodulation-cell division 
(RND) superfamilies are mainly found in firmicutes and proteobacteria, respectively 
(3). The acriflavine resistance transporter B (AcrB) from E. coli is a member of the 
RND superfamily and functions in conjunction with the periplasmic adaptor protein 
AcrA and the outer membrane channel TolC. The components form a trimeric 
complex which enables the E. coli cell to extrude a broad spectrum of substrates 
directly from the outer leaflet of the inner membrane into the media, bypassing both 
periplasm and outer membrane. AcrB is both the substrate specificity determinant and 
the energy module of this tripartite complex. Functional AcrB forms a trimer, and 
each monomer constitutes of twelve transmembrane helices (TM) and two 
periplasmic loops which protrude 70 Å into the periplasmic space (reviewed in (4-6)).  
AcrB was shown to crystallize in symmetric (7) and asymmetric conformation (8-10). 
Transport of substrate was suggested to be accomplished by a cyclic functional 
rotation of the monomers adapting three different conformations loose, tight and open 
as observed in the asymmetric structure (4-6,11). The AcrB trimer was found to 
contain a dynamic tunnel system within its periplasmic domain through which 
substrates are thought to be guided towards and away from a hydrophobic binding 
pocket. This pocket is present only in the tight conformer, where bound substrate 
(minocycline) could unambiguously be identified (8). Upon conformational change 
from the tight to the open state, the tunnels system changes its appearance so that the 
lateral entry tunnels are closed and instead a new tunnel leading from the collapsed 
binding pocket to the funnel in the centre of the trimer is formed. From here, substrate 
is thought to move into the extracellular space via TolC.  
According to reconstitution assays (12,13) and phylogenetic analysis (1), AcrB is a 
drug/proton antiporter energized by the proton motive force and protons are 
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anticipated to be transferred through the transmembrane domain driven by the 
electrochemical gradient from the periplasm to the cytoplasm. Of the approximately 
330 residues forming the twelve transmembrane helices of the AcrB monomer, 30 
polar and charged residues could be putatively involved in proton translocation. Site-
directed mutagenesis studies revealed that only four of them, D407, D408, K940, and 
R971 are essential for AcrB function (14-16). D408 was identified by DCCD labeling 
studies to be protonated at one or more monomer conformations during the transport 
cycle and is a likely candidate for protonation/deprotonation events at physiological 
pH as is apparent from its deduced pKa of 7.4 (16). T978, first thought to be an 
essential hydroxyl group carrier, showed almost no activity when changed to alanine; 
however, when mutated to valine, AcrB retains 64% of its activity (15).  
The putatively titratable side chains of residues D407, D408 and K940, also referred 
to as triad, are located on TM 4 and 10 at approximately 2/3 of the distance from the 
periplasmic membrane plane to the membrane-cytoplasm boundary. These helices are 
situated in the middle of an oval bundle formed by the twelve helices of each 
monomer. T978 is situated on neighboring TM 11. In the loose and tight monomer, 
these four residues are situated within hydrogen bond interaction distance of each 
other. The functionally essential R971 is situated close to the membrane-cytoplasmic 
border and is considered a key residue in proton transfer. Together these four 
residues, D407, D408, K940, and R971 constitute a putative proton relay network. 
In the loose and tight monomer, K940 is situated on the same parallel plane within the 
transmembrane domain in almost equal distance from the side chains D408 and D407. 
Upon conformational change from tight to open, K940 reorients from D407 and D408 
towards the polar residues T978, S979 and N941 (residing on TM 11 and TM 10, 
respectively). In addition, a coil-to-helix transition at the periplasmic end of TM 8 as 
well as a bulging of TM 5 towards TM 4 and 10 can be observed (8-10). These subtle 
conformational changes might trigger the much larger conformational rearrangements 
observed in the periplasmic domain, which ultimately lead to the extrusion of 
substrate. Despite this structural detail on the molecular level, it is still beyond 
understanding how the events in the transmembrane domain are linked to those in the 
periplasmic domain. Moreover, it remains ambiguous how protons move from the 
bulk solvent of the periplasm to the triad residing in the transmembrane domain. 
Crystallization of mutant AcrB resulted in symmetric crystals growing in the H32 
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space group ((17) and results not shown). In this report we successfully co-
crystallized AcrB mutants D407N, D408N, K940A, T978A and R971A in presence of 
Designed Ankyrin Repeat Proteins (DARPins) (10,18,19) and resolved the 
asymmetric structures using X-ray diffraction data with a resolution of 2.2 Å 
(AcrB_R971A) to 3.0 Å (AcrB_T978A). Wild-type (wt) AcrB/DARPin co-crystals 
with bound doxorubicin and minocycline diffracted to 2.0 Å and the structures 
provided molecular details on drug binding. Interestingly, only two AcrB mutants, 
D407N and R971A, show apparent different conformations in the transmembrane 
domain compared to the wt protein, whereas the other mutants, AcrB_D408N, 
AcrB_K940A, AcrB_T978A retained essentially the same conformation as shown for 
the wt AcrB structure. 
On the basis of these high resolution structures, we suggest a proton pathway through 
the transmembrane domain via the proton relay network. 
 
 
Results 
 
Binding of minocycline and doxorubicin by the AcrB wild-type protein 
The Protein Data Bank (www.pdb.org) contains at the moment of writing 24 AcrB 
structures. The first AcrB structure (year 2002, PDB entry: 1IWG) was based on 3.5 
Å X-ray diffraction data from R32 crystals containing one unliganded AcrB monomer 
in the asymmetric unit i.e. it describes a symmetric AcrB trimer (7). In the following 
years, other groups deposited symmetric (wt and mutant) AcrB X-ray structures 
(based on 3.1 - 3.8 Å data) with and without ligands (17,20-27). With one exception 
(27), most of these structures were derived from the first structure (PDB entry: 1IWG) 
taken as a template. Recently, six structures describing an asymmetric AcrB trimer 
were published (PDB entries: 2DHH, 2DR6, 2DRD, 2GIF, 2HRT, 2J8S) (8-10) with 
the best resolution structure (2.5 Å, PDB entry 2J8S) obtained with AcrB/DARPins 
co-crystals (10). Two of the deposited asymmetric structures were derived from 3.1 
and 3.3 Å data of AcrB/minocycline and AcrB/doxorubicin co-crystals, respectively 
(8).  
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We describe here the crystallization and structural elucidation of wt AcrB/DARPin 
complexes in the presence of minocycline and doxorubicin based on 2.0 Å and 2.25 Å 
diffraction data (Table S1). AcrB/DARPin complexes were co-crystallized in the 
presence of 2.0 mM and 0.4 mM minocycline and doxorubicin, respectively, yielding 
crystals in an orthorhombic space group. The structures were refined to an Rfree of 
24.11% and 22.82%, respectively. Electron densities for substrates could be clearly 
identified near the hydrophobic binding pocket of the tight monomer. Moreover, clear 
densities for ordered waters were identified, including in the transmembrane domain.  
 
Binding of minocycline is accomplished by residues F178, G179, N274, I277, V612 
and F615 (Table S2). The dimethylamino moiety of the drug is sandwiched by the 
aromatic side chains of F178 and F615. V612 and I277 make stacking contacts with 
the D and C rings, respectively. The carboxamid group of minocycline interacts with 
the polar side chain of N274 and the amido nitrogen of G179 is in 3.3 Å distance of 
the B ring (Figure 1). 
 
Figure 1: Binding of minocycline and doxorubicin in the binding pocket of the tight monomer of the 
AcrB trimer. Binding of the substrate molecules is achieved by aromatic stacking interactions, van der 
Waals contacts and polar interactions by both protein side chain and main chain atoms. The mesh 
represents the 2Fo-Fc electron density map contoured at 1.3 σ. A) AcrB/minocycline complex.  
B) AcrB/doxorubicin complex. 
 
The ring system of doxorubicin is situated in the same plane as minocycline; however, 
the positions of the two substrate molecules differ by an angle of approximately 60°. 
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F178 and F615 wedge the C and D rings of doxorubicin. At the other end of the 
molecule, Q89 interacts with the hydroxyl group of the dihydroxypropanone moiety 
and together with the side chains of S46, S128 and E130 with the daunosamine sugar 
moiety
Figure 2: Proton relay and associated residues in different states of the functional rotation of AcrB. Most 
apparent differences between the three monomers are the reorientation of D407, K940 and R971 as well 
as bulging of TM 5 upon transition from tight to open. A section of the transmembrane domain viewed 
from the periplasm and viewed from the side is shown in the upper and lower row, respectively. 
 
Ordered water molecules in the transmembrane domain of wt AcrB 
AcrB is a secondary active transporter catalyzing the exchange of protons and drugs. 
While drug binding and transport is primarily localized in the periplasmic domain 
proton transport occurs through the transmembrane domain and putatively involves 
four conserved charged and polar residues that form the proton relay network. The 
high resolution structure shows the exact geometry of these residues inside the 
transmembrane domain (Figure 2, Table 1). In the loose monomer, K940 is situated 
exactly parallel at equidistance (2.7 Å) to the carboxyl groups of D407 and D408. 
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Additionally, D407 is within hydrogen bonding distance (2.8 Å) to the hydroxyl 
group of T978. R971, with its guanidinium side chain residing approximately 6.7 Å 
from D407 is located further towards the cytoplasm on TM 11. The aromatic side 
chain of F948 is within close proximity to R971 (3.8 Å). 
Upon transition to the tight conformer, TM 4 harboring D407 and D408 displays a 
kinked conformation at position 400 to 403 (Figure 3). The geometry of the residues 
of the proton relay is hardly affected and the distances between the side chains of 
these residues remain constant.  
 
Table 1: Distance between residues of the proton relay network in wt AcrB 
       
residues  distance (Å)a 
       
  loose  tight  open 
       
D408-K940  2.7  2.5  8.8 
D407-K940  2.7  2.8  3.9 
D407-T978  2.8  2.6  4.4 
D407-R971  6.7  6.6  10.6 
       
a: shortest interatomic distance 
 
In the open monomer, D407 adopts a more tilted conformation towards the periplasm 
(Figure 2). K940 reorients in the direction of TM 11, which in turn shortens its 
distance to TM 10 at this level by approximately 2.3 Å. In this new position, K940 is 
likely engaged in polar interactions with T978, S979 and N941. At the same 
positional height, TM 5 shifts approximately 2.3 Å towards TM 4 and TM 10, into the 
space formerly occupied by K940. Thus a convergence of TM 4 and 5 as well as of 
TM 10 and TM 11 can be observed (Table 2). Intriguingly, these pairs of α-helices 
seem to be symmetry related since AcrB is considered to have evolved by a gene 
duplication event of an ancient protein consisting of six transmembrane helices and 
one soluble loop (28,29). Further towards the cytoplasm, R971 reorients away from 
the D407/D408/K940 triad and a concomitant movement of the bulky side chain of 
F948 can be observed. 
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Table 2: distance between symmetry related transmembrane helices in different conformations 
       
helices  distance (Å)a 
       
  loose 
wt/R971A/D407Nb 
 tight 
wt/R971A/D407Nb 
 open 
wt/R971A/D407Nb 
       
TM4 - TM5 
   D408 - L442 
 7.6 / 6.9 / 7.3  8.5 / 6.8 / 8.5  5.3 / 5.6 / 5.5 
       
TM10 - TM11 
   K940 - S979 
 11.9 / 10.3 / 10.9  12.5 / 10.4 / 11.5  9.5 / 9.4 / 9.7 
       
a: shortest interatomic distances between Cα atoms 
b: wt: wild-type AcrB; R971A: AcrB_R971A; D407N: AcrB_D407N 
 
The high resolution structure reveals electron density of ordered water molecules in 
the transmembrane domain in proximity to the proton relay (Figure 3). In two of the 
three monomers, clustering of water molecules is evident. In the loose monomer 
groups (clusters) of three to five water molecules are apparent. Cluster 1 is situated at 
the interface of TM 10 and TM 12 and within hydrogen bonding distance of T934 
situated on TM 10. The other clusters are localized at the lower 1/3 of the 
transmembrane domain relatively close to the D407/D408/K940 triad. Cluster 2 
resides between TM 10 and TM 11 and is coordinated by D407 and T978. Another 
cluster (cluster 3) is located between K940 and D408 and includes water molecules 
occupying the space between TM 4 and TM 6. A fourth cluster (cluster 4) appears to 
be strategically positioned between D407 and R971. Since the water molecules of 
cluster 4 are in ideal hydrogen bond of each other, D407 is continuously H-bond 
connected to R971. Proton transport between D407 (and other residues of the triad) to 
R971 and further via E414 and R418 (not shown) to the bulk solvent of the cytoplasm 
is therefore theoretically possible. 
Cluster 2 and 3 are connected by the side chains of D407, K940 and D408 and are 
located within hydrogen bonding distance from each other. Cluster 1, however, 
appears to be isolated and not in direct hydrogen bond contact with either the 
periplasm or the proton relay network (Figure 3). 
 
4. The AcrB proton pathway 9
 
Figure 3: The presence of water and water 
clusters in the transmembrane domains of the 
AcrB monomers loose (A), tight (B) and open 
(C). Residues of the putative proton relay, 
T978 and S979 are depicted. Residues S481 
and T489 situated on TM6 as well as the 
carbonyl oxygens of residues L400, G403, 
L404 and L405 are shown in stick 
presentation. The water clusters 1 to 5 and 
transmembrane helices 4, 6, 9, 11, 12 are 
indicated. To increase clarity, only K940 and 
not the entire TM 10 is shown. A) In the loose 
monomer, residues of the proton relay 
network are amply hydrated by clusters 2 to 4. 
A continuous hydrogen bonded network is 
formed by water molecules of clusters 2, 3 
and 4, between residues of the proton relay 
and the polar side chain of S481 extending 
from the interspace of TM 4 and TM 6 
towards R971. A gap of 9.6 Å is present 
between cluster 1 and cluster 2.  
B) In the tight monomer, the carbonyl oxygen 
of L400 is exposed due to the kink in TM 4, 
coordinating one water molecule (C5W1) 
within the newly formed cluster 5. These 
water molecules partially fill the gap between 
cluster 1 and 2. Between cluster 1 and cluster 
5 a gap of 4.8 Å is present. 
C) The number of water molecules in the 
transmembrane domain of the open monomer 
is drastically reduced compared to the 
hydration in the loose and tight monomer. 
Only three water molecules in vicinity of the 
triad are observed. They seem to stabilize the 
strained TM 4, interacting with the exposed 
carbonyl oxygens of L404 and L405. 
Additionally, the carboxyl oxygen of D407 is 
within hydrogen bonding distance of carbonyl 
oxygen G403, indicating that D407 might be 
protonated in the open conformer. 
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This is in quite a contrast to the water clustering in the tight monomer where cluster 1 
is neighbored by another cluster (cluster 5) made out of five water molecules. Cluster 
5 is situated in the space defined by TM 4, TM 10 and TM 11. Starting with water 
molecule C5W1, this cluster propagates from the kink in TM 4 at first laterally 
towards cluster 1 and then towards the triad. The waters of cluster 5 are separated by a 
small gap of 4.8 Å from cluster 1 and by 5.4 Å from cluster 2. In addition, water 
molecules are apparent in the structure that protrude deeper from the periplasm 
towards cluster 1 in the tight monomer compared to the situation found in the loose 
monomer. The nearest water from the periplasm is now separated from cluster 1 by 
only 4.0 Å (Figure 3).  
The number of water molecules of the transmembrane core domain of the open 
monomer is dramatically reduced compared to the hydration of the loose and tight 
monomer. From clusters 1, 2, 3 and 5, only few molecules are left. Cluster 4, which 
connects D407 with R971 in the loose and tight monomer is absent. However, two 
water molecules located just above cluster 1 are situated at analogous positions 
compared to the tight conformer. 
The water molecules in the transmembrane domain might not only be directly 
involved in proton translocation, but are also most likely engaged in the stabilization 
of the conformation in the transmembrane domain. During the conformational 
changes, the TM 4 backbone deviates from the typical α-helical constraints at various 
positions. In the tight conformation, the carbonyl oxygen of L400 is not in hydrogen 
bonding distance to the amido nitrogen of 404. Apparently, water molecule C5W1 of 
cluster 5 is situated within a distance of 2.8 Å, which allows the formation of a 
stabilizing hydrogen bond. In the open conformer, TM 4 is mainly distorted towards 
the N-terminal region just above D407. The exposed carbonyl oxygens of G403 and 
L405 appear to undergo stabilizing interactions with two water molecules of cluster 3. 
In addition, due to reorientation of D407, the carbonyl oxygen of G403 and the 
hydroxyl proton of D407 carboxylate side chain are within a distance of 2.7 Å in the 
open monomer (Figure 3). 
 
Crystal structure of AcrB proton translocation mutants 
We determined the structure of five proton translocation mutants i.e. AcrB_D407N, 
AcrB_D408N, AcrB_K940A, AcrB_R971A and AcrB_T978A at a resolution of 2.2 
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to 3.0 Å (Table S1). Visual inspection revealed that the asymmetric structures of 
AcrB_D408N, AcrB_K940A, and AcrB_T978A are very similar compared to the wt 
structure, whereas the loose and tight monomer of AcrB_D407N and AcrB_R971A 
show significant deviations. This observation is in accordance with the calculated root 
mean square deviation (rmsd) between these mutant structures and the wt (Table S1).  
 
R971A mutant 
The structure of the AcrB_R971A mutant was determined from 2.2 Å resolution 
diffraction data and after refinement resulted in an R/Rfree of 24.70/27.70%. The 
transmembrane domain of either the loose and tight conformer deviate by 1.08 and 
1.01 Å rmsd from the corresponding monomer in the wt structure (Table S1). 
In the loose monomer, the cytoplasmic end of TM 4 and TM 5 are shifted in direction 
of TM 11 for 2.0 and 1.6 Å, respectively. The position of the TM 4 backbone differs 
between residues L400 and D407 compared to the wt structure. This change includes 
a mild reorientation of D407 and the exposure of carbonyl oxygen of L400 (Figure 
4). 
In the tight conformation of the R971A mutant, the C-terminal periplasmic end of  
TM 2 bends 1.9 Å towards TM 1. TM 4 and TM 5 also differ from the wt structure, 
but this deviation is apparent further towards the periplasm: TM 4 is relaxed between 
the residues G397 and D407 and lacks the pronounced kink at L400 as seen in the wt 
structure (Figure 5). TM 5 bulges towards TM 4 and TM 10 at the level of the 
D407/D408/K940 triad and occupies a position commensurable with the one in the 
open conformer of the wt structure (Figure 6). Similarly, D407 and K940 exhibit in 
the R971A tight monomer orientations that are characteristic for the open 
conformation of the wt structure: The D407 side chain is directed towards the 
periplasm and K940 is reoriented away from D408 and D407 towards TM 11. 
Furthermore, a coil-to-helix transition at the periplasmic end of TM 8 is apparent, 
much like the wt conformation in the open monomer (Figure 6). Compared to TM 8 
in the tight conformation of the wt protein, the periplasmic end is also shifted 1.7 Å 
towards the position it occupies in the open conformer (Cα of L868).  
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Figure 4: Differences between the loose monomer of wt AcrB and AcrB_R971A. Compared to the wt 
protein, the cytoplasmic end of TM 4 and TM 5 in the loose conformer of AcrB_R971A are shifted 
towards TM 11. The intrinsical kink in TM 4 just below residue L400 is also more pronounced in the 
AcrB_R971A structure. The transmembrane domain is, compared to the wt structure (grey spheres), 
poorly hydrated (red spheres). Similar observations apply to the AcrB_D407N mutant. AcrB_R971A 
and wt AcrB are colored blue and white, respectively. Ordered water molecules of the mutant and wt 
protein are indicated with red and white spheres, respectively. All residues of TM 10 are removed for 
enhanced visibility of TM 4 and TM 5 and the ordered water molecules. 
 
The hydration of the putative proton translocation channel is also different in the 
mutant compared to the wt. Most obvious is the absence of ordered water molecules 
in the lower halfchannel (cluster 4) in all the three conformers. Whereas the proton 
relay in the loose conformer of wt AcrB is hydrated by waters of cluster 2 - 4, only 
two water molecules were detected near D408 in the R971A mutant. On the other 
hand, the exposed carbonyl oxygen of L400 on TM 4 is stabilized by a water 
molecule that is not present in the wt structure. 
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Unlike in the wt protein tight monomer, K940 repositions itself from D407 and D408 
in the tight conformation of the R971A mutant AcrB (Figure 6). However, in the 
open conformer of the wild-type, the entire TM 11 bulges towards TM 10, which 
allows K940 to tightly interact with the polar side chains of T978 and S979. This shift 
of TM 11 is not present in the tight conformation of the R971A mutant structure. 
Instead, K940 points towards a chain of ordered water molecules (cluster 6) that are 
not present in any conformation of the wt structure, hydrating the space defined by 
TM 2, TM 4 and TM 11 (Figure 5). On the other hand, cluster 5 of the tight 
conformation of wt AcrB is not present in the R971A mutant. 
 
D407N mutant 
The structure of the AcrB_D407N mutant was determined using data diffracting to a 
resolution of 2.35 Å and was refined yielding an R/Rfree of 22.78/25.51%. The 
transmembrane domain of the loose and tight conformer deviate by 0.63 and 0.80 Å 
from the corresponding monomer in the wt structure, respectively (Table S1). 
The AcrB_D407N mutant deviates from the wt protein in a similar manner as the 
R971A mutant, although to a lesser extent. In the loose conformation, the Cα trace of 
TM 4 and the N-terminal cytoplasmic end of TM 5 of the D407N mutant lies in 
between R971A and the wt (Figure 4). In the tight conformer, the same shift of the 
periplasmic end of TM 8 is observed as in R971A, although the coil-to-helix 
transition is not as extensive. TM 2 and TM 4 are reminiscent to the tight conformer 
of the R971A mutant and TM 5 bulges towards TM 4 and TM 10 by 1.1 Å compared 
to a shift of 2.3 Å in the tight to open transition in the wt protein. The side chain of 
K940, however, exhibits the same orientation as seen in the wt structure (Figure 6). 
As a peculiarity of the D407N mutant, the side chain orientation of N407 is the same 
in all three conformers. 
The putative proton translocation pathway in the loose conformer of D407N is 
hydrated even more sparsely than the corresponding monomer in the R971A mutant 
and lacks any apparent ordered water molecule. 
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Figure 5: Transmembrane domain of R971A and D407N mutant protein in tight state. A) Tight conformer of 
AcrB_R971A. In comparison to the wt protein, TM 4 in the R971A mutant is less strained between L400 and 
L404. TM5 and D407 exhibit positions that are typical for the open monomer in the AcrB wt structure. 
Similarly, K940 is oriented towards TM 11, but unlike to the open monomer of the wt protein, the amino group 
is orienting a novel cluster (6) of water molecules. B) Tight conformer of AcrB_D407N. The transmembrane 
domain of the tight conformer in AcrB_D407N is similar to the tight monomer in the R971A mutant. Cluster 6 
is not contacted by K940, but by the carboxamide group of N407. Structure of AcrB_R971A and AcrB_D407N 
are colored yellow, AcrB wt structure is shown in grey. Water molecules of the proton translocation mutants 
are shown as red spheres. 
 
The tight conformation harbors a chain of waters that is reminiscent to cluster 6 in the 
R971A mutant (Figure 5). However, the water molecule that is coordinated by the 
repositioned K940 in the R971A mutant is lacking in the D407N mutant. At the 
opposite end of cluster 6, there are three additional water molecules extending 4 Å in 
the periplasmic direction. In comparison to the wild-type, however, the numbers of 
waters in each cluster is drastically reduced and the hydrogen bond connection 
between the triad and R971 is interrupted. 
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Figure 6: Differences between tight (yellow) and open (red) monomer of wt AcrB and tight momomer 
of AcrB_R971A (orange) and AcrB_D407N (bright orange). A) Periplasmic (N-terminal) end of TM 
8. Upon conformational change from tight to open, the periplasmic end of TM 8 in wt AcrB undergoes 
a coil-to-helix transition, which leads to a relocation of the Cα atom of L868 by 7.8 Å. TM 8 in the 
tight monomer of the R971A and D407N mutant adopts an intermediate conformation between the two 
states tight and open described for the wt protein (Cα L868 shift = 2.0 and 1.6 Å in AcrB_R971A and 
AcrB_D407N, respectively). 
B) Reorientation of K940. In the wt protein, K940 reorients towards T978 and S979 of TM 11 during 
the transition from tight to open. This conformational change is concomitant with TM 11 approaching 
TM 10 and a bulging of TM 5 towards TM 4 and 10. This bulging can also be observed in the tight 
conformation of the R971A mutant and, to a lesser extent, in the D407N mutant. Whereas the 
orientation of K940 in the D407N mutant is comparable to the tight conformer of the wt protein, this 
residue is repositioned towards TM 11 in the R971A mutant, adopting a similar conformation as 
observed in the open conformer of wt AcrB. However, the amino group of K940 is not in hydrogen 
bond contact with T978 or S979, but rather with water molecules of cluster 6 (see Figure 5). Structure 
of the tight and open monomer of AcrB wt is shown in yellow and red, respectively. The tight 
conformer of AcrB_D407N and AcrB_R971A are shown in bright and dark orange, respectively. 
 
 
Discussion 
Residues D407 and D408 on TM 4 play a crucial role in the transfer of protons from 
the periplasm to the cytoplasm (14-16). Whereas the cytoplasmic half of TM 4 is a 
straight α-helix with regular hydrogen bonding interactions, the periplasmic end of 
TM 4 (residues 392 to 409) is strained at various degrees in the symmetric structure of 
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AcrB (1IWG) and in all the conformers of the high resolution structures we present 
here. The periplasmic half of TM 4 contains two aspartate, two glycine and one 
threonine side chain, all of which have intrinsically low propensity for α-helix 
formation (30). TM 4 exhibits two major kinks at positions A409 and G403. The latter 
kink is most distinct in the tight conformer, where as a consequence the carbonyl 
oxygen of L400 gets exposed. Water molecule C5W1 of cluster 5 (Figure 3) is 
coordinated by this oxygen and marks the starting point of a chain of waters in the 
upper halfchannel that expands towards the triad. This water file is separated by a gap 
of 5.3 Å from the solvent network (cluster 2 to 4) hydrating the proton relay.  
Upon conformational change from the tight to the open, the kink at G403 becomes 
less pronounced. As a consequence, water C5W1 is dislocated which disrupts the file 
of waters in the upper halfchannel. On the other hand, TM 4 is in the open 
conformation severely distorted between D408 and G403, which results in exposure 
of the carbonyl oxygens of L405, L404 and G403. The carbonyl oxygen of L405 is 
stabilized by a water molecule of cluster 3 located in the interspace of TM 4 and TM 
6. Another water molecule is sandwiched by the side chain of D408 and the carbonyl 
oxygen of L405. Computational pKa calculation of the titratable residues of the 
transmembrane domain using the PROPKA appoach (31,32) suggest that in the open 
monomer D407 is protonated. In this state, D407 orients towards the periplasm and its 
putatively protonated side chain is situated within a distance of 2.7 Å to the exposed 
carbonyl oxygen of G403, forming a hydrogen bond (Figure 3).  
In the transmembrane domain region of wt AcrB, the loose conformation is similar to 
the tight conformation. However, in the loose TM domain the helical kink at position 
G403 is less pronounced. Consequently no water molecule is present at an appropriate 
position to start the file of water (cluster 5) of the upper halfchannel as observed in the 
tight conformation (Figure 3). 
Open state K940 is surrounded by the polar side chains of residues N941, T978 and 
S979. The latter two residues reside on TM 11 which shifts towards TM 10 upon the 
tight to open transition and thereby improves the polar interaction of K940 with T978 
and S979 (Figure 6). As a consequence, the open conformation does not provide 
sufficient space between TM 4 and TM 11 to adapt water molecules. Therefore, 
proton movement via a water network does not appear to be feasible in the open 
monomer. 
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Out of the five crystallized AcrB proton translocation mutants, only two of them - 
AcrB_D407N and AcrB_R971A - differ significantly from the wt structure. Our 
interpretation is that these mutants represent intermediary conformations in the tight 
conformer, and for both mutants at different stages of the transition from tight to open 
like those observed in the wt protein. In this light, the D407N structure might 
represent an early intermediate where the coil-to-helix transition of the periplasmic 
end of TM 8 and the bulging of TM 5 is only slightly visible as a structural deviation 
from the wt tight conformation, whereas the R971A structure might be an 
intermediate of the tight to open transition at a more advanced state. In the latter 
mutant, the bulging of TM 5 is clearly observable and might be responsible for the 
reorientation of K940 towards T978 and S979 (Figure 6). However, instead of 
interacting with these polar side chains, like in the open monomer in the wt protein, 
the ε-amino group of K940 is within hydrogen bonding distance to a water molecule 
of water cluster 6, which is not present in the open monomer of the wt structure 
(Figure 5).  
Based on the high resolution structures of wt and mutant D407N and R971A AcrB, 
we propose the following order of protonation and deprotonation events during 
functional rotation from loose to tight to open and back to loose (Figure 7): the 
transmembrane domain of the loose monomer is amply hydrated. D407 is protonated, 
whereas D408 bears a negative charge. Together, they compensate for the positive 
charge of the protonated K940, which is situated at equidistance between the two 
aspartates. The proton relay residue closest to the membrane/cytoplasm interface, 
R971, might be deprotonated in order to have a charge balance in this region. A 
similar deprotonation has been postulated for the bacteriorhodopsin R82 (33,34). The 
transition from loose to tight is induced by the transfer of the proton from D407 to 
R971. As a result, TM 4 becomes distorted at G403, leading to exposure of the 
carbonyl oxygen of L400. This carbonyl oxygen is involved in the stabilization of a 
newly recruited cluster of water molecules (cluster 5) that is separated by 
approximately 5 Å from waters of cluster 1 situated close to the periplasm and from 
water cluster 2 which is hydrating the D407/D408/K940 proton relay. Simultaneously, 
an almost uninterrupted file of ordered water molecules projects from the bulk solvent 
of the periplasm towards water cluster 1 (Figure 3). A small 4.0 Å gap separates the 
bulk water from cluster 1 and it is hypothesized that due to protein conformational 
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fluctuation, these clusters converge and form a transient continuous file of water 
molecules from the bulk solvent of the periplasm to the triad.  
On the other hand, in order to avoid a continuous proton pathway through the AcrB 
transmembrane domain from the periplasm to the cytoplasm and therefore dissipation 
of the proton motive force, the pathway from the triad to the cytoplasm has to be non-
continuous before the triad is in contact with the bulk solvent of the periplasm. This 
could be accomplished by extrusion of water molecules of cluster 4 present between 
D407 and R971. Diminishing the number of water molecules would also increase the 
hydrophobicity in this part of the transmembrane domain and might facilitate lysine 
deprotonation as well as shift the pKa of D407 and D408 in order to accept protons 
from the periplasm. We propose that the open conformer is the result of protonation 
of D407 by a periplasmic proton. Concomitantly, K940 donates its proton to D408 
and reorients towards TM 11. The protonated R971 might keep its positive charge and 
reorients from the now dehydrated and rather hydrophobic region of the 
transmembrane domain towards the cytoplasm (as observable in the open monomer 
conformation). This R971 side chain conformation might be stabilized by cation-π 
interaction with the aromatic side chain of F948 (Figure 7).  
The transition from the now open state conformation into the loose conformation 
might involve the release of a proton from R971 to the cytoplasm. Subsequently, 
water molecules might re-enter the region between R971 and D407, as observed in the 
wt loose monomer conformation. K940 would be recharged by the acceptance of a 
proton from D407 and repositions to its initial position between the D407 and D408 
side chains, allowing the exchange of protons between these two aspartates (Figure 
7). 
In short, the protonation scheme depicted in Figure 7 describes one complete 
functional rotation cycle of AcrB energized by the flow of one proton from the 
periplasm to the cytoplasm following its electrochemical gradient. This theoretically 
enables AcrB to establish a maximal substrate gradient of approximately 1:1000 
between the cytoplasm and the cell exterior given the typical value of the proton 
motive force of -180 mV. To our knowledge, there is no report where the ratio of 
[substrate]in/[substrate]out was described to be smaller than 1/1000.  
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The amino acid substitutions at D407 and R971 apparently severely affect the proton 
pathway presumably due to the shifts in pKa of the other residues of the proton relay 
network and due to the effect on water cluster formation and disintegration. 
In the loose conformation of AcrB_R971A mutant, the orientation of the residues of 
the triad is similar to the wt structure and we therefore assume that the protonation 
state of these residues is the same as in the wt protein. However, the proton transfer 
from the triad in the direction of the cytoplasm, which is expected to happen during 
the loose to tight transition in wt AcrB, is interrupted due to the lack of the R971 
proton acceptor (Figure 7). Considering the sparse hydration of the transmembrane 
domain in the tight conformer of the R971A mutant, it is likely that the isolated D408 
is protonated in the tight monomer of this mutant. Some conformational change might 
still be feasible and we postulate that during transition from loose to tight, D408 
accepts a proton of K940. K940 reorients towards TM 11 and shares a proton with 
D407 in this observed position. D407 reorients slightly towards the periplasm and 
would be able to accept a proton from the periplasm (necessary to establish the open 
conformation), but cannot release the shared proton of D407 and K940 via R971. Due 
to the lack of the R971 side chain, the functional rotation would be interrupted at this 
point. 
In order to explain the conformational intermediate state observed in the D407N 
mutant, we assume that D407 is essential for the transfer of a proton from the triad to 
R971 and also presumably is the first residue of the proton relay that gets protonated 
by a periplasmic proton. Both events are abolished due to the D407N mutation, 
rendering the AcrB_D407N non-functional. Again some conformational flexibility is 
apparent and we suggest that in the loose monomer of the D407N mutant, K940 is 
protonated and shares its proton with the negatively charged D408 (Figure 7). Due to 
the isolation of the triad from the periplasm as a consequence of the loss of the D407 
carboxylic group, there is no proton redistribution during the loose to tight 
conversion. The intermediate state observed in the tight conformation of this mutant 
describes the inability of N407 to donate a proton to R971. The open conformer of 
this mutant might be a result of proton transfer from K940 to D408, and subsequent 
reorientation of the lysine side chain towards TM 11. Interestingly, the carboxyl group 
of N407 would be logically involved in hydrogen bond formation with the ε-amino 
group of K940. The oppositely oriented amino group of N407 is, however, not 
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capable of hydrogen bonding to the carbonyl group in this conformation due to the 
planar orientation of the sp2 orbitals. The protonation state of R971 might be the same 
in all three monomers. Alternatively, R971 accepts and donates protons from and to 
the cytoplasm, which however does not lead to a net influx of protons from the 
periplasm to the cytoplasm and hence prevents energization of the entire efflux pump 
leading to the inactive pump phenotype. 
In the AcrB_R971A and D407N mutant, it is mainly the loose and tight monomer that 
are different compared to the wt structure, whereas the open monomer hardly 
deviates. We hypothesize that substitution of a formal charged residue by a more 
hydrophobic amino acid severely disturbs the charge distribution between the proton 
relay residues in the loose and tight conformation, which can be expected to also 
affect the structure. In the open monomer, the residues of the triad are postulated to be 
neutral and R971 is isolated from the triad by reorientation towards the cytoplasm. 
Therefore, the structure of the open monomer is probably unaffected by the R971A 
substitution and even stabilised by the D407N exchange. 
Recently, structures of the proton translocation mutants D407A, D408A, K940A and 
T978A crystallized in the symmetric space group H32 were published. The crystals 
diffracted to a maximum resolution in the range of 3.38 to 3.65 Å (17). All of these 
mutants showed the following differences compared to the symmetric structure of 
AcrB, the only conformation known at that time: (i) distortion of the N-terminal 
portion of TM 4 with major kinks at G403 and A409, (ii) unwinding of TM 5 at the 
height of the triad and (iii) a shift of F386 and F388 located on the loop between TM 
4 and TM 5 towards the centre of the AcrB trimer. The authors attributed these 
changes to the disrupted salt bridge interactions of the proton translocation mutants. 
Remarkably, the kink on TM 4 at G403 and A409 were later shown to be features of 
the tight and open conformer in the asymmetric structure, respectively (8-10). In 
addition, TM 5 was shown to be flexible and to adopt different conformations during 
functional rotation. In the wt structure and the proton translocation mutants we 
present here, a bulging of TM 5 rather than unwinding (as described by (17)) can be 
observed, which might be explained by the increased resolution and the improved 
model. Our structures are, however, not indicative for a shift of residues F386 and 
F388 towards the central cavity.  
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Figure 7: Schematic representation of hypothetical protonation and deprotonation events in the 
transmembrane domain of wt AcrB, AcrB_R971A or AcrB_D407N during functional rotation. Key 
residues are denoted and water molecules of cluster 2, 3, 4 and 6 (AcrB_R971 and AcrB_D407N) close 
to proton relay residues are shown in red spheres. The arrows indicate redistribution of protons. The 
protonation states of the arginine, lysine and aspartate residues are indicated. R971 in the AcrB_D407N 
mutant might be either charged or neutral during the entire functional rotation. See Discussion for 
detailed description. 
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Of all the different substrates we crystallized in presence of AcrB, we could only 
identify minocycline and doxorubicin in the binding pocket. Whereas the position of 
minocycline is congruent with the structure of Murakami et al. (8), the orientation of 
doxorubicin is quite different (Figure 8). Superimposition of the two structures 
reveals that the core ring systems of the doxorubicin molecules partially overlap, but 
that they are oriented in opposite directions. Therefore, F178 of our high resolution 
structure interacts with the aromatic D ring rather than with the non-aromatic A ring. 
In the structure of Murakami et al., F617 seems to interact with the D ring, whereas in 
our structure doxorubicin and F617 are separated by 5.3 Å and the side chain of F617 
exhibits a different orientation. It has to be emphasized that only for the 
AcrB/minocyline complex the position of the substrate was confirmed by using a 
brominated derivative (8).  
 
Figure 8: Superimposition of bound substrate in the AcrB binding pocket. A) Comparison of 
doxorubicin binding in 2DR6 and in recent structure. The new AcrB/doxorubicin complex is shown in 
yellow and cyan, respectively. Doxorubicin and binding pocket residues of 2DR6 that differ 
significantly are shown in grey. B) Comparison of position of minocycline and doxorubicin in the 
binding pocket. Doxorubicin and minocycline are shown in cyan and green, respectively. The depicted 
side chains derive from the AcrB/minocycline structure, but are congruent with the orientation 
observed for the AcrB/doxorubicin complex.  
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In summary, the high resolution crystal structures described in this report reveal a 
hitherto unprecedented molecular detail of substrate binding and transmembrane 
hydration allowing to propose a detailed molecular mechanism for proton transfer in 
accordance with the observed properties of the multidrug/proton antiporter AcrB. 
 
 
Materials and Methods 
 
Bacterial strains, plasmids and growth conditions 
E. coli C43 (DE3) (35) harboring pET24acrBHis (26) and mutant derivatives (16) were 
used for protein overexpression. LB medium and LB agar (36) were used for routine 
bacterial growth at 37°C. Terrific broth (37) was used for protein overexpression. 
Kanamycin (Applichem) was applied at 50 µg ml-1 (Kan50). 
 
Crystallization of wt and mutant AcrB in presence of DARPins 
Overexpression and membrane preparation of wt and mutant AcrB was carried out as 
described previously (9,26). DARPin clone 1108_19 (10) was overexpressed and 
purified according to Binz et al. (19). To crystallize the AcrB/DARPin complex, the 
method described by Sennhauser et al. (10) with n-dodecyl-β-D-maltoside as 
detergent was applied. For the AcrB_T978A variant, buffer exchange was from Tris-
HCl to KPi buffer, instead of HEPES (pH 7.5), due to precipitation problems. 
Substrate was added prior to crystallization at a concentration of 2 mM and 0.4 mM 
for minocycline and doxorubicine (Sigma-Aldrich), respectively. Formation of 
crystals for the AcrB_T978A/DARPin complex was only observed in the absence of 
substrate. Crystals were grown by the hanging drop vapor diffusion method at 0.05 M 
ADA buffer pH 6.5, 7-9% polyethylene glycol (PEG) 4000, 6-10% glycerol, 0.2 M 
(NH4)SO4.  
 
X-ray diffraction dataset analysis and refinement procedure 
Datasets of P212121 crystals were collected at the beamline X06SA of the Swiss Light 
Source (Paul Scherrer Institut, Villigen, Switzerland) (wavelength 0.80-1.0 Å). Data 
reduction was done with the XDS package (38). Refinement was performed with the 
program PHENIX (39) and REFMAC5 (40). Model rebuilding was performed using 
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the program COOT (41). In later stages, bulk solvent correction was applied using 
phenix.refine (42) and additional water molecules were appended and analyzed 
employing COOT. Figures were created using Pymol (http://pymol.sourceforge.net/). 
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 Table S1: Crystallographic data and refinement 
               
  AcrB_wt/ 
DARPin 
& minocycline 
 AcrB_wt/ 
DARPin 
& doxorubicin 
 AcrB_D407N/ 
DARPin 
& minocycline 
 AcrB_D408N/ 
DARPin 
& minocycline 
 AcrB_K940A/ 
DARPin 
& minocycline 
 AcrB_R971A/ 
DARPin 
 AcrB_T978A/ 
DARPin 
 
               
Data collection               
space group  P212121  P212121  P212121  P212121  P212121  P212121  P212121 
               
Cell dimensions               
a (Å)  145.99  145.85  145.59  145.88  145.91  145.79  146.01 
b (Å)  161.72  161.60  161.59  161.16  162.32  160.77  164.05 
c (Å)  245.97  245.70  245.97  245.29  245.81  246.45  245.58 
α (°)  90.00  90.00  90.00  90.00  90.00  90.00  90.00 
β (°)  90.00  90.00  90.00  90.00  90.00  90.00  90.00 
γ (°)  90.00  90.00  90.00  90.00  90.00  90.00  90.00 
               
Resolution (Å)  2.00  2.26  2.35  2.40  2.35  2.20  3.00 
               
Rmeas (%)  166.8a  73.1  218.9c  59.1  122.6  83.8  119.7 
I/σI  1.38b  2.37  1.26d  3.37  2.66  2.39  2.22 
Completeness (%)  97.9  93.4  98.3  96.0%  97.7  94.2%  97.8 
redundancy  6.23  5.15  7.15  6.87  7.49  7.42  8.31 
               
Refinement               
Trimer model  2J8S  2J8S  2J8S  2J8S  2J8S  2J8S  2J8S 
Program  PHENIXe,f & 
REFMAC5 g 
 PHENIXe,f & 
REFMAC5 c 
 PHENIXe,f & 
REFMAC5 c 
 PHENIXe,f & 
REFMAC5 c 
 PHENIXe,f & 
REFMAC5 c 
 PHENIXe,f & 
REFMAC5 c 
 PHENIXe,f & 
REFMAC5 c 
               
Resolution (Å)  39.47 - 2.00  38.45 - 2.25  49.34 - 2.35  44.80 - 2.40  45.78 - 2.35  48.90 - 2.20  47.74 - 3.00 
No. of reflections  389310  275152  240370  225098  241893  288958  118297 
               
Rwork  22.07  19.84  22.78  18.89  19.04  24.70  24.62 
Rfree  24.11  22.82  25.51  23.41  22.70  27.70  27.16 
  
 
 
 AcrB_wt/ 
DARPin 
& minocycline 
 AcrB_wt/ 
DARPin 
& doxorubicin 
 AcrB_D407N/ 
DARPin 
& minocycline 
 AcrB_D408N/ 
DARPin 
& minocycline 
 AcrB_K940A/ 
DARPin 
& minocycline 
 AcrB_R971A/ 
DARPin 
 AcrB_T978A/ 
DARPin 
 
 
No. atoms 
              
macromolecule 
residues 
 26118  26124  26153  26105  26071  26164  26079 
solvent residues  3929  2293  2153  2112  2358  2244   
               
B-factors               
macromolecule  30.6  45.8  39.0  43.4  43.6  28.6  37.1 
solvent  50.0  49.9  45.8  43.1  45.5  34.6   
overall  33.12  46.1  39.5  43.4  43.8  29.1  37.1 
RMS deviations               
bond length (Å)  0.006  0.006  0.006  0.006  0.006  0.006  0.007 
bond angles (°)  0.962  1.045  0.956  1.010  1.028  0.963  1.032 
               
RMS deviation of 
transmembrane 
domain of mutant 
protein compared 
to wt (Å)h 
 
  
 
loose 
tight 
open 
    
 
0.63 
0.80 
0.40 
  
 
0.36 
0.44 
0.22 
  
 
0.37 
0.27 
0.24 
  
 
1.08 
1.01 
0.32 
  
 
0.27 
0.26 
0.25 
               
a: 102.7% at 2.12 Å 
b: 2.64 at 2.12 Å 
c: 179.6% at 2.45 Å 
d: 1.58 at 2.45 Å 
e: (1)  
f: (2) 
g: (3) 
h:  calculated with program superpose (3). Selected residues (main chain atoms): 8-29, 330-558, 862-1029. 
 
4. The AcrB proton translocation pathway 29
Table S2: Distance between binding pocket residues and AcrB substrates minocycline and 
doxorubicin 
       
residues  distance 
(Å)a 
 residues  distance 
(Å)a 
       
Doxorubicin (DM2)  Minocycline (MIY) 
       
S46 (CB) - DM2 (O4’)  3.1     
Q89 (NE2) - DM2 (O5’)  3.3     
S128 (OG) - DM2 (O4’)  4.7     
E130 (OE1) - DM2 (C6’)  3.2     
Q176 (OE1) - DM2 (C16)  4.0  Q176 (OE1) - MIY (C71)  4.7 
    L177 (O) - MIY (C7)  4.2 
F178 (CD1) - DM2 (C20)  3.4  F178 (CE1) - MIY (C71)  3.5 
G179 (N) - DM2 (C21)  3.0  G179 (N) - MIY (C16)  3.3 
    S180 (CB) - MIY (O7)  3.8 
    E273 (OE1) - MIY (C19)  4.0 
    N274 (OD1) - MIY (O7)  3.1 
I277 (CB) - DM2 (O4)  4.1  I277 (CB) - MIY (O5)  3.3 
F610 (CZ) - DM2 (C2)  4.6     
V612 (CG2) - DM2 (C2)  3.8  V612 (CE2) - MIY (C12)  4.0 
F615 (CE1) - DM2 (O13)  3.1  F615 (CD1) - MIY (CN7)  3.2 
       
a: shortest interatomic distance 
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The article essentially consists of excerpts of the introduction of this thesis providing 
a brief overview of the different mechanisms leading to antibiotic resistance and 
summarizes genetic and biochemical experiments on AcrB performed by various 
groups.  
Additionally, the different structures and conformations of AcrB are recapitulated and 
the current understanding of substrate transport and energization is presented. 
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Abstract
The tripartite efflux system AcrA/AcrB/TolC is the main
pump in Escherichia coli for the efflux of multiple anti-
biotics, dyes, bile salts and detergents. The inner
membrane component AcrB is central to substrate rec-
ognition and energy transduction and acts as a proton/
drug antiporter. Recent structural studies show that
homotrimeric AcrB can adopt different monomer confor-
mations representing consecutive states in an allosteric
functional rotation transport cycle. The conformational
changes create an alternate access drug transport tunnel
including a hydrophobic substrate binding pocket in one
of the cycle intermediates.
Keywords: AcrB; alternate access transport
mechanism; antibiotic resistance; binding change
mechanism; drug transport; membrane protein
structure; multiple drug efflux pump.
Introduction
Resistance of bacteria towards antibiotics is known to be
evoked by at least three different mechanisms: (i) target
modification we.g., resistance against macrolides medi-
ated by methylation of the ribosome (Skinner et al., 1983;
Zalacain and Cundliffe, 1989, 1990) or resistance against
fluoroquinolones by mutations in DNA gyrase (Yoshida et
al., 1990; Hooper, 1995)x; (ii) antibiotic modification (e.g.,
hydrolysis of b-lactam ring by b-lactamase; Thomson
and Smith Moland, 2000) or phosphorylation, adenylation
or acetylation of aminoglycosides (Wright, 1999); and
(iii) reduced accumulation of antibiotics in the target
compartments (periplasm, cytoplasm) through suppres-
sion of porin synthesis (Hancock and Brinkman, 2002)
and/or overproduction of efflux pumps (Nikaido, 1998,
2009; Lomovskaya et al., 1999; Li and Nikaido, 2004;
Lomovskaya and Totrov, 2005; Nikaido and Takatsuka,
2008).
Resistance conferred by antibiotic and target modifi-
cation is often restricted to a single class of antibiotics
or even a single compound. In contrast, multidrug resis-
tance (MDR) transporters enable the bacteria to efflux a
broad range of substances and hence confer simulta-
neous resistance to unrelated compounds. The central
role of MDR transporters as a primary line of defense
and, intriguingly, as mediators for the acquisition of other
resistance mechanisms have been shown in several
cases (Lomovskaya et al., 1999; Mazzariol et al., 2000;
Mahamoud et al., 2007).
Proteins of the Resistance-Nodulation-Division (RND)
superfamily (TC2.A.6) are ubiquitous in all phyla. In
prokaryotes, their main physiological function seems to
be associated with the extrusion of noxious substrates,
with notable exceptions such as the secretory accessory
proteins SecDF (Gardel et al., 1987; Pogliano and Beck-
with, 1994), lipid exporter MmpL7 (Camacho et al., 2001;
Domenech et al., 2005) and the putative lipooligosaccha-
ride nodulation factor exporter NolG (Baev et al., 1991).
In Eukarya, however, the functionally characterized RND
proteins seem to be involved in lipid homeostasis (Davies
et al., 2000; Davies and Ioannou, 2000; Sleat et al., 2004;
Infante et al., 2008a,b) and cell morphogenesis (Taipale
et al., 2002; Nakano et al., 2004). As phylogenetic anal-
yses suggest, energization via the proton (or sodium ion)
motive force might be a common feature for all RND
proteins (Saier and Paulsen, 2001).
Resistance nodulation division (RND) efflux
pump AcrB
Proteobacterial members of the RND superfamily are
located in the inner membrane. They typically assemble
with two accessory proteins, a membrane fusion protein
(MFP; TC8.A.1) and an outer membrane factor (OMF;
TC1.B.17). The so-formed tripartite MFP/RND/OMF
complex spans the inner membrane, the periplasm as
well as the outer membrane of the Gram-negative bac-
terium. Most extensively studied examples of these three
component systems are MexA/MexB/OprM of Pseudo-
monas aeruginosa or AcrA/AcrB/TolC of Escherichia coli
(Figure 1A). Both outer membrane and tripartite efflux
pumps are considered to be the main barrier for drugs
on their way to the inside of the bacterial cell (Plesiat and
Nikaido, 1992; Nikaido, 2003, 2009). It is this combina-
tion of the intrinsic impermeability of the outer
membrane, reduction of the number of outer membrane
pores and upregulation of multidrug efflux pumps which
enables effective synergistic drug resistance (Nikaido,
2 T. Eicher et al.
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Figure 1 Schematic drawing of the tripartite multidrug efflux
system AcrAB-TolC of Gram-negative E. coli and AcrB structural
features.
(A) Inner membrane component AcrB (RND component)
accounts for substrate recognition/selection and energy trans-
duction. Drugs might be captured from the outer leaflet of the
inner membrane and are extruded in a coupled exchange with
protons. The TolC channel (OMF component) mediates the exit
through the outer membrane and connects to AcrB via a long
periplasmic conduit. AcrA (MFP component) connects AcrB and
TolC. The presence of all three components is essential for the
MDR phenotype. (B) Topological view of the transmembrane
(TM) domain perpendicular to the membrane plane. TM4 and
TM10 are surrounded by the other 10 TM helices. The TM
domains of the three monomers confine a large central cavity.
(C) Side view of trimeric AcrB. A central pore located in the por-
ter domain separates a funnel-like structure in the TolC-docking
domain from the central cavity located in the TM domain. The
central pore, however, does not appear to allow direct passage
of drugs. The trimeric state of AcrB is mainly stabilized by the
intermonomer connecting loops. (D) Top view of the porter
domain with its subdomains PN1, PN2, PC1 and PC2 perpen-
dicular to the membrane plane. The central pore is formed by
three a-helices, donated by the PN1 subdomains of each AcrB
monomer. A cleft is apparent between the PC1 and PC2
subdomains of each monomer.
1996). Strikingly, dysfunction of only one component of
the tripartite system results in a complete drug-sensitive
phenotype.
RND proteins, such as MexB (Mex: multiple efflux) and
AcrB (Acr: acriflavine resistance), represent the energy
module and the substrate specificity determinant of the
tripartite RND/MFP/OMF efflux system. The substrate
variety of MexB or AcrB, compared to the many other
MDR proteins, is staggering. It includes dyes, bile salts,
organic solvents and antibiotics of different chemical
classes; molecules that are anionic, cationic, zwitterionic,
aromatic or just aliphatic; chemicals of bulky or planar
geometry. However, since export of membrane lipids and
co-factors, such as flavins, is expected to be detrimental
for bacterial cells, additional criteria to discriminate
between noxious compounds and vital cell constituents
must exist, a matter of ongoing research. Like most
proteobacterial RND proteins, AcrB consists of 12 trans-
membrane (TM) a-helices and two extensive periplasmic
loops which account for approximately half of the 1049
amino acids of the protein. The loops connect TM1 with
TM2 and TM7 with TM8, respectively. The topology of
the TM domain – five-plus-one-TM helices, repeated
twice – is also referred to as RND signature (Ioannou,
2001). The repetition of the motif suggests that RND
transporters arose as a result of an intragenic tandem
duplication event.
It appears that the substrate specificity determination
is residing in the periplasmic loops, which was shown
through the design of chimeric proteins. Specifically, the
two extracellular loops of the Escherichia coli aminogly-
coside exporter AcrD were replaced by the periplasmic
loops of AcrB (Elkins and Nikaido, 2002). The resulting
transporter exhibited a resistance pattern that was typi-
cal for AcrB. Conversely, when the periplasmic loops of
AcrB were replaced by the corresponding domains of
AcrD, the chimeric protein lost the ability to confer resis-
tance towards substrates of AcrB, but the resistance
towards aminoglycosides was enhanced. Domain swap-
ping experiments between MexB and MexY led to similar
results (Eda et al., 2003). Here, the periplasmic loops of
MexB were combined with the TM domain of MexY.
Again, the resulting protein conferred resistance towards
typical MexB substrates, while the cells were susceptible
towards MexY specific drugs. Additional evidence on the
role of the periplasmic domain in substrate specificity
determination came from a study where six single site
mutations causing altered substrate specificity were all
found to be located on the extracellular loops (Mao et al.,
2002). Crystallographic studies provided further insights
on the role of the periplasmic loops in substrate recog-
nition and transport (Murakami et al., 2006; Seeger et al.,
2006; Sennhauser et al., 2007).
Structure of AcrB
The first AcrB structure (Murakami et al., 2002) was
based on 3.5 A˚ X-ray diffraction data from crystals con-
taining one unliganded AcrB monomer in the asymmetric
unit and for which the trimer is generated by exact crys-
tallographic symmetry. Each monomer contains a TM
domain with 12 TM helices which form a bundle with two
central helices (TM4 and TM10) in its topological core.
On these central a-helices, three titratable residues,
Asp407, Asp408 and Lys940, were found to be essential
for protein function (Guan and Nakae, 2001; Su et al.,
2006; Takatsuka and Nikaido, 2006; see Figure 1B).
The periplasmic part – formed by the periplasmic loops
described above – extends 70 A˚ into the periplasm. It
can be further divided into a TolC docking domain which
is most distal from the membrane plane and a porter
domain, formerly known as pore domain (Figure 1C).
The TolC-docking domain is the expected interaction
site of the outer membrane channel TolC (Tikhonova and
Zgurskaya, 2004; Tamura et al., 2005; Bavro et al., 2008;
Pietras et al., 2008). The TolC docking domain of each
monomer furthermore exhibits a hairpin-like loop that
protrudes into the neighboring monomer, which appears
Multidrug efflux pump AcrB 3
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Figure 2 Tunnels in the porter domain of trimeric AcrB peristaltic drug efflux pump.
The AcrB monomers are presented in blue (loose), yellow (tight) and red (open). The tunnels are highlighted as green surfaces in a
ribbon model of the AcrB trimer and might function as transport paths of drugs. Tunnel 1 might serve as entrance for drugs from
the outer leaflet of the inner membrane towards the hydrophobic substrate binding pocket. Tunnel 2 might serve as an alternative
entrance for substrates entering via the periplasm or as an exit duct for non-substrates. Tunnel 3 in the open monomer is the exit
pathway for substrates towards TolC and the outside medium. Inset: in the T monomer (yellow), a hydrophobic pocket is defined by
phenylalanine, valine, isoleucine and tyrosine side chains at the PN2/PC1 interface. Bound minocycline is depicted with the observed
electron density in a 2Fo-Fc electron density map contoured 1 s (T. Eicher, M. Seeger, K.M. Pos and colleagues, unpublished data).
Panels (A) and (B) represent in each case a one-third conversion of a full L™T™O™L cycle wadapted from Pos (2009) and modifiedx.
to be the main stabilizing factor for the trimeric AcrB
complex.
The porter domain is divided into subdomains PN1,
PN2, PC1 and PC2, which are coupled by sequential
proximity (PN1–PN2, PC1–PC2) or by sharing b-strands
to form common b-sheets (PN2–PC1, PC2–PN1; see
Figure 1D). The PN1 subdomains are located in the
center of the trimer, surrounded by the PN2, PC1 and
PC2 subdomains towards the periphery. A cleft is appar-
ent between the PC1 and PC2 subdomains, which is
approximately perpendicular to the membrane plane. In
the center of the trimer, the TolC docking domain exhibits
a funnel-like structure narrowing to a central pore,
defined by a-helices (designated pore helices) of the PN1
subdomains of each monomer. This pore has a small
diameter and therefore does not allow drug passage in
this conformation. Towards the membrane plane, the
central pore leads to a central cavity and further to a
30–35 A˚ wide, presumably lipid-filled TM hole defined by
the ring-like arrangement of the TM helices of the trimer.
Three vestibules at the monomer interface located just
above the membrane plane lead towards the central cav-
ity. It is postulated that substrate might access the cen-
tral cavity via these vestibules (Murakami et al., 2002).
Indeed, there have been several reports on AcrB/sub-
strate co-crystals with positive densities in the electron
density maps derived from (symmetric) R32 crystals that
have been interpreted as substrate molecules bound to
the inner wall of the AcrB central cavity (Yu et al.,
2003a,b, 2005; Pos et al., 2004; Tornroth-Horsefield et
al., 2007; see Figure 1B, C).
In 2006 and 2007, three groups independently pub-
lished an asymmetric structure of AcrB grown in the
monoclinic space group C2 (2.8–2.9 A˚; Murakami et al.,
2006; Seeger et al., 2006), triclinic space group P1 (3.0
A˚; Seeger et al., 2006) and an AcrB structure including
bound designed ankyrin repeat proteins (DARPins) grown
in orthorhombic space group P212121 (2.5 A˚; Sennhauser
et al., 2007). The DARPin bound AcrB structure was
almost identical with the AcrB structures crystallized
without binder with root mean square deviation (rmsd) of
the superimposed trimeric structures F1 A˚. The DARPin
molecules only bind to the loose and the tight conform-
ers, resulting in a ratio of two DARPin molecules per AcrB
trimer. This stoichiometry was verified by sedimentation
velocity experiments, suggesting that in solution and
probably also in vivo AcrB adopts mainly the asymmetric
conformation (Sennhauser et al., 2007).
Within the asymmetric AcrB trimer, each monomer has
a different conformation denoted as loose, tight and open
(access, binding and extrusion, respectively; Murakami et
al., 2006; Seeger et al., 2006), while the loose state is
closest to the conformation of the monomers in the
symmetric structure (Murakami et al., 2002). Although the
pore helices are differently oriented in the asymmetric
structure as compared to the symmetric structure, the
pore diameter is similar and hence there does not appear
to be a substrate export pathway through the pore.
Instead, conformer specific cavities and tunnels could be
identified in the porter domain (Murakami et al., 2006;
Seeger et al., 2006; Sennhauser et al., 2007; see Figure
2). In the loose conformer, a tunnel (tunnel 2) starts in the
PC1/PC2 subdomain cleft approximately 15 A˚ above the
membrane plane and protrudes in the direction of the
pore. In the tight conformer, an additional new tunnel
(tunnel 1) with an entrance situated in a groove formed
by TM8 and TM9 at the height of the membrane plane is
apparent. Due to reorientation of the PN2 subdomain in
the tight monomer, a hydrophobic pocket at the interface
of PN2 and PC1 subdomains is created (Figure 2). This
pocket is situated close to the end of tunnels 1 and 2 in
the tight conformer (defined by the PN1 subdomain of
the adjacent open monomer) and is rich in aromatic
amino acids (Bohnert et al., 2008), a feature that is often
observed for binding pockets of MDR proteins (Zhelez-
nova et al., 1999; Schumacher et al., 2001, 2004; Murray
et al., 2004; see Figure 2, inset). Indeed, Murakami et al.
(2006) detected electron densities for the AcrB sub-
strates minocycline and doxorubicin in the hydrophobic
pocket. By using a brominated derivative of the former
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Figure 3 Schematic representation of the AcrB binding change
functional rotation transport mechanism.
The conformational states loose (L), tight (T) and open (O) are
indicated in different levels of gray. The lateral grooves in the L
and T monomer indicate the substrate binding sites. The differ-
ent geometric forms reflect low (triangle), high (rectangle) or no
(circle) binding affinity for the transported substrates. State TTT
is postulated to occur at high substrate concentration. The
states LLL and LLT are postulated to occur in the absence or at
low substrate concentrations. In this model, bi-site activation is
essential for the complete transport cycle wadapted from Pos
(2009) and modifiedx.
compound (9-bromo-minocyclin), they unambiguously
could assign the position of this substrate within the
binding pocket. In the open monomer, the lateral peri-
plasmic entrance of the tunnel observed in the loose and
tight conformation is now closed owing to coil-to-helix
transition of TM8, whereas another tunnel (tunnel 3) is
created due to tilting of the pore helix (PN1 subdomain).
The latter tunnel leads from the now collapsed binding
pocket to the funnel located in the center of the AcrB
trimer (Figure 2).
Transport mechanism
It is postulated (Murakami et al., 2006; Seeger et al.,
2006, 2008b; Sennhauser et al., 2007; Murakami, 2008;
Pos, 2009) that substrate transport by AcrB is accom-
plished via functional rotation in which each monomer
changes its conformation in a concerted fashion (Figure
3). The mechanism resembles that of Boyer’s binding
change mechanism of the F1Fo ATPase, where confor-
mational cycling of the (a and) b subunits through the
states loose, tight and open leads to the synthesis of ATP
(Hackney et al., 1979; Hutton and Boyer, 1979; Boyer,
1997).
One transport hypothesis assumes the substrates to
be garnered from the outer leaflet of the inner membrane
(Figure 2). Substrate might enter the loose monomer via
the TM8/TM9 groove (Murakami et al., 2002; Seeger et
al., 2008a; Pos, 2009) or via tunnel 2 approximately 15 A˚
above the membrane plane. While it is not clear how
hydrophobic compounds might enter tunnel 2 once these
have been partitioned in the inner membrane, several
groups provided structural data of symmetric AcrB
(where all the monomers adopt the loose conformation)
based on 3.2–3.8 A˚ data with presumably bound AcrB
substrates in the tunnel 2 region (Yu et al., 2005; Drew
et al., 2008). High resolution (2.5 A˚) data describing the
asymmetric trimer show clear densities in the TM8/TM9
groove of the loose monomer, which has been attributed
to the highly concentrated detergent and AcrB substrate
n-dodecyl-b-D-maltoside (Sennhauser et al., 2007). Upon
conformational change from the loose to the tight state,
tunnel 1 appears and might provide one of the pathways
for substrates towards the hydrophobic pocket which
accommodates the substrate molecule. Structural flexi-
bility within the trimer (Takatsuka and Nikaido, 2007;
Seeger et al., 2008b) suggests that the loose and even
tight conformational states might be adoptable in the
absence of substrates and that substrate binding to the
hydrophobic pocket specifically stabilizes the tight con-
formation. This might also present an alternative role for
tunnel 2 in these conformations as an exit pathway for
compounds which are not substrates of the pump (Figure
2). In analogy with the binding change mechanism (Mil-
grom et al., 1998), the conversion of the tight monomer
to the open monomer is energy-consuming and subject
to bi-site activation, i.e., only occurs upon binding of
substrate to the neighboring monomer (Figure 3). Upon
transition from the tight to the open state, the binding
pocket closes again; substrate is squeezed out and fol-
lows a newly formed tunnel (tunnel 3) to the TolC-docking
domain funnel, and is from there finally extruded into the
media via TolC.
In summary, upon conformational change from loose
to tight to open and back to loose, an alternating access
tunnel is formed through which substrates are transport-
ed from the outer leaflet of the inner membrane towards
the outside medium. The mode of action is suggested to
be based on occlusions migrating from the lateral
entrance(s) to the central funnel and is reminiscent of a
peristaltic pump.
To test the proposed conformational cycling in vivo,
subdomains that undergo substantial rearrangement dur-
ing cycling were locked by the introduction of disulfide
bonds (Takatsuka and Nikaido, 2007; Seeger et al.,
2008b). As could be demonstrated by tracing the efflux
of a fluorescent substrate, formation of disulfide bonds
significantly decreased AcrB mediated transport. When
the disulfide bonds were broken by the addition of the
reducing reagent dithiothreitol, transport activity was
restored, which was in strong support of the functional
rotation mechanism. Even more convincing, Takatsuka
and Nikaido designed a functional covalently linked AcrB
trimer, which could be inactivated by the introduction of
a mutation in the proton relay network (D407A) or by
disulfide formation in only one of the protomers (Takat-
suka and Nikaido, 2009). These results are in accordance
with the proposed functional rotation mechanism. More-
over, using quantitative measurements using b-lactams
as substrates, Nagano and Nikaido (2009) found positive
cooperativity for cephalosporins with low apparent affin-
ity to AcrB (but not for nitrocefin, a cephalosporin with
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high affinity), which might indicate bi-site activation as
postulated (Seeger et al., 2008a; Pos, 2009).
The interaction between each AcrB monomer and its
affiliated AcrA molecule has been investigated very
recently (Symmons et al., 2009) and might suggest that
during functional rotation of AcrB subtle conformational
changes are transmitted towards AcrA. Rather than just
being a rigid adapter, AcrA might actively transduce ener-
gy generated by AcrB and induce subtle peristaltic
motions in the TolC channel. Similar to the tunnels
observed in a single AcrB protomer during functional
rotation (Murakami et al., 2006; Seeger et al., 2006;
Sennhauser et al., 2007), TolC is possibly not a rigid hol-
low cylinder but changes its diameter by conformational
change of each monomer, thereby pushing substrate
unidirectionally from the closing aperture into the media
(Vaccaro et al., 2006, 2008; Seeger et al., 2008a; Pos,
2009).
Proton transport and energy transduction
AcrB utilizes the proton motive force to energize the
extrusion of its cognate substrates from the cell into the
medium (Zgurskaya and Nikaido, 1999; Saier and Paul-
sen, 2001). The TM domain of AcrB harbors four func-
tionally essential charged residues that are conserved
throughout the HAE-1 family: Asp407, Asp408, Lys940
and Arg971 (Su et al., 2006; Takatsuka and Nikaido,
2006). Another highly conserved TM residue, Thr978, is
in hydrogen bonding distance from Asp407 in the loose
and tight monomer and with Lys940 in the open mono-
mer. However, when Thr978 was replaced by valine,
isoleucine, leucine or asparagine, the relative activity of
these mutants remained 40% to 60% as revealed by
drug susceptibility assays (Takatsuka and Nikaido, 2006).
In the asymmetric structure of AcrB, the four above-
mentioned essential residues Asp407, Asp408, Lys940
and Arg971 have distinct different conformations in at
least one of the three conformers loose, tight and open
(Murakami et al., 2006; Seeger et al., 2006; Sennhauser
et al., 2007). Both structural and mutagenesis studies
suggest that proton translocation is mediated by these
titratable residues. The conformational changes during
the putative conformational cycling in the TM domain are
much more subtle compared to the porter domain:
Lys940 is sandwiched between Asp407 and Asp408 in
the loose and tight states, but becomes reoriented
towards Thr978 in the open state; the N-terminal end of
TM8 in the loose and tight monomers is marked by
Pro874, but becomes elongated by four full turns in the
open monomer, whereas TM5 bulges towards TM4 and
TM10 in the open conformation. These conformational
changes are thought to be the result of protonation and
deprotonation events on these titratable, membrane
embedded residues. The geometry of the titratable resi-
dues is reminiscent to the situation observed in bacterio-
rhodopsin, an archaeal integral membrane protein
intensively studied since its discovery in the early sev-
enties (Oesterhelt and Stoeckenius, 1973). It is therefore
tempting to look for analogies between AcrB and the
well-characterized bacteriorhodopsin. How these confor-
mational changes are levered to the porter domain and
cause the large conformational changes observed there
is subject to ongoing investigation.
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An examination of all 31 HAE1 members present in the Transport Classification 
Database (http://www.tcdb.org/, autumn 2008) revealed that the percentage of 
identical and similar amino acid residues in this subfamily ranges from 17% (MexY 
and TriC from P. aeruginosa) to 99% (SrpB and TtgH from P. putida). However, in 
the transmembrane domain, there are stretches where conservation is strong for all the 
listed HAE1 members. The longest stretches comprise up to 30 amino acids and 
reside on TM4, TM10 and TM11. These regions comprise the essential residues 
D407, D408, K940, and R9716 (Figure 23) (145,146,178,179). In 30 out of the 31 
HAE1 transporters listed in the transport classification database, D407, D408, R971, 
K940 and also T978 are highly conserved, with only MexK and TriC (both from P. 
aeruginosa) showing an arginine substitution for the corresponding K940. A striking 
difference, however, can be found for VexF of Vibrio cholerae: D408, is substituted 
by a glycine, and the positively charged K940 is exchanged for a polar glutamine 
(Figure 23). Interestingly, Rahman et al. (214) reported that heterologously expressed 
VexF transports ethidium and R6G out of E. coli cells only when Na+ is present. It is 
therefore tempting to speculate that VexF is driven by the electrochemical gradient of 
Na+ and not of protons like the hitherto characterized RND transporters. 
                                                 
6 AcrB numbering is used throughout unless indicated differently. 
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Figure 23: Conserved stretches among HAE1 transporters listed at Membrane Transport Protein 
Classification Database (http://www.tcdb.org/, autumn 2008). The most conserved stretches comprise 
almost the entire transmembrane helices 4, 10 and 11. Note that VexF (arrow) has different residues at 
the highly conserved positions 408 and 940. AcrB numbering is used throughout. Multiple sequence 
alignment was performed using the program Mafft (67). 
a: AcrB of Francisella tularensis 
 
6.2 The putative sodium binding site of VexF  
 
The fact that electrochemical gradients of both H+ or Na+ can be used as secondary 
driving force has been known since the establishment of Na+ energetics by the 
characterization of the oxaloacetate decarboxylase and the methylmalonyl-CoA 
decarboxylase (215,216). For MDR proteins belonging to the MATE family, both 
proton motive force (PMF) (for example PmpM of P. aeruginosa, He 2004 (51)) and 
sodium-ion motive force (SMF) (for example NorM of V. parahaemolyticus (50,217)) 
are known to energize the transport of substrates. The differences between the 
consensus sequence of the putative proton translocation pathway in HAE1 
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transporters and VexF might account for the changed preference of the coupling ion. 
A comparative analysis of the Na+ binding sites of known Na+ transporting membrane 
proteins like the c subunit of the F1Fo ATPase (Ilyobacter tartaricus, (218)) as well as 
of the Na+ driven transporters LeuT (Aquifex aeolicus (219)), GltPh (Pyrococcus 
horikoshii (220)) and vSGLT (V. parahaemolyticus (221)) described here evaluates 
the possibility whether VexF from V. cholerae might use Na+ as coupling ion. 
LeuT is a Na+ coupled leucine transporter. The crystal structure (219) was solved at 
1.65 Å and showed the membrane protein in complex with two Na+ ions and its 
cognate substrate leucine. LeuT revealed two Na+ binding sites which differ in the 
number of coordinating oxygen atoms as well as in charge. The Na+ ion in binding 
site 1 is coordinated by two carbonyl oxygen atoms of a partly unwound α-helix (A22 
and T254), a hydroxyl oxygen of T254, two side chain carbonyl oxygen atoms of N27 
and N286 and one carboxyl oxygen of the substrate leucine. At Na+ binding site 2, the 
ion is bound by three carbonyl oxygen atoms located on partially unwound α-helices 
(G20, V23, A351) and two hydroxyl oxygens of T354 and S355 (Figure 24).  
The structure of the galactose/ Na+ cotransporter vSGLT was solved at 2.7 Å (221). 
At this resolution, electron densities from water molecules and Na+ cannot be 
distinguished. However, comparison between the putative Na+ binding site of vSGLT 
and the Na+ binding site 2 of LeuT revealed that they are very analogous. The 
coordination of Na+ was postulated to be accomplished by three carbonyl oxygen 
atoms that are located on a partially unwound α-helix (A62, I65 and A361) as well as 
by the two hydroxyl oxygens of T364 and S365 (Figure 24). 
GltPh is a Na+ coupled aspartate transporter (220). The two Na+ binding sites are again 
very similar to those observed in LeuT. The Na+ ion in binding site 1 is coordinated 
by two main chain carbonyl oxygen atoms of a partly unwound α-helix (G306 and 
N310), the main chain carbonyl oxygen of N401, a hydroxyl oxygen of S278 and a 
carboxy oxygen of D405. At Na+ binding site 2, the ion is bound by one carbonyl 
oxygen atom of the same partly unwound α-helix (T308) and by the three carbonyl 
oxygens of S349, I350 and T352 that reside at the C-terminus of an α-helical hairpin. 
Stabilizing coordination might be accomplished by the dipole moments of the C-
termini of the α-helical hairpin and the partly unwound α-helix (Figure 24).  
Although LeuT, GltPh and vSGLT do not share similarities on the amino acid 
sequence level , the three dimensional architecture of the Na+ binding sites exhibit 
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significant analogy with some of the coordinating oxygen atoms at equivalent 
positions. Most prominent are the unwound regions within transmembrane α-helices 
(one region for vSGLT and two regions for LeuT and GltPh). These regions provide 
main chain carbonyl atoms which appear to be essential for Na+ binding.  
The crystal structure of the undecameric c ring of the Na+ coupled F1Fo ATPase was 
solved at 2.4 Å by Meier et al. (218). The Na+ ions are coordinated by the hydroxyl 
oxygen of S66, the carboxyl group of E65, the carboxamide oxygen of Q32 and the 
backbone carbonyl oxygen of V63 located at the bend of transmembrane helix A 
(Figure 24). 
The coordinating oxygen atoms involved in Na+ binding derive from hydroxyl groups, 
carboxamide oxygens, carboxyl groups and backbone carbonyl oxygens of unwound 
or kinked α-helices. The number of oxygen atoms coordinating one Na+ ion is four 
(F1Fo ATPase, binding site 2 of GltPh), five (binding site 2 of LeuT, vSGLT, binding 
site 2 of GltPh) and six (binding site 1 of substrate loaded LeuT) and the formal over 
all charge of the polar binding pocket is either 0 (binding site 2 of LeuT and GltPh, 
vSGLT) or -1 (binding site 1 of GltPh and substrate loaded LeuT, c ring of F1Fo 
ATPase). 
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Figure 24: Na+ binding sites in Na+ coupled primary and secondary active transporters. Na+ ion are shown 
as red spheres. A) Residues forming Na+ binding site 1 (blue) and 2 (orange) of LeuT are shown as sticks. 
The substrate leucine which is part of binding site 1 is colored yellow. B) The Na+ binding site in vSGLT 
was found by structural alignment with LeuT (221). Note that this putative Na+ binding site is composed of 
a very similar set of amino acid residues as Na+ binding site 2 of LeuT and exhibits essentially the same 
geometry (Na+ coordinating carbonyl oxygens of residues in vSGLT: An – In+3, Tm – Sm+1, A; Na+ 
coordinating carbonyl oxygens of residues of Na+ binding site 2 of LeuT: Gn – Vn+3, Tm – Sm+1, A). C) In the 
undecameric ring of the F1Fo ATPase, the Na+ ion is bound at the interface of monomern (V63 and S66) and 
monomern+1 (Q32 and E65). D) Residues forming Na+ binding site 1 (blue) and 2 (orange) of GltPh. GltPh 
exhibits a similar Na+ binding motif as LeuT: a break in the geometry of a core α-helix of three to five 
residues results in an opened up, non-α-helical peptide chain. The exposed carbonyl atoms of the first and 
fifth residue in GltPh (G306 and N310) or the first and forth residues of the Na+ binding motif in LeuT (G20 
and V23) are part of Na+ binding site 1 (blue). In both proteins, the third residue of this motif (T308 and 
A22 in GltPh and LeuT, respectively) participate in forming Na+ binding site 2 (orange). Pictures prepared 
with pdb coordinate files 3F3E (LeuT), 3DH4 (vSGLT), 1YCE (F1Fo ATPase) and 2NWX (GltPh). 
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By taking the structure of asymmetric AcrB (pdb-ID: 2GIF) as a template and 
aligning the amino acid sequence of VexF with AcrB, a homology model of the VexF 
structure was built by using SWISS-MODEL workspace (222-226) (Figure 25).  
The model suggests that in VexF D401, N922 and T959 are located in spatial vicinity 
and oriented towards each other as this is the case for the analogous residues D407, 
K940 and T978 in AcrB. The hydroxyl oxygens of T960 and T959, the carboxamide 
oxygens of N922 and N923 and the carboxyl oxygen of D401 all point towards a 
center defined by TM4, TM5, TM10 and TM11. Based on genetic experiments 
(144,179) and considering the asymmetric structure of AcrB (40,41,142), exchange of 
the essential residues D408 and K940 in conventional HAE1 transporters are expect 
to render the proteins functionally inactive due to impairment of protonation and 
deprotonation of the proton relay and impairment of the transfer of protons from the 
periplasm to the cytoplasm. 
In light of the reported Na+ dependence of VexF function (214) however, the altered 
amino acid composition in the transmembrane domain could indeed indicate an 
altered cation specificity: (i) as in Na+ coupled transporters mentioned above, the 
putative Na+ binding site in VexF is devoid of any formally positively charged residue 
due to the exchange of lysine to asparigine. (ii) By the replacement of aspartate by 
glycine, the second formally negative charge is omitted. As from the known cases 
discussed above, the Na+ binding site harbors one (c ring of F1Fo ATPase, binding site 
1 of GltPh and the Na+ binding site 1 of substrate loaded LeuT) or none (vSGLT, 
binding Na+ binding site 2 of GltPh, Na+ binding site 2 of LeuT) negatively charged 
residue. (iii) Exchange of the highly conserved D408 and K940 by amino acids with 
considerably smaller side chains enlarges the space between charged and polar 
residues, makes this region more flexible and may facilitate binding of (a) Na+ ion(s). 
The potential Na+ binding site in VexF is shown in Figure 25. 
 
6. Discussion 
124 
 
 
Figure 25: Superimposition of transmembrane domain of the open monomer of AcrB (pdb-ID: 2GIF) 
and the homology model of VexF. D408 and K940, both highly conserved within HAE1 transporters 
are substituted in VexF by a glycine and a asparagine residue, respectively. A putative Na+ binding site 
is created in VexF by the hydroxyl oxygens of T959 and T960, the carboxamide oxygen of N922 and 
N923 and the carboxyl oxygen of D401. In the open monomer, TM4 is considerably tilted, which 
opens up the peptide chain and may allow the carbonyl oxygen of G397 to contribute in coordinating 
Na+ (orange sticks, residues are indicated in italics). For comparison, the analogous residues in AcrB 
are shown as white sticks. Residues of VexF and AcrB are indicated in italics and regular, respectively. 
The transmembrane helices are denoted. 
 
6.3 Composition of putative proton relay network in HME vs. HAE1 
superfamily 
 
The Heavy Metal Extrusion (HME) family members are proteobacterial transporters 
of the RND superfamily that extrude heavy metal ions in exchange with cations. 
Prominent members of this family are listed in Table 1 according to the transport 
classification database (www.tcdb.org). HME transporters share between 20% and 
22% identical residues with AcrB and accomplish transport of monovalent (2.A.6.1.3, 
2.A.6.1.4) or divalent (2.A.6.1.1, 2.A.6.1.2, 2.A.6.1.5) heavy metal ions, respectively. 
To check whether the proposed protonation and deprotonation mechanism in the 
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transmembrane domain of AcrB may also apply for HME transporters, SilA, CusA, 
CnrA, CzcA, CzcA1 and further 76 homologous proteins identified by a blast search 
(227) were analyzed (Table 2). 
 
Table 1: Prominent HME proteins transporting monovalent and divalent HM 
     
HME protein  organism  substrate 
     
SilA  S. typhimurium  Ag+  a 
CusA  E. coli  Ag+/Cu+  b 
     
CnrA  Ralstonia metallidurans  Ni2+/Co2+  c 
CzcA  Alcaligenes eutrophus  Co2+/Zn2+/Cd2+  d 
CzcA1  P. putida  Zn2+/Cd2+/Pb2+  e 
     
a: (228) 
b: (229-231) 
c: (232) 
d: (62) 
e: (233) 
 
Intriguingly, some of the conserved stretches among the members of the HAE1 family 
are also similar in the HME family. These include TM4, TM11 and to a lesser extend 
TM10 which harbor the essential residues D407, D408, R971, T978 and K940 in 
AcrB. At the corresponding position of D408 however, there is an alanine residue in 
the HME members transporting monovalent heavy metal ions and their homologs7 
and a glycine residue in case of HME proteins transporting divalent heavy metal ions8 
as reported by Franke et al. (230). Moreover, the corresponding position to K940 of 
AcrB is substituted by glutamate in case of the monovalent HMEs and by leucine in 
the divalent HMEs (Tabel 2). This observation questions the AcrB paradigm, as K940 
and D408 are essential residues for function in AcrB and central to the proton 
translocation hypothesis. Moreover, striking differences between HME members 
seem to correlate with the substrate specificity of the transporters, questioning the 
exclusive role of the periplasmic domain in substrate transport and the spatial 
separation of energy transduction and substrate transport as has been postulated for 
AcrB (40,41,139). 
                                                 
7 hereafter referred to as monovalent HMEs 
8 hereafter referred to as divalent HMEs 
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Table 2: Putative proton translocating residues in HAE1a and HME proteins 
         
   monovalent HMEs  divalent HMEs 
         
position HAE1a  SilA CusA  CzcA CzcA1 CnrA 
         
407 D  D D  D D D 
408 Db  A A  G G G 
940 Kc  E E  L L L 
971 R  R R  R R Rd 
978 T  T T  T T Te 
         
76 Homologous proteins of the HME transporters SilA, CusA, CzcA, CzcA1 and CnrA were identified by 
a blast search at the Swiss Institute of Bioinformatics using the BLAST network service 
(http://www.expasy.ch/tools/blast/, (227)). The proteins were aligned with AcrB using the program Mafft 
(67). Residues putatively involved in proton translocation in HAE1 proteins (40,41,144,145) were 
compared with the analogous residues in the HME proteins. 
a: 31 HAE1 proteins listed in tcdb (autumn 2008) 
Homologous proteins having different amino acids at the indicated position (name of protein and/or 
UniProtKB/Swiss-Prot accession number) are indicated: 
b: VexF (A6P7H3): G 
c: MexK (Q9HXW4) and TriC (Q9I6X4): R; VexF (A6P7H3): Q 
d: A9IF41 and Q1GPY7: K 
e: B3PGJ3: V 
 
 
6.4 Substrate specificity determinants in HAE1 vs. HME superfamily 
 
In AcrB, a hydrophobic binding pocket is formed by the residues F136, V139, Q176, 
F178, N274, I277, Y327, F610, V612, F615, F617, I626, F628 (Figure 12) 
exclusively in the tight monomer (40,41). Densities for the AcrB substrates 
minocycline and doxorubicin could be identified in respective co-crystallized crystals 
((40), Eicher unpublished). Since similarity in amino acid sequence often coincides 
with similar structure and might be an indication for a similar catalytic mechanism, 
the binding pocket residues at the corresponding positions in HME proteins might be 
involved in binding of their substrates (heavy metal ions).  
These putative HME binding pocket residues were analyzed in 76 homologous 
proteins of SilA, CusA, CzcA, CzcA1 and CnrA and compared with the residues in 
AcrB (Table 3). 
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Table 3: Putative binding pocket residues in AcrB and HME proteins 
         
   monovalent HMEs  divalent HMEs 
         
position AcrB  SilA CusA  CzcA CzcA1 CnrA 
         
136 F  W W  I I V/I 
139 V  E/Q E  W Wf Y/F 
176 Q  A A  N N G 
178 F  V/I/L V/I/L  I I Y/Fi 
274 N  M/I/A/La M/I/A/La  Lc Lc L/V/I/j 
277 I  G G  G G G 
327 Y  Y Y  Y Y L/Y 
610 F  - -  Fd Fg Y/Fk 
612 V  - -  R/K R/K R/K 
615 F  F/Yb F/Yb  T T Tl 
617 F  K K  E E S/E/D 
626 I  I/V I/V  D D D 
628 F  L/F L/F  Y/Fe Y/Fh Y/Fm 
         
76 Homologous proteins of the HME transporters SilA, CusA, CzcA, CzcA1 and CnrA were identified 
and aligned as described before. Residues forming the binding pocket in AcrB (40,41) were compared 
with the analogous residues in the HME proteins. 
Homologous proteins having different amino acids at the indicated position (UniProtKB/Swiss-Prot 
accession number) are indicated: 
a: B3IK35 and Q1GQC4: T; A6V8I4: V 
b: Q1LD81: Q 
c: Q88AL5, Q4ZLZ2 and Q48CG6: M 
d: A6SYY5 and Q3JB89: V 
e: A6SYY5 and Q3JB89: L; Q1GY56: T 
f: A7ICX5: Y 
g: A6SYY5: V 
h: A6SYY5: L; Q1GY56: T 
i: B3RCX3 and Q0JYI5: H; A6SYW2: Q 
j: B4W715, B2FNF1, B4WBU0, B4SNN7: P 
k: A6SYY5 and Q9A5Q7: V 
l: Q1NFT2: Q 
m: B4W715, B2FNF1, B4WBU0, B4SNN7: V; Q134C4: I; A6SYY5: L 
 
The residues that form the putative binding pocket of HMEs are considerably 
different from AcrB. G277 is conserved amongst all the HME transporters analyzed. 
For almost all the other investigated residues of the putative binding pocket, there is a 
clear distinction between monovalent and divalent HMEs. At position 617, lysine is 
conserved in monovalent HMEs, whereas the divalent HMEs have a negatively 
charged residue or a polar serine. The divalent HMEs all have an aspartate at position 
626, whereas the monovalent HMEs exhibit an isoleucine or a valine. Tryptophane at 
6. Discussion 
128 
 
position 136 is 100% conserved amongst the monovalent HMEs, whereas divalent 
HMEs all have isoleucine or valine. Position 139 is occupied with glutamate or 
glutamine in monovalent HMEs, while there are exclusively aromatic residues in 
divalent HMEs. 
Unlike monovalent HMEs, divalent HMEs have conserved polar residues in the 
putative binding pocket. Most prominent is threonine at position 615. This position is 
occupied by aromatic phenylalanines and tyrosines in monovalent HMEs. 
In the monovalent HMEs, there are some profound differences in the PC1 domain 
compared to AcrB. According to the alignment, there is an insertion of eleven 
conserved residues between Q622 and N623 which might therefore be important for 
substrate binding. This hypothesis is supported by mutational analysis of CusA (230). 
Upon mutation of M623 to isoleucine (CusA numbering), sensitivity towards copper 
was increased as was shown by MIC experiments. Additionally, there is a gap 
between residues 609 and 615. This missing stretch includes V610 and F612, residues 
that are directly involved in binding of minocycline in AcrB ((40), Eicher 
unpublished). In divalent HMEs, these positions are occupied by conserved aromatic 
phenylalanines and tyrosines and with formally positive charged arginines and 
lysines, respectively (Figure 26). 
 
LTKEKNNVESVFAVNGFGFAGRGQ-----------NTGIA
LIKSVPEVASV-----FGKTGKAETATDSAPLEMVETTI
LIMSVPEVARV-----FGKTGKAETATDSAPLEMVETTI
SilA :
CusA :
AcrB  :
599 610 612 615 622 623 626
l l l l l l l
 
Figure 26: Excerpt of alignment of AcrB with SilA, CusA and homologous proteins identified by a 
blast search. Compared to AcrB, SilA, CusA and their homologous proteins lack residues 610 - 614. 
Instead, they have an insertion of eleven amino acids between Q622 and N623, most of which are 
conserved. M623 (CusA numbering), which is important for copper resistance in E. coli (230) is 
highlighted. 
 
Alignment of AcrB with divalent HMEs revealed that their PN2 domain is elongated 
(Figure 27): homologues of CzcA and CzcA1 have an insertion of five amino acid 
residues at position 140, whereas homologues of CnrA have an insertion of five to 18 
residues at the same position and four to 16 residues at position 148. This statement 
can be extended from AcrB to all the 31 members of the HAE1 family. 
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GVSVEKSSSSFLMVV-----GVINTDGT
VMGPVSTGLGEIFLWTVEAEDGAVKEDGT
AMGPISTGLGEIYLWTVEAEEGARKADGT
126 140 141 148
I I I I
CzcA :
CzcA1 :
AcrB :
 
Figure 27: Excerpt of alignment of AcrB with CzcA, CzcA1 and homologous proteins identified by a 
blast search. Compared to AcrB, CzcA, CzcA1 and their homologous proteins have an insertion of five 
amino acids between V140 and G141, some of which are conserved. 
 
Apart from different residues in the putative binding pocket, the monovalent HMEs 
show an insertion of 10 amino acids at position 422 and up to twelve amino acids at 
position 956. This corresponds to the C-terminal end of TM4 and TM10, respectively, 
both residing in the cytoplasm. Hence, the cytoplasmic loop connecting TM4 with 
TM5 and TM10 with TM11 is longer in SilA and CusA and their homologues. This 
observation is a general difference between monovalent HMEs and all the HAE1 
listed in tcdb. 
 
 
6.5 Substrate specificity determinants within HAE1 superfamily 
 
AcrB is known to confer resistance towards a broad spectrum of unrelated noxious 
compounds. One criteria that distinguishes substrates from non-substrates might be 
the overall hydrophobicity, since AcrB does not transport hydrophilic substances like 
aminoglycosides. 
The composition of the binding pocket might correlate with the substrate range, 
especially regarding the hydrophobicity of the substrates. In this light, AcrB and 15 
homologues whose substrates are known were analyzed. These transporters are AcrF 
(E. coli), AdeJ (Acinetobacter baumanii), YhiV (E. coli), ArpB (P. putida), MexB, 
MexD and MexF (P. aeruginosa) (24,234-240), which are known to transport 
substrates with similar hydrophobicity as AcrB; AcrD (E. coli) (139,241,242), MexY 
(P. aeruginosa) (243-245) and AmrB (P. pseudomallei) (246) transport the more 
hydrophilic aminoglycosides; and EmhB (P. fluorescens), SrpB, TtgH, TtgE and TtgB 
(P. putida) (247-249) which are classical organic solvent transporters. 
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At a first glance (Table 4), many residues are quite conserved in most selected HAE1 
transporters (V139, F178, Y327, F617), whereas others are more variable (N274, 
I277). 
Of all the selected transporters, AcrD, which is capable of exporting hydrophilic 
aminoglycosides (logPOW of kanamycin = -6.30), deviates most from the consensus 
binding pocket of AcrB-like transporters. At positions 139 and 612, aliphatic valines 
are substituted by polar threonines and aromatic phenylalanines are exchanged for 
polar serines at positions 615 and 617. At position 176, AcrD bears an acidic aspartate 
whereas the AcrB-like transporters all have glutamine. The binding pockets of the 
selected AcrB-like transporters are devoid of formal positive charges while AcrD 
features basic amino acids at positions 274 and 626. 
The deviations observed in MexY and AmrB from the common AcrB-like binding 
pockets are less dramatic: MexY features an acidic glutamate at position 176 (AcrB-
like transporters have N176), it has a tryptophan residue at position 178 (AcrB-like 
transporters have F178) and at position 610 a hydrophilic tyrosine is observed 
compared to F610 in AcrB-like transporters. As MexY, AmrB features a tryptophan at 
position 178, an acidic aspartate at position 274 where most AcrB-like transporters 
have a polar residue and an aromatic tyrosine at position 277 where most AcrB-like 
transporters have an aliphatic residue. 
The amino acid residues forming the putative binding pocket in organic solvent 
transporters are conserved and correspond to the residues of AcrB-like transporters 
with the following exceptions: TtgH, TtgE and SrpB exhibit a methionine at position 
610 and a leucine at position 628, whereas TtgB and EmhB – as the AcrB-like 
transporters – have phenylalanines at the corresponding positions. Interestingly, TtgB 
and EmhB were shown to confer resistance towards a variety of antibiotics and dyes9, 
whereas for TtgH, TtgE and SrpB, the only substrates reported up to date are organic 
solvents. 
 
There appears to be a coupled variation of residues 610 and 612 with respect to 
substrate specificity. In HMEs transporting divalent HM ions, a basic amino acid goes 
with an aromatic residue and in HAE1 transporters that exclusively transport organic 
                                                 
9 carbenicillin, nalidixic acid, chloramphenicol, tetracycline and ampicillin for TtgB and 
chloramphenicol, nalidixic acid, R6G, dequalinium, ciprofloxacin and streptomycin for EmhB 
(247,249) 
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solvents, the aliphatic methionine 610 pairs with aliphatic valine 612. The 
aminoglycoside transporters AcrD shows coupling of a polar with an aromatic 
residue, whereas in AcrB-like transporters, pairing of an aliphatic with an aromatic 
residue seems to be conserved. In most AcrB-like transporters, aromatic and aliphatic 
residues are located at positions 610 and 612, respectively, except for MexF, where 
the aromatic and aliphatic side chains are positionally exchanged. Interestingly, the 
similar observations was made in MIC experiments with acrB, acrB_F610A, 
acrB_V612F and the acrB_F610A_V612F double mutant: resistance towards most 
antibiotics was reduced when 610/612 pairing was of aliphatic-aliphatic or aromatic-
aromatic nature, but could be restored to almost wt levels by re-establishing a random 
aliphatic-aromatic pairing (Eicher, unpublished).  
 
Table 4: Residues of the putative binding pocket in selected HAE1 transporters 
              
 AcrB-like transporters 
              
residue 136 139 176 178 274 277 327 610 612 615 617 626 628 
              
AcrB F V Q F N I Y F V F F I F 
AcrF Y V Q F N V Y F V F F M F 
AdeJ F V Q F N F Y F V F F I F 
MexB F V Q F D I Y F V F F M F 
ArpB F V Q F N V Y F V F F M F 
YhiV I V Q F D T Y F V F F L F 
MexD F I Q F S I Y F I F F L F 
MexF L V Q F Q L Y V F L I I F 
              
 aminoglycoside transporters 
              
residue 136 139 176 178 274 277 327 610 612 615 617 626 628 
              
AcrD N T D Y K Y Y F T S P R F 
MexY I I E W E F Y Y V F L M F 
AmrB A I Q W D Y Y F L Y L M F 
              
 solvent transporters 
              
residue 136 139 176 178 274 277 327 610 612 615 617 626 628 
              
TtgB F V Q F N V Y F V F F M F 
TtgH F V Q F S I Y M V F F L L 
TtgE F V L F N I Y M V F F L L 
EmhB F V Q F N I Y F V F F L F 
SrpB F V Q F S I Y M V F F L L 
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7. Conclusions and outlook 
 
AcrB is the most potent MDR transport protein in E. coli and probably one of the 
most intensively studied bacterial multidrug transporters. This integral membrane 
protein associates with the accessory proteins AcrA and TolC and forms a tripartite 
complex which allows the extrusion of noxious substrates from the inner membrane 
directly into the extracellular space. The clinical importance of AcrB and its intrinsic 
properties – high recombinant overproduction potential and the presence of a large 
soluble domain – makes it an attractive candidate for structural analysis by X-ray 
crystallography. The high affinity Designed Akyrin Repeat Proteins (DARPins) are an 
excellent tool to improve on crystallizability of recalcitrant mutants and to enhance 
resolution. The results presented in this thesis initiate the understanding of the 
molecular mechanism of substrate transport and energization by AcrB and might be 
valid for other members of the RND superfamily as well.  
 
7.1 Energization of AcrB 
 
One of the obstacles in generating a model for energization of the AcrB efflux pump 
was the lack of essential polar or charged residues between the periplasm and the 
proton relay residues D407/D408/K940/R971 and postulating a proton transfer 
pathway. The problem was reminiscent to the situation observed in bacteriorhodopsin. 
In this light-driven archeal proton pump, the prosthetic group retinal is situated in the 
middle of the membrane and deprotonates upon photoisomerization. While the 
extracellular halfchannel is lined with polar and charged amino acids, the cytoplasmic 
halfchannel is very hydrophobic and contains only one aspartate and two threonines 
(Figure 21) thus representing a hydrophobic barrier between the cytoplasm and the 
prosthetic group. Due to insertion of mutations, illumination at different wavelengths 
and improving on resolution, electron densities for ordered water molecules inside the 
cytoplasmic halfchannel could be identified. According to the current hypothesis, 
these water molecules join due to protein conformational fluctuation and form a 
transient continuous water file at a given step of the photocycle connecting the 
cytoplasm with the chromophore. It therefore seems that the hydrophobic barrier 
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prevents the backflow of protons from the extracellular space to the cytosol along 
their electrochemical gradient (reviewed in (181,196,197)). 
Our high resolution structures of wt and mutant AcrB/DARPin complexes show the 
position of waters during different stages of the pumping process. Water molecules 
are coordinated by polar side chains and backbone atoms of flexible transmembrane 
helices. It is most probably along these intermediary files of ordered waters that the 
proton travels from the bulk solvent of the periplasm to the D407/D408/K940 triad 
penetrating the hydrophobic barrier during functional rotation. The hydrophobic 
barrier ensures that the inflow of protons is coupled to the conformational changes in 
the transmembrane domain, which ultimately trigger the large conformational changes 
seen in the porter domain and hence energize the transport of substrate against their 
concentration gradient. In order to elucidate how reorientation of D407, K940 and 
R971, the bulging of TM5 and the distortion of TM4 are linked to the coil-to-helix 
transition of TM8 and the movement of the subdomains of the porter domain, more 
structural information might be required. 
 
7.2 Substrate binding by AcrB 
 
Commensurable to the MDR binding protein QacR of S. aureus, binding of drugs to 
the AcrB binding pocket is promiscuous (39,156,157). Upon mutation of V612 to 
phenylalanine, substrate transport and binding was not abolished, but only mildly 
decreased for most substrates tested and even improved for linezolid. For the substrate 
minocycline, we could show that the position inside the binding pocket is shifted by 
2.1 Å, which leads to improved interactions with the polar side chains of E273 and 
N274, whereas π-stacking with F178 seems to have weakened. Regarding the 
multitude of substrates transported by AcrB, it is rather remarkable that in the 
numerous AcrB/substrate co-crystallization trials, only in two cases positive 
difference electron density peaks were observed, i. e. for minocycline and 
doxorubicin. These drugs both belong to the tetracycline class of antibiotics and are 
hence structurally very similar. Both are composed of a planar ring system which is 
substituted by different functional groups. If the resistance to the other compounds is 
due to the recognition and binding of the substrate to the observed hydrophobic 
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pocket, the following might account for lack of their electron densities in the 
measured crystal diffraction data:  
(i) AcrB might bind the compounds tested in co-crystallization experiments, but at 
different locations inside the binding pocket and hence not in a single, discrete 
binding mode. In this case, the electron density of the bound ligand is expected to be 
weak and spread according to the multiple conformation adapted inside the binding 
pocket. This phenomenon has been described for the MDR binding protein QacR in 
complex with the bivalent aromatic diamidines DB75 and DB359 (250). In these 
structures, the coil-to-helix transition of the DNA binding domain, the extrusion of 
Y92 from the binding pocket and the fact that QacR does not form crystals in the 
absence of substrate was indicative for ligand binding. However, the positive 
difference electron densities inside the binding pocket were not continuous and 
therefore could not be attributed to a bound ligand. 
(ii) Binding of substrates added in co-crystallization experiments might be competed 
by other substances present in the crystallization set up such as polyethyleneglycol 
(PEG) or detergent. In fact, the detergents used in our crystallization studies, n-
dodecyl-β-D-maltoside (DDM) and cyclohexyl-n-hexyl-β-D-maltoside (CHM) are 
substrates of AcrB. Their concentration in the protein crystal is estimated to be 
approximately 400 mM and may therefore interfere with the added drug molecules. 
(iii) Binding of substrates might be impeded by the putative non-native conformations 
of AcrB inside the crystal lattice. The non-physiological crystal contacts are of special 
concern. In any of the asymmetric structures as well as in the symmetric all-tight 
conformation of AcrB_V612F, the protein-protein contacts at the surface of the PC1 
and/or PN2 subdomais of the tight monomer are extensive and might account for the 
allegedly reduced movement of the PC1 subdomain during conformational cycling. 
To analyze the distances between different AcrB subdomains in vivo, we introduced 
pairs of cysteines and investigated the extent of cross-link formation by mass 
spectrometric means (160). Interestingly, we found strong cross-link formation 
between Q229C and E585C located on the intermonomer connecting loop and the 
PC1 subdomain, respectively (unpublished data), although the minimal distance 
measured in the AcrB 3D-structure is 8.9 Å and thus exceeds the threshold for cross-
link formation by far (6.4 Å). We therefore hypothesize that the crystal contacts might 
impose a constraint for further opening of the binding pocket, which is situated at the 
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interface of the PN2 and PC1 subdomain. As a consequence, the range of substrates 
that are able to bind to AcrB in the 3D crystal might be narrowed to relatively small 
planar compounds such as antibiotics of the tetracycline class. Recent structure and 
cross-link driven docking approach experiments suggest that the surface of the PN2 
and to a lesser extent of the PC1 subdomain are involved in contact formation with 
AcrA (121). Additionally, MFPs are known to influence the substrate specificity of 
the trimeric MFP/RND/OMF complex (132,133), indicating that probably also in vivo 
protein-protein contact at the PN2 and PC1 subdomains affect binding of substrate by 
the binding pocket. 
 
7.3 Methods to obtain structural information on AcrB in additional 
conformations 
 
Additional structural information of AcrB in alternative conformations is crucial to 
deepen our understanding of the working mechanism of this important MDR protein. 
Since formation of crystal contacts is one of the major bottlenecks in 3D 
crystallization, chances for the protein to crystallize in a novel conformation are 
improved when the crystal contacts are tackled specifically. Therefore, several 
methods were developed aiming to allow formation of new crystal contacts. Besides 
co-crystallization of the target protein with high affinity binding proteins such as 
fragments of monoclonal antibodies (251,252) or DARPins (142), an approach termed 
Rational Surface Engineering proved to be successful in improving crystallization 
behavior of some proteins (253). This method is based on the observation that 
residues with large polar side chains located on the surface of proteins are 
disadvantageous for the crystallization process. Glutamates and lysines are 
particularly unfavorable since integration of the protein into the crystal and especially 
the formation of crystal contacts involves the ordering of surface side chains which is 
affiliated with a loss of entropy. We therefore mutated subsequently four clusters 
containing nine lysine and glutamate residues located on flexible loops at the surface 
of AcrB to alanine. Since the R32 crystal forms were still predominant, we 
specifically mutated nine formally charged residues involved in the R32 crystal 
contacts in a later step. With this method, we were able to crystallize AcrB in the 
space group C2 with novel cell parameters diffracting up to 3.3 Å. 
7. Conclusions and outlook 
136 
 
 
One method that not only circumvents the issue of crystal contacts in part but allows 
addressing the conformational state of AcrB in absence of substrate is 2D 
crystallography. To obtain 2D crystals, detergent solubilized membrane proteins are 
supplemented with membrane lipids. Detergent molecules are then removed by 
dialysis, which drives integration of the membrane protein into the planar lipid 
bilayer. If reconstitution is successful, the protein molecules might arrange in a 
regular 2D lattice and the structure of the protein in its native environment can be 
analyzed by electron transmission microscopy (TEM). Furthermore, 2D 
crystallography seems to be well suited to crystallize AcrB in presence of its 
accessory proteins AcrA and TolC, both of which are essential for substrate transport 
in vivo. We therefore established collaboration with Prof. Dr. Alok Mitra from the 
University of Auckland, who is well known internationally for his work in high-
resolution electron crystallography of membrane proteins (254,255).  
Purified AcrB was successfully integrated into the lipid bilayer by slow detergent 
removal using standard protocols (256). As shown in Figure 28, the AcrB 2D crystals 
exhibited tubular geometry. As a consequence, the electron beam is scattered by two 
layers of 2D crystals, which severely exacerbates data processing. However, upon 
addition of 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 
to preformed tubular AcrB 2D crystals, the tubules got partially dissolved and were 
present as single layered sheets. 2D crystals were negative-stained or cryo-protected 
and analyzed by TEM. The diffraction limit of the negative-stained specimen was 
found to be 20.6 Å and of the cryo-EM sample 18.5 Å, respectively. A 2D projection 
map of the crystal was generated after data processing. In the case of negative-stained 
AcrB crystals, the monomers of trimeric AcrB can be clearly distinguished. For 
vitrified AcrB crystals, the preliminary data did not indicate clear subunit 
morphology. Interestingly, both sample preparation methods resulted in a lattice with 
two-fold, but no three-fold symmetry. Attempts to improve resolution and 
reconstitution of AcrB with its accessory proteins AcrA and TolC are subject of 
current research in the laboratory of Prof. Dr. Alok Mitra. 
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Figure 28: 2D crystallization of AcrB - preliminary data. A) Representative picture of 
negative stained AcrB 2D crystals. Upon integration into the lipid bilayer, AcrB mainly forms 
crystals with tubular geometry. The suspension containing 2D crystals of AcrB was placed on 
a glow-discharged EM grid covered with a continuous carbon film and stained with 1.5% 
uranyl acetate. 
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B) Single layered AcrB 2D crystal obtained after treatment of preformed crystals with 0.2 – 
0.3% CHAPS.  
C) Fourier transform (diffraction) of negative stained AcrB 2D crystal after masking of noise. 
Red circle indicates resolution limit (20.6 Å). The unit cell dimensions of the negative stained 
specimen were a = 165 Å, b = 177 Å, γ = 90°. 
D) Diffraction of vitrified AcrB 2D crystal after masking of noise. Resolution limit was found 
to be 18.5 Å (red circle) and the unit cell dimensions were a = 164 Å, b = 168 Å, γ = 90°. 
After applying AcrB 2D crystals onto the EM grids, the samples were vitrified by snap-
freezing in liquid ethane using Vitrobot Mark IV (FEI Company) 
E) and F) 2D projection map of negative stained and cryo-EM AcrB 2D crystals, 
respectively. The continuous lines represent protein. Length of the a- axis is indicated. 
Negative-stained and cryo-EM grids were examined at 120kV in a low-dose mode using 
Philips CM12 and Philips Tecnai12, respectively. The images of the 2D crystals were 
recorded at a nominal magnification of 42’000 and at 0.8 µm to 1.0 µm underfocus.  
Images of 2D crystals of AcrB were processed by using the MRC program suite for 2D 
crystallography (195,257). The unit cell dimensions of the crystal lattice were determined and 
the amplitudes and phases were extracted after two rounds of lattice unbending procedure (as 
for example in (258)). At the defocus used, the highest resolution spot was located within the 
first node of contrast transfer function, and thus no correction for the phase reversal was 
applied. The extracted phases and amplitudes for the image were queried using the program 
ALLSPACE to determine the most likely plane group of symmetry. Extracted phase and 
amplitude were used to create 2D projection maps without imposing any symmetry 
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